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ABSTRACT OF THE DISSERTATION 
INSIGHT INTO THE INHIBITION OF RIBONUCLEOTIDE REDUCTASES BY 2'-
CHLORO-2'-DEOXYNUCLEOTIDES AND 2'-AZIDO-2'-DEOXYNUCLEOTIDES: 
BIOMIMETIC STUDIES WITH MODEL SUBSTRATES 
by 
Mukesh Madan Mudgal 
Florida International University, 2016 
Miami, Florida 
Professor Stanislaw Wnuk, Major Professor 
Ribonucleotide Reductases (RNRs) are crucial enzymes that catalyze reduction of 
ribonucleotides to deoxyribonucleotides, required for the biosynthesis of DNA. Vital role 
played by RNR in the biosynthesis of DNA and its control on cell growth made it one of 
the main targets for anticancer therapy. Several laboratories clarified the aspects of 
reaction cascades at active site of RNR. Biochemical studies of RNR by Stubbe for the 
inactivation of RDPR by 2'-chloro-2'-deoxyuridine-5'-diphosphate emphasizes departure 
of chlorine as an anion, while biomimetic studies by Robins with 6'-O-nitro-2'-chloro-
homonucleosides emphasizes the elimination of chlorine substituent from 2'-position as a 
radical. To clarify the ambiguity in the mechanism of inhibition of RNR by 2'-chloro-2'-
deoxyuridine, biomimetic reactions with model 6-O-nitro-1,5-dideoxyhomosugar 
derivatives were investigated. The study includes several modes: (i) synthesis of 6-O-
nitro-1,5-dideoxyhomosugar derivatives with chlorine, bromine or tosyl substituent at the 
C2 position with ribo and arabino configurations, (ii) biomimetic studies of 6-O-nitro-
1,5-dideoxyhomosugar derivatives with Bu3SnH/AIBN to provide chemical evidences to 
viii 
 
distinguish the nature of elimination of chlorine from 2'-chloro-2'-deoxyuridine upon its 
incubation with enzyme, and (iii) kinetic studies to differentiate between heterolytic or 
homolytic C2'-chlorine bond cleavage.  
In the second half of this dissertation, azido and sulfenamide modified 
nucleosides and 2-azidolyxofuranoside derivatives have been synthesized with the azido 
or sulfenamide substitution at a specific site in the sugar or in the base moiety. The 
electron-induced site specific formation of neutral aminyl radicals (RNH●) and their 
subsequent reactions have been investigated using ESR spectroscopy. In 2'-AZdC the 
RNH● site is attached to a 2o C-atom, where as in 4'-AZdC, the RNH● site is attached to 
a 3
o
 C-atom, respectively. These studies elucidated how stereo and electronic 
environment affect formation and subsequent reactivity of various types of RNH● 
generated from azidonucleosides. To avoid the interaction of transient radical with 
nucleoside heterocyclic bases, 2-azidolyxofuranoside derivatives as a simpler abasic 
model were synthesized and studied with ESR spectroscopy. Aminyl radical generated 
from 2-azidolyxofuranoside derivatives subsequently abstracted hydrogen from C5 
intramolecularly. These studies were designed to understand the mechanism of damage in 
various DNA model structures.  
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1. INTRODUCTION 
 
 1.1. Anticancer and antiviral nucleoside analogues 
Nucleosides consists of nitrogenous base and a sugar component (ribose or 
deoxyribose), whereas nucleotides contains sugar, a nucleobase, and one or more 
phosphate groups. Nucleosides and nucleotides are involved in numerous cellular 
processes such as synthesis of DNA and RNA, cell signaling, metabolism and regulation 
of enzymes. Analogues of nucleosides and nucleotides are prepared by chemical 
modifications of sugar and/or the base and are designed to mimic their physiological 
counterparts. These analogues affect cellular metabolism and further are incorporated 
into the DNA and RNA to inhibit cell division and viral replication.
1
 Thus nucleoside and 
nucleotide analogues can serve as therapeutic agents and can be used to inhibit growth of 
cancer cells and inhibit viral replication. Besides being incorporated into the nucleic 
acids, these analogues can interact with important enzymes like DNA polymerases, RNA 
polymerases, kinases, ribonucleotide reductase, DNA methyltransferases, purine and 
pyrimidine nucleoside phosphorylase and thymidylate synthase to inhibit their activities.
1
 
Mechanisms of action of nucleoside analogues  
Nucleoside and nucleotide analogues follow the same metabolic pathways as of 
endogenous nucleosides or nucleotides in cells and also interfere with the normal 
metabolic processes within cells. These analogues enter the cell through a group of 
membrane transport proteins called nucleoside transporters.
2,3
 Once these analogues enter 
into the cells they get phosphorylated with nucleoside kinase enzymes. Di-
phosphorylated and triphosphorylated nucleoside analogues are active forms of these 
2 
 
drugs which get accumulated in cancer or virus-infected cells. Further these drugs act by 
inhibiting the enzymes such as viral polymerases, human polymerases or ribonucleotide 
reductase, as well as by getting incorporated into newly synthesized DNA and RNA. The 
incorporation of the nucleoside or nucleotide analogues into DNA leads to termination of 
the chain elongation or the induction of apoptosis.
1
 In addition to their antiviral and 
anticancer activities the nucleoside and nucleotide analogues are also used in treatment of 
hyperuricemia (abnormally high level of uric acid in the blood), immunosuppression, 
phosphodiesterase inhibitions (inhibit the production of second messengers within cells, 
such as cyclic adenosine monophosphate), neuroprotection (regeneration of nervous 
system, its cells, structure and function)  and cardioprotection.
1
  
Antiviral nucleoside analogue 
Nucleoside analogues are an important class of antiviral agents used to treat 
human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), 
cytomegalovirus (CMV) and herpes simplex virus (HSV) infection.
4
 The first antiviral 
nucleoside analogue approved by FDA in 1969 was a thymidine analogue edoxudine, but 
is not currently in use. Presently, there are 25 FDA approved nucleoside and nucleotide 
analogues used as antiviral agents.
1
  
Viral infection is broadly classified into three main classes; (i) Chronic viral 
infections like HIV, HBV and HCV, which has affected around 600 million people 
worldwide, (ii) Acute viral infections like influenza and haemorrhagic fever and (iii) 
Benign viral infections, e.g., common cold etc. Selected antiviral molecules available in 
the market depicted in Figure 1 are deoxyadenosine analogues e.g., didanosine (HIV), 
vidrabine (chemotherapy), adenosine analogs e.g., BCX4430 (Ebola), deoxycytidine 
3 
 
analogues e.g., cytarabine (chemotherapy), lamivudine (HIV, hepatitis-B), zalcitabine 
(HIV), guanosine and deoxyguanosine analogues e.g., abacavir (HIV), telbivudine 
(hepatitis-B), zidovudine (HIV), deoxyuridine analogues e.g., idoxuridin. 
 
Figure 1. Selected nucleosides with antiviral activity 
New anti-HCV nucleosides 
Derivatives of 2'-deoxy-2'-fluorocytidine (FdC) like, methylated FdC (PSI-6130)
4
, 
2'-C-methylcytidine (Met-dC) derivative valopicitabine, are examples of new anti-HCV 
compounds. Mericitabine, another derivative of FdC has successfully completed several 
phase I and II studies alone or in combination with pegylated interferon (group of 
proteins produced and released by host cells in response to viruses, bacteria, parasites and 
tumor cells). 
Sofosbuvir (Figure 1) is a uridine nucleotide analog and is recently approved as 
anti-HCV drug. It is a potent inhibitor of the NS5B polymerase (proteins essential for 
viral RNA replication) in the Hepatitis C virus. The NS5B has been found to be a 
valuable target for antiviral agents. Sofosbuvir is a phosphoramidate prodrug that has to 
be triphosphorylated within the cells to produce its action. Once administered into the 
body, sofosbuvir gets converted into the active form with the help of enzymes present in 
the human hepatic cells. Thus it is directly converted into the active metabolite during 
4 
 
metabolism in the liver. This analog further acts as competitive inhibitors by  mimicking 
the physiological nucleotide and blocks the NS5B polymerase, thus inhibiting the HCV-
RNA synthesis by RNA chain termination.
5
 
New anti-HIV nucleosides 
Human Immunodeficiency virus (HIV) is a retrovirus which causes acquired 
immunodeficiency syndrome (AIDS). Human Immunodeficiency virus inhibitors are 
classified into two broad categories non-nucleoside inhibitors and the nucleoside 
inhibitors. Festinavir is the analogue of the first generation anti-HIV nucleoside 
stavudine, prepared by attachment of the ethynyl group in the 4'- position of the ribose 
ring of stavudine (Figure 2). Festinavir is more potent than stavudine and has reduced 
toxicity.
6
  It is now in phase II of clinical trial. Another new and potent anti-HIV 
molecule is apricitabine. It is a second-generation deoxycytidine analogue. Apricitabine 
has high barrier to resistance and no mutation detected during the in vivo studies of this 
molecule.
7
 
 
Figure 2. Selected anti-HIV nucleosides 
The field of antiviral agents is active and novel anti-HCV compounds are under 
development. Molecules are also developed against HIV, HBV, herpes simplex virus, 
5 
 
cytomegalovirus, influenza and emerging viruses. However more attention is required for 
the development of selective antiviral agents to reduce their side effects by not getting 
incorporated into genomic and mitochondrial DNA of host cells.  
Anticancer nucleoside analogues 
Numerous anticancer molecules are synthesized and evaluated for the treatment of 
cancers after the approval of cytarabine in 1969 by the US FDA for the treatment of acute 
myeloid leukemia. Currently approved anticancer agents includes, cytarabine (acute 
myeloid leukaemia  and acute lymphocytic leukaemia), fludarabine (chronic lymphocytic 
leukaemia non-Hodgkins lymphoma), cladribine (hairy cell leukaemia), gemcitabine 
(Figure 3),  (non-small lung cancer, pancreatic cancer,  bladder cancer and  breast 
cancer), clofarabine (acute lymphocytic leukaemia), nelarabine (T-cell acute 
lymphoblastic leukaemia), capecitabine (metastatic breast cancer, metastatic colorectal 
cancer), floxuridine (advanced colon cancer, kidney cancer and stomach cancer), 
deoxycoformycin (hairy cell leukemia chronic lymphocytic leukaemia), azacitidine 
(myelodysplastic syndrome), decitabine (myelodysplastic syndrome, acute myeloid 
leukemia. 
 
Figure 3. Selected anticancer nucleoside analogues 
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New anticancer nucleosides 
Very few examples of anticancer nucleoside analogues are known which cure 
cancer in patients. Cytarabine halts myeloid leukemia (uncontrolled growth of abnormal 
white blood cells and its accumulation in bone marrow which interferes with production 
of normal blood cells) in less than 30% of all adult patients. Most of the other cytotoxic 
agents provide temporary relief or prolong life with no definitive cure. Thus there is a 
strong need to improve the cytotoxicity of currently available cytotoxic nucleoside 
analogues.  
The Cytarabine analogue CNDAC [1-(2-C-cyano-2-deoxy-
β-d-arabinopentofuranosyl) cytosine] (Figure 3), induces DNA strand breakage upon its 
incorporation into DNA because of the nucleophilic attack of the cyano group. It showed 
good cytotoxic activity in vivo on human cancer xenografts (graft of tissues from human). 
Sapacitabine is an oral nucleoside analogue prodrug. It is a derivative of CNDAC and is 
under phase III of clinical trials.  
The 8-chloroadenosine and 8-aminoadenosine analogues decrease the 
concentration of the ATP intracellularly by reducing the RNA synthesis and inducing cell 
death.
8,9
 The 8-chloroadenosine induces cytotoxicity by decreasing MET expression,
10
 a 
tyrosine kinase receptor responsible for embryonic development, organogenesis and 
wound healing in myeloma cells. It also reduces the cyclin E (a member of cyclin family 
binds to G1 phase of cell cycle, which further determines cell division) expression in 
breast cancer cells. The 8-chloroadenosine is under phase-I clinical trial with chronic 
lymphocytic leukemia.
1
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New cytotoxic nucleoside analogues are capable of altering the role of nucleoside 
analogues in cancer therapy. To accomplish this they need to have their own and original 
mechanism of action.  
1.2. Ribonucleotide Reductase: Function and inhibitions 
1.2.1. Mechanistic aspects 
Ribonucleotide reductases (RNRs) convert the nucleotides to 2'-deoxynucleotides.
11
 
The 2'-deoxynucleotides act as monomeric precursors required for DNA replication and 
repair.
12
 Inhibition of RNRs leads to depletion of the deoxyribonucleotides pool available 
for DNA synthesis and therefore is an appealing concept for rational drug design.
13,14
 
Number of 2'-modified pyrimidine nucleotides have been synthesized such as 2'-chloro
15
 
and 2'-azido 5'-di(or tri)phosphates and are found to be potent inhibitors of RNRs.
16-19
 
Gemcitabine is an analog of cytidine with two fluorine atoms at the 2'-position of the 
ribose ring. It is a first-line chemotherapeutic agent used for the treatment of pancreatic 
and non-small cell lung cancers.
13,14,20,21
 
 
Figure 4. Structure of class I RNR
22
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Ribonucleoside 5'-diphosphate reductase (RDPR) from Escherichia coli (Gram 
negative bacteria) have been studied extensively. Escherichia coli have similar 
composition as of mammalian RDPRs.
23
 It was found to contain two non-identical 
subunits (R1 and R2) (Figure 4). The R1 subunit of the Escherichia coli consists of 
allosteric control sites (site other than enzyme's active site where effector binds and 
regulates the protein) and cysteine. While the R2 subunit contains a di-iron chelate and 
essential tyrosine free radical which produce a proximate thiyl radical
24
 on Cys439 on R1 
subunit via electron and proton transfer reactions. The thiyl radical abstracts the hydrogen 
from 3' position of the ribonucleotide substrate to initiate nucleotide reduction.
25
 This 
reaction cascade further leads to the elimination of water from 2' position.
25
 These initial 
steps in the mechanism of the reduction of the ribonucleotides to deoxyribonucleotides 
catalyzed by RNR are consistent with the Stubbe's  enzymatic studies with gemcitabine
26-
30
 along with theoretical modeling studies performed by Ramos and Siegbahn,
31,32
 and 
chemical biomimetic studies by Giese
33
 and Robins
34,35
 as well as McCarthy's 2'-deoxy-
2'-fluoromethylenecytidine.
36,37
 Nevertheless the detection of the ribosyl-based radical 
during RNR-catalyzed deoxygenation of the natural substrates remains elusive.
38
 
1.2.1.1. Enzymatic studies by Stubbe 
Stubbe et al. proposed the mechanism for the reduction of the nucleoside 
diphosphate substrates (Figure 5).
12
 It has been postulated that in the first step of RNR-
catalyzed reduction of the ribonucleotides to deoxyribonucleotides reactions, a thiyl 
radical SCys439 abstract H3' of the ribosyl (A, X = OH) to generate the C3' radical. Base 
promoted (Glu441) removal of the 3'-hydroxyl proton leads to loss of water (C2'-H2O) in 
a heterolytic manner (B → C) to produce 3'-keto-2'-deoxydeoxynucleotide.24,39 Enzyme 
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inactivation by 2'-azido substituted nucleotides (A, X = N3) are accompanied by loss of 
azide ions and formation of 3'-keto-2'-deoxynucleotides
12,15,17
 (e.g., D), which dissociate 
further from protein and generate 2-methylene-3(2H)-furanone Michael acceptor, which 
alkylates the nucleophiles on enzyme and causes covalent enzyme inhibition. Incubation 
of RNR by gemcitabine results in inhibition of both R1 and R2 subunits of ribonucleotide 
reductase (RNR).
26-30
 Transfer of the hydrogen atom from cysteine thiols gives 3-keto 
intermediate D. Further the electron and proton transfer takes place to produce E, 
cysteine and the glutamate. The original hydrogen atom (Ha) is recaptured from SCys439 
by the C3' radical to complete reduction of the substrate to give 2'-deoxynucleoside 5'-
diphosphate, F with regeneration of the SCys439 radical for the next catalytic cycle. 
 
Figure 5. Proposed mechanism for the reduction of ribonucleoside diphosphates with RDPR.
12
 
 
Stubbe, et al.
25
 also proposed hypothesis for the inactivation of the RDPR by 2'-
chloro-2'-deoxyuridine (Figure 6). Proton and electron transfer takes place from R2 
subunit to R1 subunit to generate SCys439 free-radical. The SCys439 radical abstracts 
10 
 
hydrogen from C3' position to generate radical at C3', H. Hydroxyl proton from C3' 
position forms the hydrogen bonding with the carboxylate group of glutamate and leads 
to loss of chloride as anion from C-2' to give α-keto radical I. The α-keto radical I 
abstracts proton from cysteine C439 to give 2'-deoxy 3'-keto NDP J. Successive β-
eliminations of base from H2' and iPP (pyrophosphate) from H4' gives furanone K. The 
α-keto radical I can alternatively abstract hydrogen atom from the dithiol pair to give 
intermediate L, which upon successive β-eliminations generates furanone K. But in the 
transformation of L to K, regeneration of cysteine C439 free radical does not take place 
which, in turn, avoids the initiation of another catalytic cycle. The furanone K is a 
Michael acceptor which alkylates the nucleophiles on enzyme and causes covalent 
enzyme inhibition.
40
 This hypothesis proposed by Stubbe, et al. is based on the departure 
of chlorine as an anion. 
 
Figure 6. Proposed mechanism for inactivation of RDPR by 2'-chloro-2'-deoxy-NDPs.
25
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1.2.1.2. Biomimetic studies by Robins and Giese 
 Robins et al.
34,35
 and Giese
33
 worked on the biomimetic reactions designed to 
simulate the initiation/elimination cascade that occurs during reductions and mechanism-
based inactivation mediated by RNRs. Biomimetic reactions are performed to study the 
nature of elimination of substituent from C2' position upon generation of radical at C3' 
position.  
Robins et al. designed the 6'-O-nitro-2'-(substituted) homonucleosides that upon 
treatment with tributyltin hydride and AIBN allow generation of 6'-oxyl radical which 
were positioned to abstract H3' and produce hydroxyl C3' radical. Scheme 1 demonstrates 
the plausible mechanism for the conversion of 2'-chloro-6'-O-nitro-homouridine 
derivative 1 into furanone 5 and Scheme 2 demonstrates the plausible mechanism for the 
conversion of 6'-O-nitro-2'-O-tosyl homoadenosine derivative 6 into 11. The 6'-oxy 
radical, generated from the treatment of substrate 1 with Bu3SnD/AIBN, abstracts 
hydrogen from the C3' (by [1,5]-hydrogen shift via a six member cyclic transition 
state)
41,42
 and eventually leads to the loss of chlorine as a radical rather than as an anion. 
The β-elimination of uracil base from the enol intermediate results in furanone 5 without 
incorporation of deuterium. Instead, the deuterium transfer from Bu3SnD to chlorine 
occurs and that propagates the radical chain reaction. Similarly, treatment of 6'-O-nitro-
2'-O-tosylhomoadenosine 6 with Bu3SnD/AIBN gives 6'-oxy radical
43
 leads to the 
abstraction of H3' (by [1,5]-hydrogen shift via a six member cyclic transition state)
44
 to 
give C3' radical 8. Loss of tosylate from 8
45
 leads to a C2'-radical 9 which, after capturing 
a deuterium radical from Bu3SnD and subsequent β-elimination of adenine, gives 
12 
 
partially deuterated furanone 11. Thus no deuterium incorporation into 5 was observed 
upon treatment of 2'-chloro homouridine derivative with Bu3SnD whereas furanone 11 
with deuterium incorporation was formed upon treatment of 2'-O-tosyl homouridine 
derivative with Bu3SnD. Proposed mechanisms prove the ionic vs radical cleavage of 
substituents from C2' position of nucleosides. However, deuterium transfer into 11 takes 
place selectively from the less hindered α-face46 to give unstable 2'-deoxy-2'-deuterio-3'-
ketohomoadenosine 10 [α/β~4:1]. The β-elimination of adenine from ketone 10 would 
give 11 with only 15-30 % deuterium incorporation at C2' position. They found that 
chlorine atom eliminates (as radical; 1→5 )47 and toluenesulfonic acid (as anion, 6 → 
11 )
48
  from C2' upon generation of α-hydroxy radicals at C3'. 
 
Scheme 1. Proposed mechanism for the one-electron (chlorine atom) elimination upon generation of 
C3' radicals
34,47,48
 
 
 
Scheme 2. Proposed mechanism for the two-electron (toluenesulfonate anion) elimination upon 
generation of C3' radicals
34,47,48
  
 
Robins et al also found that departure of the substituents from C2' upon generation of 
3'-deoxy C3' radicals lacking 3'-hydroxyl group underwent elimination via different 
13 
 
paths.
49
 Hence, treatment of 2'-(azido, bromo, chloro, iodo, and methylthio) nucleoside 
3'-thionocarbonates with Bu3SnH/AIBN produced 3'-deoxy C3' radicals that underwent 
loss of the 2'-substitutent to give 2',3'-didehydro-2',3'-dideoxynucleosides. On the other 
hand, analogous 3'-thionocarbonates with 2'-fluoro or 2'-O-(mesyl or tosyl) substituents 
(anionic leaving groups) underwent hydrogen transfer to the C3' radical to give the 3'-
deoxy-2'-[fluoro or O-(mesyl or tosyl)] derivatives (Figure 7). Thus treatment of 2'-
deoxy-3'-O-phenoxythiocarbonyl nucleosides, 12 with azido, bromo, chloro, iodo, or 
methylthio substitution at 2'-position with Bu3SnH generates C3' radicals, 13 (Figure 7). 
Further the reaction cascade leads to the elimination of the substituent as a radical from 
the C2' with formation of 2',3'-unsaturated derivative 14. While treatment of 2'-deoxy-3'-
O-phenoxythiocarbonyl nucleosides, 12 with fluoro, mesyloxy, or tosyloxy substituents 
at the 2'-position with Bu3SnH generates radical at 3'-position, 13 which abstracted 
hydrogen from the stannane to give 3'-deoxy-2'-(fluoro, mesyloxy, or tosyloxy) 
derivatives 15. Since the homolytic scission to release a high energy fluorine atom or a 
mesyloxy or tosyloxy radical is energetically prohibitive the elimination did not occurred.  
 
Figure 7. Fragmentation of 2'-substituted-3'-thionocarbonates upon treatment with Bu3SnH/AIBN/. 
  
Conversion of nucleotides to 2'-deoxynucleotides catalyzed by RNR starts with 
generation of radical at C-3′ of nucleotide with further loss of hydroxyl from C-2'.24,39 
14 
 
Several attempts have been made to trap radical at C-3′ in the enzymatic system50 and in 
the biomimetic systems
51
 but the direct observation of the nucleotide radical were not 
possible.  Giese et al
33
 performed biomimetic studies to trap radical at C-3′ nucleoside. 
They developed a method to selectively generate a radical at the C-3′ of the nucleoside. 
They introduced the selenol ester group at the C-3′ which is chemically stable but can be 
cleaved off homolytically under mild conditions. The Se-C bond in the selenol ester 
moiety is weak and can be cleaved off easily with either by directly using UV light (λ > 
320 nm) or in a photochemically induced radical chain process using Bu3SnH. 
Photolysis of the precursors was achieved by subjecting them to radiations at 20 
°C in methanol or acetonitrile/water (1:1) and in the presence of an H-donor such as 
Bu3SnH or 
t
BuSH as radical scavenger. Mixtures of acetonitrile and aqueous buffer 
solutions like triethylammonium acetate buffer (TEAA buffer, pH 7) were employed to 
mimic the reaction conditions found in an enzyme pocket.  
 
Scheme 3. Traping C-3′ radical generated from selenol ester precursor 
 
Precursor 16 led to the formation of reduction product 20 as exclusive product of 
the reaction (Scheme 3). Deuteration at C-3′ observed when the reaction was performed 
15 
 
using deuterated solvent indicating that the selenol ester 16 is an excellent radical 
precursor and the radical can be selectively generated at C-3′ either by photo induction 
chain reaction or direct photolysis. In this case since the Bu3SnH or 
t
BuSH are highly 
efficient in trapping the radical at C-3′ the formation of 2'-deoxygenated product could 
not compete with the direct reduction. In order to achieve the formation of the 2'-
deoxygenated product 28 Giese et al
33
 used Bu6Sn2 as a radical mediator. Because the 
much slower radical trapping reaction with the use of Bu6Sn2, 57% of adenine 26, 10% of 
2,3-dihydro-2-hydroxymethylfuran-3-one 28, and only 35% of product 20 was produced.  
Photolysis of the precursor 17 having acetate at C-2′ as a better leaving group, 
clarifies that formation of free nucleobase is fully related to the 2′-deoxygenation. Same 
reaction when performed employing Bu3SnD as trapping reagent >90% of deuteration at 
C-2′ of 25 and 52% at C-3 of 28 was observed. When the highly reactive radical 
scavenger 
t
BuSH was used direct reduction product 21 was formed. Deuterium 
incorporation at C-3′ (>80% by NMR) was observed when reaction was performed using 
CD3OD and 
t
BuSH.  
1.2.1.3. Enzymatic studies by Begley 
 
Recently Begley et al. proposed mechanism of the MoaA catalyzed reaction of 2'-
chloroGTP, 29 to probe the mechanism of molybdoterin biosynthesis.
52
 MoaA is a radical 
S-adenosylmethionine enzyme which catalyzes the first step in molybdoterin 
biosynthesis.
53
 Interestingly the authors proposed that in the MoaA catalyzed reaction of 
2'-chloroGTP, the substituent from 2'-position departs as a radical upon generation of the 
radical at C3'-position (Scheme 4),
52
 which is in agreement with the Robins biomimetic 
studies (see scheme 1). 
16 
 
 
 
 
Scheme 4. Mechanism of the MoaA catalyzed reaction of 2'-chloroGTP 
 
1.2.1.4. Theoretical considerations by Ramos 
Ramos et al.
32
 noted that the enzymatic and the biomimetic systems are different. 
In biomimetic systems the basic group capable of protonating/deprotonating the 3'-HO 
group is absent. The basic group is crucial for the enzymes. It allows the transfer of 
charge from and into the substrates as needed.  In most of the enzymes E441 serve as a 
basic group capable of protonating/deprotonating the 3'-HO group, and is fundamental to 
several enzymatic reaction steps.
54
 As in the enzymatic system the basic function is 
present, the inhibitor can eliminate an anion without generating a system with a charge 
separation (Scheme 5). The substituent from the 2'-position eliminates as an anion while 
the proton from the 3'-OH eliminates as cation thus circumventing the charge separation.  
In contrast biomimetic systems do not contain the basic function and therefore the 
elimination of a substituent from the 2'-position as an anion will result in a system with a 
charge separation: a negative charge in the leaving substituent and a positive charge an 
unstable carbocation radical in the 2'-C position (Scheme 5). Thus according to Ramos et 
al. this is why in biomimetic experiments the substituents are not eliminated as anions 
17 
 
and depart as radicals. Also, biomimetic experiments were performed in benzene/toluene 
which is known to stabilize chlorine radicals. 
  
Scheme 5. Elimination of the substituents as anions with (top) and without (bottom) a basic group 
able to deprotonate 3'-hydroxyl group 
 
In order to check this hypothesis Ramos et al. designed a simple model system 
and performed the theoretical calculations. System-A (Scheme 5) includes a basic group 
(E441) capable of protonating/deprotonating the 3'-HO group and system-B does not 
include the basic function. They found that in the system A the basic function takes the 
proton from the 3'-HO group, and further the substituent from the 2'-position eliminates 
chlorine as anion. However in system B the substituent did not eliminate spontaneously 
and leaves as a radical.  
Thus they concluded that the nature of the elimination of the substituents from 2'-
position can be controlled.  Substituents will depart as anion if the basic group is present 
(as in the enzymatic system) or it will depart as a radical in absence of the basic residue 
18 
 
capable of protonating/deprotonating the 3'-HO group. Since enzymes contain such basic 
functionality they eliminate anions and not radicals.   
1.3. Chemistry of azido nucleosides: Synthesis and applications 
The first organic azide compound, phenyl azide, was synthesized by Peter Grieb 
in 1864.  A few years later the Curtius rearrangement was developed. Organic azide 
compounds gained industrial interest because of its use in the synthesis of heterocycles 
such as triazoles and tetrazoles as functional groups in compounds having medicinal 
properties. Azides are represented by following resonance structure. 
 
 
Synthesis of the modified azido nucleosides gained high importance after the 
discovery of 3′-azido-3′-deoxythymidine for the treatment of AIDS. Following are the 
established methods for the synthesis of the azido modified nucleosides.  
1. Nucleophilic displacement by azide: 2′-azido-2′-deoxyadenosine could be prepared by 
direct nucleophilic displacement of suitably protected 2′-sulfonate of arabino-
furanosyladenines. The triflate 35 (Scheme 6) upon reaction with LiN3 produced product 
in high yields in comparison to the mesylated, 33 or tosylated, 34 starting material.
55,56
  
 
 
Scheme 6. Synthesis of 2′-azido-2′-deoxyadenosine 
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2. Opening of nucleoside epoxides by azide: Derivatives of nuclosides like, 2′-O-anhydro 
and epoxides also acts as starting material for the synthesis of azidonucleosides. LiN3 
does not cleave the epoxides preferentially at the C-3′ site and therefore this method is 
not suitable for the synthesis of 2′-azido-2′-deoxynucleosides. For example treatment of 
lyxofuranosyladenosine with LiN3 yielded mixture of arabino, 38 (79%) and xylo, 39 
(8%), respectively (Scheme 7).
57
 
 
Scheme 7. Synthesis of azido nucleosides from epoxides 
 
3. From azidosugars: Azidouridine, 42 was prepared from readily available uridine, 40 
via 2,2'-O-anhydrouridine (Scheme 8). Further the glyosidic bond was cleaved by 
hydrazine hydrate to obtain 2-azido-2-deoxy-D-ribose 43. Methyl glycoside 44 was 
prepared from 43 and which upon acetylation gave 45.  Diacetate, 45 subsequently 
coupled with adenine followed by deactylation gave anomeric mixture of 46 and 47.
58
 
 
 
Scheme 8. Synthesis of azidonucleosides via 2,2'-O-anhydrouridine 
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Applications of azido nucleosides: 
1. 2′-Azido-2′-deoxynucleosides: The 2′-azido-2′-deoxynucleosides analogue, 48 (Figure 
8) displayed significant cytotoxic and antiviral activities.
59
 The 2′-azido-2′,3'-
dideoxynucleoside compound 49 inhibits the HBV replication in concentrations between 
2.2 and 5.0 µM.
60
 Similarly, the didehydronucleoside compound 50 displayed inhibitory 
activity against HIV-1 and HIV-2 in vitro.
61
 
 
Figure 8. Selected 2′-azido-2′-deoxynucleosides with biological activities 
 
2. 3'-Azido-3'-deoxynucleosides: AZT, 51 (Figure 9) also known as Zidovudine is an 
antiretroviral drug,
62
 approved by FDA for the treatment of HIV. It is marketed under the 
brand name of Retrovir. It acts by reducing the replication of virus. The AZT can also be 
used for the prevention of the HIV transmission from mother to child during birth. 
 
Figure 9. Selected 3'-azido-3'-deoxynucleosides with biological activities 
 
3. 4'-Azidonucleosides: 4'-azido-2'-deoxy-α-D-nucleosides displayed HIV inhibitory 
activity.
63
  These compounds showed reduced activity upon modifications at the 2'- or 3'-
position. 4'-azidothymidine, 52 (Figure 10) and were evaluated against cells infected with 
HIV. These compounds displayed similar inhibitory activity to that of AZT. 
21 
 
 
Figure 10. Selected 4'-azidonucleosides with biological activities 
 
4. 5'-Azido-5'-deoxynucleosides: Trichlorobenzimidazole derivative, 53 (Figure 11) 
displayed significant activity against human cytomegalovirus in plaque.
64
  
 
Figure 11. Selected 5'-azido-5'-deoxynucleosides with biological activities 
 
1.3.1. Azido nucleosides as inhibitors of RNR  
 Sjoberg, Stubbe and coworkers used EPR spectroscopy to study the reaction between 
ribonucleotide reductase and substrates and substrate analogues. Studies with the 
mechanism-based inhibitors of RNR substrate, 2'-azido-2'-deoxyuridine-5'-diphosphate 
have provided insight into the mechanism(s) of reduction of natural NDPs into dNDPs.
16-19
 
They studied the characteristics of the new EPR signal and determined the localization of 
the unpaired electron at nucleotide molecule, which was the first direct evidence for free 
radical chemistry with RDPR.   
 Studies have been done with the various isotopically labeled derivatives: (1'-, 2'-, 3'-, or 
4'- [2H])-N3UDPs and 2'- [
15
N3, 
13
C]-N3UDP to examine the mechanism of inactivation of 
RDPR by 2'-azido-2'-deoxynucleoside 5'-diphosphate (N3UDP).
17
 Experiments with 
doubly labeled 2'[
15
N3]-azido-2'-[
13
C]-UDP showed that the resulting nitrogen-centered 
radical was derived from the azide moiety and had no hyperfine interaction with the 
13
C 
22 
 
nucleus, which required cleavage of the 2'-carbon-nitrogen bond.
17
  Furthermore, EPR 
studies with a [β-2H] cysteine-labeled RDPR have indicated that the nitrogen centered 
radical is covalently bound to the sulfur of a cysteine of the R1 subunit of RNR.
65
 
 Cys439 thiyl radical abstracts the H3' in substrate and subsequently the loss of azide 
anion takes place from the initial C3' radical intermediate to give the ketyl radical B  
(Figure 12). Further proton-coupled electron transfer generates the 2'-deoxy-3'-
ketonucleotide C to generate the thiyl radical in the active site. Conversion (B  C) is 
analogous to the proposed mechanism for the reduction of natural NDP, which also leads 
to generation of the identical 3'-keto-2'-deoxynucleotide intermediate,
12,66
 which make 
study of the inhibition of RNR by N3UDP more significant. 
 Reaction of hydrazoic acid with the thiyl radical generates N2 and a sulfinylimine 
radical H. The sulfinylimine radical H was not detected by EPR. It is postulated that the 
protonated azide is essential for this mechanism since it is unlikely that the thiyl radical 
would react with an azide ion.
17,19
 The initial nitrogen-centered radical H reacts further 
with the oxygen or carbon atoms of a carbonyl group of the 3'-keto-2'-deoxynucleotide to 
generate radicals D or G, respectively.
18
 The inactivation of the enzyme with 3'[
17
O]-
N3UDP
67
 A were most consistent with the formation of G and provided the first evidence 
for the trapping of a 3'-ketonucleotide in the reduction process by a nitrogen-centered 
radical H.
19
 The chemical requirements also favor formation of G (over D) and there is 
precedent in literature for the analogous addition of aminyl radicals to the carbonyl
68
 and 
imino groups.
69
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Figure 12. Proposed structures for the nitrogen centered radicals and pathways for their generation 
during inactivation of RDPR by N3UDP 
 
 Pereira and coworkers performed theoretical modeling study and provided the 
alternative
70
 hypothesis, in which the released azide ion is proposed first to add to the 2'-
ketyl radical B with the concomitant protonation of the ketone oxygen by E441. The 
resulting radical E is then reduced at the 2'-position by C225 to generate the C225 thiyl 
radical F. Subsequent attack of the thiyl radical on an alkyl azide (instead of HN3) would 
lead to the same nitrogen center radical G, which was detected experimentally.
19
  
1.3.2. Reduction of azido nucleosides to amino nucleosides 
1.3.2.1. Staudinger reduction  
Staudinger and Meyer developed in 1919 a method for the reduction of azides to 
amines with phosphines (Figure 13).
71
 Triphenylphosphine reacts with azide to produce 
phosphazide intermediate which subsequently loses N2 to form iminophosphoranes. 
Further the aqueous workup leads to formation of the amine and phosphine oxide.  
 
24 
 
 
 
Figure 13. Reaction mechanism for the Staudinger reduction 
 
The phosphoroamidite-based solid phase synthesis of azido modified nucleosides can be 
problematic because of the Staudinger reduction of the azide group to amino group with 
the trivalent phosphrous reagent used.   
1.3.2.2. Radical reduction 
Radical mediated reduction of azide to amine can be accomplished by 
stoichiometric Bu3SnH (Figure 14 (1)).
72-76
 This reduction of azide is an example of a Sn-
N bond-forming process. The most efficient route for the synthesis of primary amines 
from alcohol is the activation of the alcohols to make it a good leaving group and 
subsequent displacement of the oxy anion by azide. Methods available for the reduction 
of the azide to amine are catalytic hydrogenolyses, reduction with Raney nickel with or 
without hydrazine, hydrogen sulfide/mecaptans, and the Staudinger phosphine/phosphite 
method. Robins et al.
74 
developed and reported the Bu3SnH mediated reduction of azide 
to amine from unprotected azidonucleosides. Treatment of unprotected 2'-azido-2'-
deoxyuridine 42 with Bu3SnH/AIBN in hot benzene yielded the 2'-amino-2'-deoxyuridine 
60 (Scheme 9). Analogues treatment of 5'-azido-5'-deoxyadenosine, 61 with 
Bu3SnH/AIBN afforded 5'-amino-5'-deoxyadenosine, 62 (Scheme 10).  
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Scheme 9. Bu3SnH-mediated reduction of 2'-azido-2'-deoxyuridine to 2'-amino-2'-deoxyuridine
74
 
 
 
Scheme 10. Bu3SnH-mediated reduction of 5'-azido-5'-deoxyadenosine to 5'-amino-5'-
deoxyadenosine 
 
Fu et al.
77
developed reaction condition where this reduction of azide to amine can 
be achieved by catalytic use of Bu3SnH and a silicon hydride fills the role of 
stoichiometric reductant. Bu3SnH-catalyzed, silicon hydride-mediated azide reduction 
process (Figure 15) has not proved to be practical and afforded the product in low yield. 
Fu et al. employed another strategy which relies upon reduction of Sn-O to Sn-H
78
 
(Figure 16). Addition of alcohol to the reaction transfer SnBu3 group from the 
RNHSnBu3 to the oxygen of alcohol. The silicon hydride reduces resulting tin hydride to 
regenerate the catalyst, Bu3SnH.  
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Figure 14. Bu3SnH-mediated reduction of azide to amine.
77
 
 
Reaction of primary, secondary, tertiary or aryl azide with Bu3SnH (5 mol %) and 
PhSiH3 (0.6 equiv) employing less hindered n-PrOH (2 equiv) gave primary amine in 
good yield.
77
 
 
 
Figure 15. Bu3SnH-catalyzed, silicon hydride-mediated azide reduction.
77
 
 
 
 
Figure 16. Bu3SnH-catalyzed, silicon hydride-mediated azide reduction: Alternate approach
77
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1.3.2.3. One electron reduction of 3'-azido-3'-deoxythymidine   
Sevilla and coworkers reported the formation of the neutral aminyl radical 
(RNH•) from 3′-azido-3′-deoxythymidine (3′-AZT) and 3′-azido-2′,3′-dideoxyguanosine 
(3′-AZG).79 The 3′-AZT, 51 upon electron attachment in γ-irradiated aqueous glassy (7.5 
M LiCl) systems at 77K in the absence of oxygen, results in an unstable azide anion 
radical intermediate, 63 (RN3•
-
) which was not spectroscopically detected. Loss of N2 
from (RN3•
-
) forms a highly basic and unstable nitrene anion radical 64 (RN•-) which has 
also not been detected spectroscopically.  Nitrene anion radical 64 upon subsequent 
protonation give neutral aminyl radical 65 (RNH•) (Scheme 11). 79 
 
Scheme 11. Formation of aminyl radical in 3'-AZT 
 
 The aminyl radical 65 (RNH•) is highly reactive and has been found to be potent H-
atom abstracting agent leading to base damage and formation of sugar radicals. On 
annealing to higher temperatures (ca. -113 to -103 
o
C), aminyl radical in 3′-AZT undergoes 
a bimolecular H-atom abstraction either from the methyl group at C5 in a thymine base to 
give dUCH2• radical 66 or from the C5′-atom to give C5′• radical 67 of a proximate 3′-
AZT (Scheme 13).
79
 Azide group in the modified nucleoside showed more attraction 
towards the electron compared to the thymine moiety which is consistent with the 
theoretical calculations and the ESR spectral calculations. 
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Scheme 12. Intermolecular H-atom abstraction by 3'-AZT aminyl radical 
 
Generation of the aminyl radical is also observed in case of the 2'-azido-2'-
deoxyuridine (2'-AZdU, 42) (Scheme 13).
80
 As like 3'-AZT, subjection of the 2'-azido-2'-
deoxyuridine (2'-AZdU, 42) to γ-irradiation in homogeneous aqueous glassy (7.5 M LiCl) 
solutions produces the aminyl radical (U(C2')-NH•, 68). The aminyl radical in (2'-AZdU, 
68) undergo bimolecular hydrogen atom abstraction at C5' of 2'-AZdU to produce a 
carbon-centered radical or can add bimolecularly to the C5=C6 double bond yielding a 6-
yl (addition to C5), 70 as well as a 5-yl (addition to C6), 71 radicals. 
 
Scheme 13. Intermolecular H-atom abstraction by 2'-AZdU aminyl radical 
1.3.3. Azido nucleosides as substrates for Cu (I)-catalyzed reaction (CuAAC) and 
strain-promoted azide-alkyne cycloaddition (SPAAC). 
Azido-modified oligonucleotides are widely used for the synthesis of 
bioconjugates employing azide-alkyne click chemistry approach.
81-87
 Phosphoramidite 
reagents are used to introduce the terminal alkynes or cyclooctynes into the 
29 
 
oligonucleotides. However this approach cannot be used for the azido modified 
compounds
88
 as the azide with P (III) in the phosphoramidite undergoes Staudinger 
reaction with the azide. Therefore the H-phosphonate
89,90
 and the phosphotriester
91-94
 
protocols are used for the synthesis of azide-modified oligonucleotides. Other options are 
post synthetic incorporation of azides into oligonucleotides
95-97
 and enzymatic
98-100
 
methods for the incorporation of the azide-modified triphosphates. The use of azido 
oligonucleotides gained interest with the introduction of strain-promoted azide−alkyne 
cycloaddition (SPAAC).
101
 The azido compounds can be coupled with both terminal 
alkynes in a Cu (I)-catalyzed reaction (CuAAC) and strained cycloalkynes. It has been 
reported that the Staudinger reaction does not take place between the azide group in the 
support-bound growing nucleotide chain and the phosphoramidite reagents.
89
 Thus 
automated phosphoramidite synthesis could be used for the azide-containing solid 
supports to produce 3′-azidemodified oligonucleotides.102-104  
Fauster et al.
105
 synthesized the cytidine and guanosine 2′-azido modified 
analogues. Synthesis of oligonucleotides using phosphoramidite chemistry is generally 
not possible since azides are proven to be susceptible to Staudinger reduction in the 
presence of P (III).
86
 Inspite of this finding Fauster proved that the azido group at the C2′-
position of furanose are compatible to the phosphoramidite reagent with the steps of 
automated oligonucleotide synthesis (Scheme 14). 
Phosphoramidites were incorporated site-specifically into the growing 
oligonucleotides using 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT). 
Automated addition of remaining residues of phosphoramidities continued without 
affecting the free C2'-azide group. 
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Scheme 14. Synthesis of azido-modified RNA fragments using phosphoramidite chemistry.
86
 
  
Sekine et al.
88
 prepared 2-azidodeoxyadenosine, 56 from deoxyguanosine by 
using combined reagent of TMSN3-BuONO. Further to incorporate 56 into DNA they 
tried two approaches. First approach is the phosphoramidite method and the other is H-
phosphonate approach.  
Although it is known that the azide compounds react with trivalent phosphorus 
compounds
106-108
 to yield iminophosphorane derivatives. To check the compatibility of 2-
azidodeoxyadenosine with phosphoramidite reagents Sekine et al. performed reaction of 
56 with diethyl N,N-diisopropylphosphoramidite, 57 in DMF-CD3CN (Scheme 15). 
Initial product was the intermediate 58 of Staudinger reaction, and the final product was 
iminophosphorane 59. 
 
Scheme 15. Reaction of 2-azidodeoxyadenosine with N,N-diisopropylphosphoramidite reagent.
88
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Further the synthesis of the oligodeoxynucleotides containing 2-azidodeoxyadenosine 
was achieved by H-phosphanate approach.  
1.3.4. Formation of aminyl radicals in nucleosides and its importance in DNA 
damage 
Deoxyribonucleic acid (DNA) in the living organisms is more prone to generate 
radicals upon subjection to the ionizing radiations. Mostly the radicals are formed in the 
heterocyclic bases purine and pyrimidine compared to the sugar part of the nucleoside.
109
 
These radicals are responsible for the most of the damage in the nucleotides e.g., strand 
breaks and interstrand cross-links.
110
 Studies have been done to generate the reactive 
intermediates of interest employing techniques like UV photolysis and -radiation.111 It is 
difficult to study the free radical generation and its reactions in actual DNA because of its 
complex nature. To understand the mechanism of formation of the radical and its reaction 
simpler model systems are developed and the experiments were performed in aqueous 
solution. Formation of the hydroxyl radicals is also reported but lifetime of this radical is 
very short while the nitrogen centered radicals have longer lifetime.
112
 Several research 
groups worked to study the reactivity of these radicals and these studies helped 
understand the reaction mechanisms and revealed complexities in damage pathways. 
Therefore to understand the formation and reactivity of the radicals it is important to 
design and synthesize the precursors that could generate aminyl radical. 
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1.4. Sulfenamides: Synthesis and medicinal relevance 
 
1.4.1. Sulfenamides in organic chemistry  
 
Sulfenamides is a class of organosulfur compounds which is represented by the 
general formula of RSNR'2, where R and R' are H, alkyl, or aryl groups. Sulfenamides are 
sometimes spelled as sulphenamides and are designated by different ways such as 
sulfamines, sulfur amines, mercaptoamines, aminothio compounds, amino sulfides, sulfur 
amides, and thiohydroxylamines. They are considered as a derivative of sulfenic acids. 
Sulfenamides are named in the similar way as sulfonamide but the prefix "sulfon" should 
be changed to "sulfen". The nomenclature of the sulfenamides has not been systematized 
thoroughly.
113
 
The chemistry of sulfenamides is much less explored. Number of workers 
reported the thermal instability of the sulfenamides.
114,115
 Interactions between the lone 
pairs of electrons on sulfur and nitrogen may destabilize the S-N bond polarization.
116
 
Introduction of electron withdrawing group (EWG) on the aryl group attached to either N 
or S atom increases the stability of sulfenamide significantly.
113,117
   
Sulfenamides are photolabile compounds classified as type-1 phototherapeutic 
agents.
117
 They are reported to generate abundant free radicals upon photoexcitation with 
UV/Visible light. These photolyzed compounds cause cell death in a dose dependent 
manner. Photochemotherapy is a form of therapy which uses light sensitive compounds 
that are nontoxic and upon exposure to light, they become toxic to the targeted malignant 
and other diseased cells. Phototherapeutic agents are classified into two broad categories 
type-1 and type-2.
117
 In type-1, absorption of light by the photosensitizer causes bond 
fragmentation to produce reactive intermediates such as free radicals, which induces cell 
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death. Type-2 processes induce cell death by generation of reactive oxygen species 
(ROS) like hydroxyl radical, superoxide radical anion. Photosensitizer upon excitation 
transfers energy to nearby molecular oxygen to produce singlet oxygen and subsequently 
produce ROS like, hydroxyl radical, superoxide radical anion which are responsible for 
the cell death. Thus type-2 process is facilitated by singlet oxygen and needs red light for 
optimal generation of singlet oxygen, in contrast the type-1 process does not require 
oxygen for activity and therefore the type-I process could be useful for removal of lesions 
under hypoxic conditions.  
Sulfenamide modified nucleosides are underdeveloped as compared to the azido 
modified nucleosides. If sulfenamide modified nucleosides will generate the aminyl 
radical successfully, they can have advantage over azido modified nucleosides as they 
should be stable under the conditions required for the standard solid phase synthesis of 
deoxynucleosides.
105,107,118
   Thus the sulfenamides can serve as more convenient 
substrates for the synthesis of nucleotides and oligo nucleotides. 
1.4.2. Sulfenamides as potential antitherapeutics 
 
Several sulfenamide derivatives have been developed in past few decade 
possessing medicinal values. The pyridinamine sulfenamide, 72 and oxazolidinone 
sulfenamide, 73 (Figure 17) are reported to inhibit platelet lipoxygenase and leukocyte 
migration.
113
 Sulfenamide 73 also displayed the antiasthmatic properties. The pyridyl 
sulfenamide, 74 showed the antitumor activity against tumor cells in female mice. 
Omeprazole, 75 is used for the treatment of gastric ulcers and shows its activity by 
inhibiting the gastric (H+/K+)-ATPase present in the acidic compartments of the 
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parietal.
119,120
 Omeprazole is a prodrug and is transformed into the active form in acidic 
media to produce the effect.  
 
 
Figure 17. Structure of sulfenamide derivatives with medicinal applications 
 
1.4.3. Nucleosides modified with sulfenamide moieties 
 
Kuttappan and coworkers observed the formation of the nitrogen (N
6
) centered 
aminyl radical in 2'-deoxyadenosine (dAdo).
121 
They prepared two different modified 2'-
deoxyadenosines, N
6
-[phenylsulphenyl]-2'-deoxyadenosine, 79 (Scheme 16) and N
6
-[2-
nitrophenylsulphenyl]-2'-deoxyadenosine, 80 (Scheme 17) to study the photochemical 
properties. N
6
-[phenylsulphenyl]-2'-deoxyadenosine was prepared from 2'-
deoxyadenosine, 76. Silyl protection of hydroxyl groups in the deoxyadenosine gave 
silylated deoxyadenosine 77.
122,123
 Nucleophilic attack of the exo 6-amino group of 77 on 
the phenylsulphenyl chloride, afforded protected sulfenamide 78. Further TBAF assisted 
removal of silyl protection group in 78 afforded N
6
-[phenylsulphenyl]-2'-
deoxyadenosine, 79.
124
  
 
Scheme 16. Synthesis of N
6
-[phenylsulphenyl]-2'-deoxyadenosine 
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Similarly the N
6
-[2-Nitrophenylsulphenyl]-2'-deoxyadenosine, 80 was prepared 
from 2'-deoxyadenosines, 76 in one step. Treatment of 2'-deoxyadenosines, 76 with 2-
nitrophenylsulphenyl chloride, in presence of TMSCl and pyridine afforded N
6
-[2-
nitrophenylsulphenyl]-2'-deoxyadenosine, 80.
125
 
 
Scheme 17. Synthesis of N
6
-[2-nitrophenylsulphenyl]-2'-deoxyadenosine
121
 
 
The UV photolysis of compound 79 (Scheme 18) and 80 was performed in 20% 
acetonitrile/water. Both compounds displayed good absorption in the near UV region, 
and were irradiated at 302 nm. Cleavage of the N-S bond in 79 and 80 observed to afford 
dAdo as a major product. The products from the photolysis of N
6
-[2-
nitrophenylsulphenyl]-2'-deoxyadenosine 80 were analyzed by HPLC and characterized 
by mass spectrometry.  They also checked the reactivity of both compounds 79 and 80 by 
irradiating them with γ-rays and observed that the N6-[phenylsulphenyl]-2'-
deoxyadenosine 79, was more reactive than the compound 80. Also the aminyl radical 
formation was confirmed by pulse radiolysis method.  
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Scheme 18. Mechanism for the formation of aminyl radical from N
6
-[phenylsulphenyl]-2'-
deoxyadenosine
121
 
 
Wagner et al
126 
reported the formation of the dAdo N
6
-aminyl radicals from the 
2'-deoxyadenosine (dAdo) containing photoactive hydrazone substituents (Scheme 19). 
They prepared three derivatives 86a, 86b and 86c of 2'-deoxyadenosine containing the 
hydrazine substituent at N
6
 to generate N
6
-aminyl radicals of dAdo. 
 
 
Scheme 19. Synthesis of 2'-deoxyadenosine containing the hydrazine substituent at N
6
.
126
 
 
All three derivatives of dAdo showed UV absorption between 300 and 400 nm 
and upon UV photolysis in presence of glutathione, H-donor produced dAdo N
6
-aminyl 
radicals and benzylidene iminyl radicals. The photolysis studies were performed in the 
presence of non-modified dAdo in order to mimic the reactions taking place in DNA. N
6
-
aminyl radical, 87 and benzylidine radicals, 88 recombined to yield 2-
(benzylideneamino)-2'-deoxyadenosine 92 (Scheme 20) alternatively the N
6
-aminyl 
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radical also undergoes intramolecular addition to non-modified dAdo. Subsequently 
compound 92 undergoes autooxidation to produce 93. 
 
 
Scheme 20.  Generation of the aminyl radical and its subsequent reactions from 6-N-hydrazine-2'-
deoxyadenosine substrates.
126
 
 
   2. RESEARCH OBJECTIVES 
The first goal of my dissertation was to clarify the ambiguity in the previously 
described mechanism of inhibition of ribonucleotide reductase (RNR) enzyme by 2'-
chloro-2'-deoxyuridine. The initial target was to synthesize 6-O-nitro-1,5-
dideoxyhomosugar derivatives with chlorine, bromine or tosyl substituent at the C2 
position from diacetone glucose via multistep synthetic routes. The biomimetic model 
reactions (intended to mimic the radical-initiated reactions postulated to occur at active 
sites of RNR) with these 2-substituted hexofuranoses were designed to provide chemical 
evidence which would distinguish the nature of the elimination of chlorine from 2'-
chloro-2'-deoxyuridine upon its incubation with the enzyme.  
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The model 6-O-nitro-1,5-dideoxyhomoribofuranose derivatives with halo (chloro, 
94 or bromo, 95; Figure 18) substituent at C2 position upon treatment with 
Bu3SnH/AIBN were expected to undergo radical-initiated fragmentation with elimination 
of the C2 halo substituent as radical to give furanone e with no deuterium incorporation 
at C2. In contrast, tosyl group from 6-O-nitro-2-O-tosyl precursors was expected to 
depart as anion upon subjection to radical fragmentation with Bu3SnH/AIBN to give 
furanone h with 100% deuterium incorporation at C2 (Scheme 21).  
 
Scheme 21. Expected results from the biomimetic fragmentation of 6-O-nitro-1,5-dideoxyhomoribose 
derivatives 
 
To probe the effect of streochemical inversion corresponding 6-O-nitro-1,5-
dideoxy homoarabinofuranose derivatives 97, 98 and 99 were designed with substituents 
at C2 position in anti-orientation to the C3-hydroxyl group (Figure 18). I also designed 
the 3-O-methyl substrates with ribo (syn) and arabino (anti) configurations (100- 105). 
These 3-O-methyl precursors were expected to probe the role of proton on the 3-hydroxy 
group. The 3-O-methyl precursors lack the possibility to be converted to 3-keto product, 
an important intermediate during the RNA-catalyzed reactions.  
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Figure 18. 2-Substituted hexofuranoses and 3-O-methyl hexofuranoses 
  
Kinetic experiments were also planned to provide additional evidence to support 
the results obtained from biomimetic model reactions. Kinetic experiments would allow 
discrimination between heterolytic C2'-chlorine bond cleavage (with departure of 
chloride anion) and homolytic C2'-chlorine bond cleavage (with departure of chlorine 
radical) upon regioselective generation of radical at C3' (carbon-β). In order to study the 
kinetics, the progress of the reaction (rate)  for 6-O-nitro-1,5-dideoxyhomohomosugar 
derivatives with chlorine, bromine or tosyl substituent at the C2 position were proposed 
to be investigated by 
1
H NMR. The rate of reaction is expected to be lower in the case of 
departure of C2 chlorine as an anion when compared to the elimination of C2 tosyl group 
as an anion. Whereas, the rate is expected to be higher for the departure of chlorine as a 
radical than that of tosyl anion.  
In the second objective of my dissertation I proposed to synthesize azido modified 
nucleosides, sulfenamide modified nucleosides and 2-azidolyxofuranoside derivatives.  
The nucleosides are designed to have the azido or sulfenamide substitution at a specific 
site in the sugar or in the base moiety. These compounds upon subjection to a radiation 
produced electrons, were expected to generate aminyl radical (RNH•) at a specific site. 
Generation of the RNH• and their subsequent reactions were proposed to be monitored 
40 
 
using electron spin resonance (ESR) spectroscopy. These studies were designed to 
understand the mechanism of damage in various DNA model structures 
I planned to synthesize 2'-azido-2'-deoxycytidine (2'-AZdC, 106) and 4'-
azidocytidine (4'-AZC, 107) to explore the possibility of formation of aminyl radical and 
to study its subsequent reactions (Figure 19). In 2'-AZdC the aminyl radical site is 
attached to a 2
o 
C-atom (2'), where as in 4'-AZdC, the aminyl radical site is attached to a 
3
o 
C-atom (4') in the sugar moiety, respectively. The difference in the stereo and 
electronic environment of these site-specific RNH• would be expected to clarify the 
difference in their reactivity. 
 
Figure 19.  Structure of 2'-AZdC and 4'-AZC  
 
To avoid the interaction of the transient radical with the nucleoside heterocyclic 
bases, I also designed 2-azidolyxofuranoside derivatives as a, simpler abasic models. I 
proposed to synthesize methyl 2-azido-2-deoxy-α-D-lyxofuranoside and its deuterium 
labeled analogues. The 2-azidolyxofuranoside derivatives (e.g., 108; Scheme 22) were 
expected to generate aminyl radical, 109 and the reactive aminyl radical was further 
anticipated to participate in the intramolecular C5 hydrogen abstraction to generate 5'-
sugar radical, 110. In 2-azidolyxofuranoside derivatives the substituents at C1 and C2 
have the trans relative configuration and with removal of base we could further drive 
intramolecular interaction to produce the expected 5'-sugar radical. The deuterium 
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analogues of the 2-azidolyxofuranoside were designed to provide additional evidences 
about the position of the radical species that formed from the bi- or uni-molecular 
abstraction of hydrogen in sugar. 
 
Scheme 22.  Formation of aminyl radical from [
2
H3]-methyl 2-azido-2-deoxy-α-D-lyxofuranoside and 
its subsequent reaction 
 
I was also interested to examine if sulfenamide modified nucleosides which might 
also serve as a suitable substrate for the site specific generation of aminyl radical via 
radiation produced electrons. The synthesis of nucleosides with sulfenamide substitution 
at specific sites, either in the sugar (111 and 112) or base (113) were planned (Figure 20). 
Although, nucleosides with sulfenamide modifications are less studied compared to azido 
analogues, the formation of RNH• from sulfenamides has been reported. If these 
sulfenamides would generate the aminyl radical successfully they could be incorporated 
into the deoxyoligonucleotides.  Compared to the azido modified nucleosides the 
sulfenamide modified nucleosides are expected to be more stable towards the 
phosphoramidite reagents used for the solid phase deoxyoligonucleotides synthesis.  
 
Figure 20.  Sulfenamide modified nucleosides for generation of N-centered radical at sugar or base 
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3. RESULTS AND DISCUSSION  
3.1. Modeling inhibition of ribonucleotide reductase by 2-substituted hexofuranoses 
3.1.1. Synthesis of 2-substituted 1,5-dideoxyhomosugar analogues 
Synthesis of methyl 5-deoxy-2,3-O-isopropylidene-β-D-ribo-hexofuranoside 120 
which served as convenient starting material for the preparation of model compounds, 
started with regioselective oxidation of 1,2-O-isopropylidene-α-D-glucose 114. The 
critical steps in this synthesis of 120 were stereochemical inversion of configuration at 
C3 and regioselective deoxygenation at C5. Thus treatment of 114 with (Bu3Sn)2O in 
chloroform and Br2 afforded the 5-ulose 115. Silylation of the hydroxyl group in 115 
using TBDMSCl gave 116. Deoxygenation of 116 using tosyl hydrazine via formation of 
tosylhydrazone yielded 5-deoxy sugar 117. The configuration of hydroxyl group at C3 
position in 117 is inverted by oxidation and further stereoselective reduction using 
sodium borohydride. Thus treatment of 117 with CrO3 in pyridine afforded 118 and 
subsequent stereoselective reduction with sodium borohydride yielded 119. Methanolysis 
of 119 and one-pot treatment with acetone gave 120 (~40% overall)
48
(Scheme 23). 
 
Scheme 23. Synthesis of methyl 5-deoxy-2,3-O-isopropylidene-β-D-ribo-hexofuranoside 
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Benzoylation of 120 using benzoyl chloride and selective deoxygenation of the 
resulting 121 at the anomeric carbon with excess (5 equiv.) boron trifluoride etherate and 
triethylsilane
127,128
 produced a mixture of 122 and 123 due to the partial removal of the 
isopropylidene protection group (Scheme 24). Treatment of 122 with 1,2-
dimethoxypropene/acetone/TsOH gave protected 1,4-anhydroalditol 123 (44% overall 
from 120). Debenzoylation of 123 and subsequent iodination and deacetonization 
produced 6-iodo furanitol 126 (53% from 123).  
 
Scheme 24.  Synthesis of 6-O-nitro-3-hydroxy-2-O-tosyl homosugar precursor 
Displacement of iodide with AgNO3/CH3CN yielded 1,4-anhydro-5-deoxy-6-O-nitro-
D-ribo-hexofuranitol 127 (89%); a key substrate for further studies. Direct tin-mediated 
tosylation
129
 of 127 produced a mixture of two isomers, from which the major 2-O-tosyl 
regioisomer 96 was isolated in 43% yield. 
 Alternatively 96 was obtained by tin-mediated benzylation of 127 with p-
methoxybenzyl (PMB) chloride which also yielded a mixture of isomers from which 3-O-
PMB regioisomer 128 was isolated (Scheme 25). Subsequent treatment of 128 with 
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TsCl/pyridine followed by removal of PMB group from resulting 129 with ceric 
ammonium nitrate (CAN) afforded 96 (54% from 128).  
 
Scheme 25.  Alternative synthesis of 6-O-nitro-3-hydroxy-2-O-tosyl homosugar precursor 
Mitsunobu-assisted chlorination of 128 with freshly prepared HCl•pyridine gave 
protected 2-chloro-D-arabino-hexofuranose 130 (62%) a substrate for further studies. 
Similar treatment of 128 with freshly prepared HBr•pyridine gave 2-bromo counterpart 
131 (49%). Debenzylation of 130 and 131 with CAN gave 2-chloro substrate 97 (78%) 
and 2-bromo substrate 98 (79%), respectively (Scheme 26). 
 
Scheme 26.  Synthesis of 6-O-nitro-3-hydroxy-2-chloro/bromo homosugar precursor  
 
The 2-chloro(or bromo)-D-ribo-hexofuranose was also prepared from 128 via double 
inversion approach. Thus, Mitsunobu-treatment of 128 with benzoic acid produced 2-O-
benzoyl-D-arabino-hexofuranose 132. Debenzoylation of 132 and treatment of the 
resulting 133 with TfCl/DMAP produced reasonably stable 2-O-triflate 135. 
Displacement of triflate with LiCl or LiBr followed by debenzylation of the resulting 136 
45 
 
or 137 with CAN gave 2-chloro(or bromo)-D-ribo-hexofuranose 94 or 95. Tosylation of 
133 followed by debenzylation of the resulting 134 afforded 2-O-tosyl-arabino substrate 
99 (Scheme 27). 
 
Scheme 27. Synthesis of 6-O-nitro-3-hydroxy-2-chloro/bromo/tosyl homosugar precursor 
 
I also prepared 2-substituted 6-O-nitro-3-O-methylhexofuranitol precursors for 
comparative studies. Thus, tin-mediated methylation of 127 produced a mixture of 
isomers 138/139 from which the 3-O-methyl regioisomer 138 was isolated in 38% yield 
(Scheme 28). Treatment of 138 with TsCl in pyridine yielded ribo 2-O-tosyl sugar 102 
whereas Mitsunobu-treatment of 138 with benzoic acid followed by debezoylation of 
resulting 140 and subsequent tosylation of 141 gave arabino 2-O-tosyl epimer 142a. 
Mitsunobu-assisted halogenation of 138 with HCl•pyridine or HBr•pyridine gave 2-
chloro(or 2-bromo)-3-O-methyl-D-arabino-hexofuranose 103 or 104. Triflation of 141 
and subsequent displacement of triflate in 142b with LiCl or LiBr gave 2-chloro(or 
bromo)-D-ribo epimers 100 or 101. 
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Scheme 28.  Synthesis of 6-O-nitro-3-O-methylhexofuranitol precursors 
 
3.1.2. Biomimetic studies 
 3.1.2.1. 6-O-Nitro-3-hydroxy-2-O-tosyl homosugar precursors 
Treatment of the 6-O-nitro-2-O-tosyl ribo precursor 96 with Bu3SnH/AIBN with 
toluene at 95 
o
C for 1 h gave 3-keto product 143a [(R)-2-(hydroxyethyl)-3(2H)-
dihydrofuranone] which was found to be in equilibrium with cyclic hemiacetal 144a 
(66%, ~1:1; 
1
H and 
13
C NMR; Scheme 29) in addition to 6-hydroxy byproduct resulting 
from homolysis of nitrate ester without elimination of tosyl group (Table 1, entry 1). 
13
C 
NMR shows ketone peak at 215.9 ppm for 143a and hemiacetal peak at 114.9 for 144a. 
Analogous treatment of 96 with Bu3SnD, instead of Bu3SnH gave 2-deuterio epimers 
(2R/S, ~1:1) of 143b in equilibrium mixture (~ 1:1) with 144b (71%, entry2). 
1
H NMR 
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spectrum of 143b/144b corresponded to that of the 143a/144a with reduction of the 
integrated intensity for the H2/2' signal to half and simplification of the H1/1' signals. 
The 
13
C NMR spectrum 143b/144b showed triplets (with 1:1:1 intensity) at 36.7 and 38.9 
for carbons 2 as results of splitting to deuterium while MS and HRMS showed up to 95% 
of isotopic ([
2
H]) incorporation. Formation of 143a or 144b is consistent with generation 
of 6-oxyl radical 146 and abstraction
34,48 
of H3 to give hydroxyl-containing C3 radical 
147a. Loss of toluenesulfonic acid from 147a, with a concerted [1,2]-electron shift, 
would produce the C2-radical intermediate 147b. Hydrogen or deuterium transfer from 
the stannane to 147b would give 143a or 143b (Scheme 29). Treatment of the 143a/144a 
mixture with BzCl provided a stable 6-O-benzoyl keto product 145a. Analogous 
treatment of 143b/144b with BzCl provided 6-O-benzoyl 2-deuterio epimer 145b.  
 
Scheme 29. Proposed mechanism for elimination of tosyl group from 6-O-nitro-3-hydroxy-2-O-tosyl 
homosugar precursor, 147a 
 
These results are in agreement with Barton’s nitrite130 and Wagner’s δ-substituted 
aryl ketone
131
  photolysis studies that had shown that a six-membered transition state is 
favorable for abstraction of hydrogen by an oxyl radical. Also [1,5]-hydrogen shift was 
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observed with oxyl radicals generated from nitrate esters with Bu3SnH in 
carbohydrates.
44
 The radical-induced loss of toluenesulfonic acid (147a to 147b) is 
analogous to the rearrangement which converts 2'-O-tosyladenosine into 9-(2-deoxy-α-D-
threo-pentofuranosyl)adenine via [1,2]-hydride shift from C3' to C2' with loss of 
tosylate.
45,132
 The present concerted [1,2]-electron shift with generation of a carbonyl 
group at C3' provides the driving force for expulsion of toluenesulfonic acid via seven-
membered hydrogen-bonded intermediate 147a is also in agreement with a theoretical 
studies
31,133
 on RNR-catalyzed deoxygenation reactions as well as biomimetic studies.
33,48
 
 
entry substrate reagent product ratio
b
 yield
c 
(%)
 
No X Y 
1 96 OTs H Bu3SnH 143a:144a 1:1 66
d
 
2 96 OTs H Bu3SnD 143b:144b 1:1 71
d
 
3 99 H OTs Bu3SnH 143a:144a 1:1 93 
4 99 H OTs Bu3SnD 143b:144b 1:1 93 
                      
                       Table 1. Biomimetic studies with 6-O-nitro-3-hydroxy-2-O-tosyl homosugar precursors
a
 
a 
Reactions were performed on 0.057 mmol (96 or 99) scale of substrates (0. 029-
0.047 M) with 5 equiv. of Bu3SnH(D) and 2 equiv. of AIBN in toluene (95
°
C, 1-2 h.). 
b 
Determined by 
1
H NMR. 
c
 Isolated yields. 
d
 1,5-Dideoxy-2-O-tosyl-D-ribo-hexofuranose 
was also formed (19%).  
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3.1.2.2. 6-O-Nitro-3-hydroxy-2-chloro (or bromo) homosugar precursors  
Similar treatment of 2-chloro 94 and 2-bromo 95 ribo precursors with Bu3SnH also 
produced a 3-keto/hemiacetal mixture 143a/144a (~1:1; 81%, entry 1 and 64%, entry 3; 
Table 2). Analogous treatment of 94 or 95 with Bu3SnD yielded mixture of 143b/144b as 
2-deuterio epimers indicating elimination of chloride and bromide, as anions, rather than 
as chlorine or bromine radical.  
 
 
entry substrate reagent product ratio
b
 yield
c 
(%)
 
No X Y 
1 94 Cl H Bu3SnH 143a:144a 1:1 81 
2 94 Cl H Bu3SnD 143b:144b 1:1 67 
3 95 Br H Bu3SnH 143a:144a 1:1 64 
4 95 Br H Bu3SnD 143b:144b 1:1 68 
5 97 H Cl Bu3SnH 143a:144a 1:1 97 
6 97 H Cl Bu3SnD 143b:144b 1:1 82 
7 98 H Br Bu3SnH 143a:144a 1:1 67
d
 
8 98 H Br Bu3SnD 143b:144b 1:1 54
d
 
 
Table 2. Biomimetic studies with 6-O-nitro-3-hydroxy-2-chloro(or bromo)-
homosugar precursors
a
 
a 
Reactions were performed on 0.094 mmol (94 or 97), or 0.078 (95 or 98) scale of 
substrates (0. 029-0.047 M) with 5 equiv. of Bu3SnH(D) and 2 equiv. of AIBN in toluene 
(95
°
C, 1-2 h.). 
b 
Determined by 
1
H NMR. 
c
 Isolated yields. 
d 
The reduced 
hydrodebrominated 2-deoxy byproduct was also isolated (~10-15%). 
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These results were unexpected since analogous radical cascade decomposition 
reactions with 2'-chloro-2'-deoxy nucleoside resulted in the elimination of chlorine 
radical giving sugar decomposition product without incorporation of deuterium.
34,47
 
Formation of hydrogen-bonded intermediates (e.g., 148; Scheme 30), leading to 
intramolecular deprotonation of C3-hydroxyl group, might facilitate loss of chloro or 
bromo substituent as chloride or bromide anion (as HCl or HBr) via heterolytic cleavage 
of C2-halogen bond. These results are in agreement with theoretical calculations
32
 and 
experimental results on inhibition of RNR by 2'-chloro-2'-deoxynucleotides
12,15
 and also 
reinforce the importance of deprotonation of C3'-OH group by E441 during enzymatic 
deoxygenation reaction.
12,134
 It is also noteworthy here that treatment of 2'-chloro(or 
bromo)-3'-thionocarbonate nucleosides with  Bu3SnH which generates 3'-deoxy C3' 
radical (depleted from participation in hydrogen-bonding interaction with C2' 
substituents) resulted in the loss of chlorine or bromine radical to give 2',3'-unsaturated 
nucleosides, while the analogous radical fragmentation of 2'-O-tosyl-3'-thionocarbonates 
nucleosides effected hydrogenolysis of C3' radical to give 3'-deoxy-2'-O-
tosylnucleosides.
49
 
 
Scheme 30. Proposed mechanism for elimination of halo substituents (chloro or bromo) from 2-
chloro 94 and 2-bromo 95 ribo precursors  
 
Heating of compounds 94, 95 and 96 in toluene without tin hydride and AIBN at 95 
o
C or even at 110 
o
C for up to 4 h resulted in the recovery of the intact substrates in 
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almost quantitative yields. This proved thermal stability of substrates 94, 95 and 96 under 
conditions used for model reactions and excluded possibilities of heterolytic dissociation 
of C2-substituents. The substrate 96 was also stable upon heating (95 
o
C/2.5 h) in polar 
aprotic solvent such as DMF.   
Since the hydrogen bonding to C2'-hydroxyl group (or other C2'-substituents) in 
nucleotide substrate is believed to play a critical role in the RNR-catalyzed heterolytic 
cleavage of C2'-heteroatom bond,
12,31
 we also performed model reaction on two sets of 
substrates which should preclude formation of the intramolecular hydrogen bonding 
between C3-hydroxyl group and  C2-substituent. One set was 2-substituted arabino 
precursors 97, 98 and 99 (with anti relations between substituents at C2 and C3) while 
the second set was 3-O-methyl precursors with both ribo (syn) and arabino (anti) 
configurations (100, 101, 102, 103,104 and 105). The second set also precludes formation 
of the crucial 3-keto intermediate, formed during RNA-catalyzed reactions. However, 
treatment of 6-O-nitro-2-chloro 97 or 2-bromo 98 substrates with Bu3SnH also, 
unexpectedly, produced a 3-keto/hemiacetal mixture 143a/144a (~1:1; 97%, entry 5 and 
67%, entry 7; Table 2) indicating elimination of chloride or bromide as anions rather than 
as chlorine or bromine radical. Analogous treatment of 97 and 98 with Bu3SnD yielded 
mixture of 143b/144b as 2-deuterio epimers (entries 6 and 8).  These results were 
especially surprising since hydroxyl group at C3 and halogen substituent at C2 are in -
anti-orientation what should preclude formation of hydrogen-bonded complexes between 
them. Apparently, elimination of halide anion via heterolytic cleavage of carbon-halogen 
bond might be facilitated by an eight-membered hydrogen-bonded intermediate of type 
150 between 6-OH group and chloro or bromo substituent (Scheme 31). 
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Scheme 31.  Proposed mechanism for elimination of C-2 substituents from 2-substituted arabino 
precursors 97, 98 and 99. 
 
3.1.2.3. 6-O-Nitro-3-O-methyl-2-substituted homosugar precursors 
The biomimetic reactions with 3-O-methyl precursors lacking the 3-hydroxyl group 
led to different fragmentation upon treatment with tin radical emphasizing the importance 
of deprotonation of  the 3'-hydroxyl group (and/or its participation in hydrogen bonding) 
during RNR-catalyzed reactions. Thus, treatment of 6-O-nitro-3-O-methyl-2-O-tosyl ribo 
substrate 102 with Bu3SnH/AIBN/toluene/Δ gave 2-(hydroxyethyl)-3-methoxyfuran 152a 
in 63% yield and the 6-hydroxy byproduct 152b (22%) without the loss of tosyl group 
(Table 3). These results suggest that seven-membered hydrogen-bonded intermediate 
147a, which cannot be formed with 3-O-metyl substrate 102, is critical for the ionic 
elimination of the tosylate group from C2 of 96. Treatment of 102 with Bu3SnD also 
yielded 152a and 152b without observed epimerization at C3 or deuterium incorporation 
at C3 (entry 2). The detrimental effect of the protecting groups (e.g., acetate) at C3 
hydroxyl for the deuterium exchange at C3 in the analogues homoribofuranose models 
has been noted.
135
 Fact that tosylate 102 is thermally stable while heating at 95 
o
C in 
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toluene suggest that radical or radical/ionic cascades of reaction is needed for the 
elimination of tosyl group (or tosylate) to form furane derivative 152a. 
 
 
entry substrate reagent product Yield
b
(%) 
No X Y 
1 102 OTs H Bu3SnH 152a 63
c
 
2 102 OTs H Bu3SnD 152a 61
c
 
3 105 H OTs Bu3SnH 152a 51
e
 
4 105 H OTs Bu3SnD 152a 50
e
 
 
Table 3. Biomimetic studies with 6-O-nitro-3-O-methyl-2-O-tosyl homo sugar substrates
a
 
a 
Reactions were performed on 0.055 mmol (102 or 105) scale of substrates (0. 027-
0.044 M) with 5 equiv. of Bu3SnH(D) and 2 equiv. of AIBN in toluene (95
°
C, 1.5 h.). 
b 
Isolated yields. 
c
 Compound 152b (22%) was also isolated. 
e 
Compound 152c (38%) was 
also isolated.  
A six membered transition state involving the affinity of the C1 α-proton in 102 
and the tosylate oxygen might lead to elimination of HOTs with generation of a 1,2-
double bond (Scheme 32). Further abstraction of the C4 hydrogen from the resulting 
resonance structure would produce furan 152a. Reaction of 3-O-methyl-2-O-tosyl 
arabino precursor 105 with Bu3SnH gave 2-(hydroxyethyl)-3-methoxyfuran 152a (51%) 
and the 6-hydroxy byproduct 152c (38%) without the loss of tosyl group, as was the case 
with ribo analogue 102 (entry 1). Analogous reaction with Bu3SnD also produced 152a 
and 152c without epimerization and no deuterium incorporation at C3 (entry 4). In this 
case of arabino precursor 105 the affinity of the C1 β-proton and the tosylate oxygen 
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might lead to elimination of HOTs with generation of a 1,2-double bond. Further 
abstraction of the C4 hydrogen from the resulting resonance structure would produce 
furan 152a.           
 
Scheme 32. Proposed mechanism for elimination of TsOH from 6-O-nitro-3-O-methyl-2-O-tosyl ribo 
substrate 102 
 
Reaction of 3-O-methyl-2-chloro(or bromo) ribo precursors 100 or 101 with Bu3SnD 
resulted in the formation of vinyl ether 155 without deuterium incorporation (entry 1 and 
2). 
13
C NMR spectrum of 155 shows olefinic peak at 90.2 and 157.7 ppm while 
1
H NMR 
spectrum shows olefinic hydrogen at 4.60-4.70 ppm. Formation of 155 is consistent with 
generation of C3 radical 154 and subsequent elimination of chlorine or bromine as radical 
(Scheme 33) in analogy to the β-elimination of phenylsulfinyl radical upon generation of 
the radical at vicinal carbon at similar model systems.
35
 Lack of ability to form the 
hydrogen-bonded intermediate of type 148 in 100 or 101 and their inability for the 
conversion to 3-keto product (as in case of 3-hydroxy substrates 94 or 95) can be 
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accountable for the radical elimination of the halo substituent from C2 position upon 
generation of the radical at C3. 
 
Scheme 33. Proposed mechanism for elimination of C-2 substituents from 3-O-methyl-2-chloro(or 
bromo) ribo precursors 100 and 101. 
 
Treatment of 3-O-methyl-2-chloro( or bromo) arabino precursors 103 or 104 with 
Bu3SnD also resulted in the elimination of halo substituent as radical to give the vinyl 
ether 155 without deuterium incorporation (entries 3 and 4). The reactions, apparently, do 
not involve participation of 6-hydroxyl group as in the case of 3-hydroxy-2-halo arabino 
precursors 97 and 98 in which hydrogen-bonded intermediate of type 150 was most 
probably accountable for the elimination of halo substituent from C2 as chlorine or 
bromine anion. Also since formation of 3-keto product(s) which might be a driving force 
for the reaction is precluded with 3-O-methyl substrate 103 or 104 
 
entry substrate reagent product Yield
b
(%) 
No X Y 
1 100 Cl H Bu3SnD 155 55 
2 101 Br H Bu3SnD 155 37
c
 
3 103 H Cl Bu3SnD 155 63 
4 104 H Br Bu3SnD 155 47
c
 
 
Table 4. Biomimetic studies with 6-O-nitro-3-O-methyl-2-chloro(or bromo)-
homosugar substrates
a
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a 
Reactions were performed on 0.088 mmol (103 or 100), or 0.074 (104 or 101) scale 
of substrates (0. 027-0.044 M) with 5 equiv. of Bu3SnH(D) and 2 equiv. of AIBN in 
toluene (95
°
C, 1.5 h.). 
b 
Isolated yields. 
c
The reduced hydrodebrominated 2-deoxy 
byproduct was also isolated (~15-25%). 
3.1.3. Kinetic studies 
Kinetic experiments were also planned to measure the rate of elimination of the 
substituent from the C2 position. The landmark work by Newcomb and Wagner on 
photochemistry of γ-substituted aryl ketones established high rates for the departure of 
halogen upon generation of radical at adjacent carbon.
131,136
 Scheme 34 illustrates the 
conversion of 1,4-diradical B to D via the monoradical C with β-elimination of halogen 
as radical. Wagner et al. proposed that the rate constant for the radical elimination 
reaction increases in the order Cl < Br < I. Thus, I was expecting the higher rates of 
departure of halo-substituents (Cl, Br) from C2-position upon generation of radical at C3-
position than for departure of tosyl anion.  While rate of reaction is expected to be lower 
in the case of departure of C2 chlorine as an anion when compared to the elimination of 
C2 tosyl group as an anion. 
 
Scheme 34. Photoactivated elimination of δ-substituent from aryl ketone 
 
 In order to study the kinetics for my reactions, the progress of the biomimetic reactions 
was followed by calculating disappearance of a peak for the starting material or 
appearance of a peak for the product in 
1
H NMR spectra of the crude reaction mixture. 
57 
 
Values of -log(C/C0) was plotted against time t (Figure 21). Where, C/C0 is the ratio of 
concentration of 6-O-nitrohomo sugar derivative at time t to the initial concentration of 
6-O-nitro homosugar derivative. 
Parallel experiments of substrates 96, 97, 98 or 99 with Bu3SnH in toluene have 
been examined. It was found that the fragmentation of tosylate 96 in toluene-d8 with 
Bu3SnH and AIBN at 75
o
C was easy to follow and showed 90-95% consumption of 96 in 
2.5 h with the formation of the 143a/144a mixture as the sole product (80-85% yield 
based on TLC and 
1
H NMR). (It is noteworthy that heating of 96 in toluene-d8 at 55
 o
C 
showed only 50% consumption of substrate 96 after 2.5 h.) Experiments with arabino 
tosylate 99 and arabino chloro substrate 97 at 75 
o
C revealed that the process with 99 
was only slightly faster than with 97. Interestingly fragmentation of ribo tosylate 96 with 
the formation of 143a/144a proceeded with the rate similar to the one observed for 97. 
Reaction of the bromo substrate 98 with Bu3SnH at 75 
o
C resulted in the formation of the 
reasonable quantity of the 2-deoxy byproduct(s) resulting from radical-mediated 
hydrogenolytic cleavage of carbon-bromine bond in addition to the 143a/144a mixture 
making the quantitative analysis of 
1
H NMR spectra difficult.  
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Figure 21. Pseudo-first order plots for the conversion of 97 (chloro) and 99 (tosylate) into 143a/144a 
 
3.1.4. Mechanistic considerations  
Various theoretical, chemical and biochemical mechanism have been proposed for the 
conversion of ribonucleoside 5'-diphosphates to 2'-deoxynucleotides by RDPRs. Stubbe, 
et al.
25
proposed mechanism for the inactivation of the RDPR by 2'-chloro-2'-
deoxyuridine and emphasized on the departure of chlorine as an anion from the C2 
position. The furanone K formed upon successive β-eliminations is a Michael acceptor 
which alkylates the nucleophiles on enzyme and causes covalent enzyme inhibition 
(Figure 6).
40
 
In contrast to Stubbe's hypothesis, Robins et al. proposed departure of chlorine 
substituent from 2'-position of nucleoside as a radical rather than as an anion.
49,137
 
(Scheme 1) However, the drawbacks of Robins hypothesis is that, it gives the furanone 
product 11 with only 15-30% deuterium incorporation at C2', which makes the spectral 
analysis of the product difficult. 
y = 0.0068x + 0.0204 
R² = 0.9968 
y = 0.0048x + 0.0003 
R² = 0.9993 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 50 100 150 200
-log(C/Co) 
time (min) 
Conc.[-Log(C/C0)] OTs
Conc.[-Log(C/C0)] Cl
Linear (Conc.[-
Log(C/C0)] OTs)
59 
 
In the case of 6-O-nitro-3-hydroxy-2-O-tosyl homosugar precursors I observed 
that the generation of the radical at the 6-oxy position leads to abstraction of the 
hydrogen from the 3-position. This mechanism is in agreement with the photolysis 
studies by Barton’s nitrite ester42 and Wagner’s δ-substituted aryl ketone131 photolysis 
studies wherein they have shown that a six-membered transition state is favorable for the 
abstraction of hydrogen by an oxy radical. The mechanism proposed in this dissertation 
for the expulsion of the toluenesulfonic acid via formation of the seven-membered 
hydrogen-bonded intermediate is also in agreement with theoretical studies.
31,133
 
However theoretical modeling
133
 of RDPR-catalyzed 2'-deoxygenation showed that the 
carboxylate group of glutamate forms a hydrogen bond with the 3'-OH and the H-donors 
form hydrogen bonds with 2'-OH and eliminates as water. Similarly the mechanism 
proposed in this dissertation for the heterolytic cleavage of the TsO–C2 linkage, is based 
on the attraction between the cis 3-OH in 96 and a tosylate oxygen. While in the case of 
the arabino tosylate 99 when there is no cis 3-OH, the 143b/144b mixture was obtained 
as the product. In this instance the tosyl group at the C2 position might have formed a 
hydrogen bond with the 6-oxy radical, resulting in the heterolytic cleavage of the TsO–
C2 bond.   
Treatment of 6-O-nitro-3-hydroxy-2-(chloro or bromo) precursors in ribo or arabino 
configuration with Bu3SnH also gave 143b/144b. In all of the cases loss of bromide or 
chloride anions from an intermediate C3 radical occurred rather than homolytic loss of a 
halogen atom.  
Elimination of halo substituent from the C2 position observed only in case of 3-O-
methyl precursors. Thus treatment of the 2-chloro-3-O-methyl ribo 100 and arabino 103 
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substrates with Bu3SnH gave vinyl ether 155. Similarly the 2-bromo-3-O-methyl ribo 101 
and arabino 104 epimers also gave 155. In this case since the formation of the ketone is 
precluded the elimination of the halogen atom occurred as a radical.  
Ramos et al.
32
 proposed that the substituent from the C2 position can leave as a 
radical or anion depending on the presence or absence of a basic residue capable of 
deprotonating the 3'-HO group. In the biomimetic studies I performed, clearly the 
elimination of the substituent is possible without a basic residue.  
Treatment of the 3-O-methyl-2-O-tosyl ribo 102 or arabino 105 substrates with 
Bu3SnH gave aromatized 2-(2-hydroxyethyl)-3-methoxyfuran (152a). Since in this case 
also the formation of the ketone is precluded the -proton on C1 and a tosylate oxygen 
forms hydrogen bonding and the substituent departs as anion. Also, in the stability study 
with the tosylate 102 in toluene at 95 
o
C, no elimination of tosylate observed which 
indicates that generation of a C3 radical was necessary for elimination of tosylate and 
production of 152a. 
Thus this biomimetic studies with the 6-O-nitrohomosugar precursors provide 
explanation for the two-electron elimination of hydrogen-bonded water in the mechanism 
proposed for the reduction of nucleoside diphosphate substrates by Stubbe. It also 
provides an explanation for the one-electron dissociation of chlorine radical from 
substrate 2'-chloro-2'-deoxynucleoside di(or tri)phosphate inactivators of RNR and the 
MoaA enzyme. 
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3.2. Azido sugar and nucleosides analogues as precursors to aminyl radicals 
3.2.1. 2-Azido-2-deoxy-α-D-lyxofuranosides and its labelled analogues 
 
Based on Sevilla's work on 3′-azido-3′-deoxythymidine (3′-AZT) and 5′-azido-5′-
deoxythymidine (5'-AZT) analogues,
79
 studies with the simple abasic system to avoid the 
interaction of the transient radical with the nucleoside heterocyclic bases were 
investigated. So, I designed abasic model to investigate the H-atom abstraction pathway 
by RNH•. The azido group is in trans relative configuration to H3 and H4 in cis relative 
configuration to H1 and H5,5'. By employing the abasic model we could further drive 
bimolecular interaction to produce the 5'-sugar radical and the H-atom abstraction 
pathway by RNH• could be studied without interference.  
The 2-azido-2-deoxy-α-D-lyxofuranoside, 108 and its analogues upon electron 
attachment in γ-irradiated aqueous glassy (7.5 M LiCl) systems at 77 K in the absence of 
oxygen is anticipated to generate the neutral aminyl radical (RNH•, 109). Aminyl radical, 
109 is expected to undergo intramolecular hydrogen atom abstraction to produce 110 
(Scheme 22). To learn about the position of the radical species that formed from the 
biomolecular abstraction of hydrogen in sugar, compounds are designed with deuterium 
labeled at methyl group at anomeric carbon atom, C4, C5 and C5, C5'. Formation of the 
aminyl radical (RNH•) via one electron attachment, its participation in the intramolecular 
C5 hydrogen abstraction and subsequent reactions will be investigated by EPR method 
developed by Dr. Sevilla.  
3.2.1.1. Synthesis of 2-azido-2-deoxy-α-D-lyxofuranosides and its labelled analogues.  
 
The azido sugar analogues 161a and 161b were synthesized using the modified 
Fleet and Smith procedure
138
 (Scheme 35). Treatment of the D-xylose 156a with 0.5% 
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HCl/CH3OH yielded Methyl D-xylofuranoside 157a as reported.
139
 Methyl D-
xylofuranoside 157a further treated with Conc. H2SO4/ acetone as reported
139
 resulted in 
(α/β, 3:2) mixture of 3,5-O-isopropylidine protected D-xylofuranoside. The α-anomer 
158a was isolated using column chromatography. Compound 158a was converted to 2-O-
triflate ester 159a upon treatment with trifluoromethanesulfonyl chloride (TfCl) and 4-
(dimethylamino)pyridine (DMAP) in methylene chloride.
140
 The yield and purity for 
159a is better than when the original procedure
138 
employing the triflic anhydride in 
pyridine was used. Azidation of 159a was accomplished by displacement of the triflate 
from 159a with NaN3 in DMF. In the final step of the synthesis the isopropylidene 
protection group was removed using AcOH to give methyl 2-azido-2-deoxy-α-D-
lyxofuranoside 161a.
138
 Analogous displacement of the triflate from 159a with [
15
N]-
NaN3 yielded 2-[
15
N]-azido isotopomer 160a. Subjection of 5-[
2
H]-D-xylose 156b to the 
same synthetic sequence yielded 5-deuterium labeled azido sugar 161b. 
 
Scheme 35. Synthesis of methyl 2-azido-2-deoxy-a-D-lyxofuranoside and its deuterium labeled 
analogues. 
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Analogous treatment of D-xylose 156a with 0.5% DCl/CD3OD in place of 0.5% HCl/ 
CH3OH produced methyl-d3 xylofuranoside 157c with 100% deuterium incorporation. 
Compound 157c was converted to methyl-d3 2-azido-2-deoxy-α-D-lyxofuranoside 108 
following the same synthesis method mentioned above.  
 
Scheme 36. Synthesis of deuterium labeled analogues of 2-azido-2-deoxy-α-D-lyxofuranoside.  
 
Subjection of 4-[
2
H]-D-xylose 162a to the same synthetic sequence as mentioned 
above yielded methyl-d3 4-deuterium labeled analogue 167a. Similarly, 5-[
2
H2]-D-xylose 
162b was converted to methyl-d3 5-dideuterium labeled azidolyxofuranoside 167b 
(Scheme 36). 
3.2.1.2. ESR characterization of electron-mediated formation of the aminyl radicals 
and their subsequent reactions.  
The radiation-produced electron-induced site specific formation of neutral aminyl 
radical ((RNH•/RND• (1-OMe-(C2)-NH•/1-OMe-(C2)-ND•)) and their reactions in 
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methyl 2-azido-2-deoxy-α-D-lyxofuranoside 161a, methyl 2-[15N]-azido-2-deoxy-α-D-
lyxofuranoside [
15
N]-161a, methyl 5-[
2
H]-2-azido-2-deoxy-α-D-lyxofuranoside 161b, 
[
2
H3]-methyl 2-azido-2-deoxy-α-D-lyxofuranoside 108, [
2
H3]-methyl 2-azido-2-deoxy-α-
D-4-[
2
H]-lyxofuranoside 167a, and [
2
H3]-methyl 2-azido-2-deoxy-α-D-5-[
2
H2]-
lyxofuranoside 167b in γ-irradiated homogeneous aqueous (D2O or H2O) glassy (7.5 M 
LiCl) system have been investigated.  
3.2.1.3a Assignment of the aminyl radical formed at C2 of 2-azido-2-deoxy-α-D-
lyxofuranosides and its labeled analogs 
 
From our assignment of RNH• (T(C2′)-14ND•) in 3′-AZT,79 the major HFCC 
values in 1-OMe-(C2)-
14ND• and its 15ND• isotopomer 1-OMe-(C2)-15ND• are expected 
from three sources – the axially symmetric anisotropic HFCC hyperfine coupling from 
the azide N-atom, the isotropic β-hydrogen coupling due to the H2-atom, and the 
deuterium coupling from the exchangeable NH/ND. The 77 K ESR spectrum (green) of 
1-OMe-(C2)-
14ND• formed via radiation-induced electron attachment in aqueous glassy 
(7.5 M LiCl/D2O (pH ca. 5)) sample of 161a obtained via γ-irradiation at 77 K is 
presented in Figure 22 (A). To make this assignment of 1-OMe-(C2)-
14ND• unequivocal, 
experiments were carried out using a matched sample of monoisotopically labelled 
15
N 
incorporated [
15
N]-161a and the results are presented in Figure 22 (B). Each 
experimentally recorded ESR spectrum shown in Figures 22 (A), and 22 (B) was 
obtained after subtraction of the 250 G Cl2•¯ spectrum.
79,141,142
 The red spectrum in 
Figure 22 (B) is assigned to 1-OMe-(C2)-
15ND•. The 1-OMe-(C2)-14ND• (green, Figure 
22 (A)) spectrum and 1-OMe-(C2)-
15ND• (red, Figure 22(B)) spectrum match very well 
with the simulated spectra generated using typical beta hyperfine coupling constant 
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(HFCC) value. Thus, with the aid of [
15
N]-161a, the unequivocal identification of the 
aminyl radical was achieved.  
 
Figure 22. Comparison of ESR spectra of the aminyl radical generated from methyl 2-azido-2-deoxy-
α-D-lyxofuranoside and its 15N isotopomer.  
 
Figure 22. The simulated spectra (blue) (for simulation parameters, see text) are 
superimposed on the top of the each experimentally recorded spectrum. The three 
reference markers (open triangles) in this figure and in other figures show the position of 
Fremy’s salt resonance with the central marker at g = 2.0056. Each of these markers is 
separated from each other by 13.09 G. 
 
3.2.1.3b Assignment of the radical species formed due to the reactions of 1-OMe-
(C2)-
14ND• in 2-azido-2-deoxy-α-D-lyxofuranosides and its labeled analogs 
 
Studies employing matched samples of [
2
H3]-methyl 2-azido-2-deoxy-α-D-
lyxofuranoside 108 and 161a yielded very similar ESR spectra. Similarities of the total 
hyperfine splitting, of the center of the spectra, and of line shapes in these two spectra 
clearly established that the aminyl radical spectrum is not affected by the deuteration of 
the methyl group at the anomeric carbon atom. Moreover, loss of the line components at 
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the wings owing to the axially symmetric anisotropic hyperfine coupling from the azide 
N-atom at 150 K and onwards (spectra 23 (C) to 23 (F)) showed that the site of radical 
generation due to subsequent reaction of the aminyl radical in lyxofuranose is not located 
at the OCD3 group or at the anomeric carbon atom C1. The site for the secondary radical 
is rather at C3, or at C4, or at C5 of the furanoside ring (Figure 23). This is further 
supported by the annealing studies (ca. 140 to ca. 165 K) of matched sample of [
15
N]-
161a which yielded spectra with similar total hyperfine splitting, similar center, and 
similar line shapes to those shown in Figures 23 (B) to 23 (F) (data not shown) 
 
Figure 23. Comparison of ESR spectra of the aminyl radical generated from methyl 2-azido-2-deoxy-
α-D-lyxofuranoside and [2H3]-methyl 2-azido-2-deoxy-α-D-lyxofuranoside 
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Figure 23. Comparison of the aminyl radical formation via (A) electron attachment at 77 
K and (B) to (F) the subsequent reactions of the aminyl radical shown via progressive 
annealing from 77 K to ca. 170 K in matched samples of methyl 2-azido-2-deoxy-α-D-
lyxofuranoside (OCH3) (161a black) and of [
2
H3]-methyl 2-azido-2-deoxy-α-D-
lyxofuranoside (OCD3) (108 blue).   
  
We have tested the hypothesis that 1-OMe-(C2)-
14ND• from 161a could abstract 
H-atoms from sugar carbons by employing matched samples of 161a (black, Figure 24) 
its 5-deutereo, 161b (green, Figure 24) and 5-dideutereo lyxofuranoside, 167b (pink) 
isotopomers, (Figure 25). Following the spectral results shown in Figure 22, the spectra 
in Figures 24 (A) and 25 (A) are assigned to 1-OMe-(C2)-
14ND• and 5-D-1-OMe-(C2)-
14ND• owing to the presence of the Azz component of the anisotropic nitrogen HFCC of 
ca. 41 G and isotropic β HFCC value of 2-H at (49.0 G). These results further establish 
that 5-deuteration does not show any observable effect on the spectra of these aminyl 
radicals. Upon annealing from 77 K to 145 K (spectra shown in Figure 24 (B) and Figure 
25 (B)), we find that owing to the softening of the glass caused by the temperature 
increase, 1-OMe-(C2)-
14ND• migrates and reacts with the 5-H atom in the 2-
azidolyxofuranoside resulting in the central anisotropic doublet of ca. 20 G owing to the 
α-hydrogen in C5•. Collapse of this central doublet to a singlet in the matched sample of 
161b (Figure 24) and 167b (see Figure 25) under identical conditions has led to this 
unequivocal assignment of the central anisotropic doublet of ca. 20 G due to C5•.  
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Figure 24. Comparision of the (A) electron attachment at 77 K and and (B) the subsequent reaction 
shown via progressive annealing at 145 K in matched samples of 161a (black) and 161b (green). 
 
 
Increasing the concentration (0.5 to 10 mg/ml) of the lyxofuranoside in the solution 
appeared to have no effect on the extent of C5• formation from the spectra recorded 
under the same microwave power, modulation, and gain. From these results, we conclude 
that the 1-OMe-(C2)-
14ND• mediated C5• formation observed in these lyxofuranoside 
sample occur via intramolecular H-atom abstraction. This can be explained by the 6-
membered transition state where the aminyl radical generated at C2 nitrogen atom 
abstracts the C5 hydrogen, 109 → 110 (Scheme 22).  
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Figure 25. Formation of aminyl radical in 161a, 108 and 167b and it's subsequent reactions 
 
Figure 25. Comparison of the aminyl radical formation via (A) electron attachment at 77 
K and (B) to (F) the subsequent reactions of the aminyl radical shown via progressive 
annealing from 77 K to ca. 170 K in matched samples of 161a (OCH3) (black), of 100 
(OCD3) (blue), and of 167b (pink). The data of 161a and 100 were taken from Figure 23.    
 
Analyses of spectrum F in Fig. 23 and spectrum F in Fig. 25 show that these two 
spectra have similar total hyperfine splitting, similar center, and similar line shapes. 
However, comparison of spectra from Fig. 23 (C) to 23 (F) and 25 (F) show that most 
probably C5• is converted to another radical. Simulation experiment, which matches 
experimental data, suggest that C5• B most probably undergo conversion to the stable 
A 
 77 K 
161a(OCH3) vs. 108(OCD3) vs. 167b 5'-DD-OCD3 7.5 M LiCl / D2O 
B 
15 min 140 K 
C 
15 min, 160 K 
15 min, 150 K 
D 
E 
15 min, 165 K 
F 
55 min, 165 K 
 15 min, 170 K 
1-OMe-(C2)-ND
SIM 
15 min, 155 K 
15 min, 160 K 
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C4• E via ring opening. Therefore, we have concluded that in the azido furanose 
substrates 161b, 100, 167a and 167b, the intermediary C5• underwent the rapid 
conversion to the ring opened C4• (see Scheme 37).   
 
Scheme 37. Conversion of the C5• to the ring opened C4• 
 
3.2.2. Design and synthesis of methyl 2-azido-2-deoxyriboside. 
 
In lyxofuranoside derivatives 108, 161 and 167 the azido group is in trans 
configuration to H3 and in cis configuration to the H5,5' and anomeric H1. It is also in 
the opposite geometric configuration to H4. To explore the possibility of generation of 
aminyl radical and its subsequent reactions when the azido group is in cis configuration 
to H4 and trans to H3, H5,5’, I designed methyl 2-azido-2-deoxyriboside, 169 an 
alternative abasic model compound. Since it is abasic compound the interaction of the 
transient radical with the nucleoside heterocyclic bases can be also avoided. 
The methyl 2-azido-2-deoxyriboside, 169 upon electron attachment in γ-irradiated 
aqueous glassy (7.5 M LiCl) systems at 77 K is expected to generate the neutral aminyl 
radical (RNH•). Further the aminyl radical could undergo intramolecular/intermolecular 
hydrogen abstraction. Formation of the aminyl radical (RNH•) and its subsequent 
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reactions in methyl 2-azido-2-deoxyriboside, 169 will be studied using the EPR method 
developed by Dr. Sevilla group.  
The azido sugar analogue 169 can be synthesized using the method reported by 
Eckstein et al. which utilized glycosylic bond cleavage in 2'-azido-2'-deoxyuridine 66 for 
the preparation of 2-azido-2-deoxyribose, 168.
58
 The 2'-azido-2'-deoxyuridine, 66  was 
prepared according to the modified Verheyden method (Scheme 38).
143
 Treatment of 
uridine, 166 with diphenyl carbonate in hexamethylphosphoramide and catalytic amount 
of sodium bicarbonate leads to insitu formation of O
2
,2'-cyclouridine, 167. Addition of 
sodium azide to the same reaction mixture yielded 2'-azido-2'-deoxyuridine, 66 in a "one-
pot" reaction. Treatment of 2'-azido-2'-deoxyuridine, 66 with 15% hydrazine hydrate at 
65
o
C leads to cleavage of the glyosidic bond with the formation of 2-azido-2-
deoxyribose, 168. Further 2-azido-2-deoxyribose, 168 treated with 0.5% HCl/CH3OH to 
give methyl 2-azido-2-deoxyriboside, 169.  
 
Scheme 38. Possible synthesis of methyl 2-azido-2-deoxyriboside 
 
3.2.3. 2'-Azido-2'-deoxycytidine (2'-AZdC) and 4'-azidocytidine (4'-AZC). 
 
3.2.3.1. Design of 2'-AZdC and 4'-AZC. 
 
Following the work regarding the formation of radicals in 3'-AZT and the 5′-
azido-5′-deoxythymidine (5'-AZT) analogues as well as 2'-azido-2'-deoxy uridine after 
attachment of electron in γ-irradiated aqueous glassy (7.5 M LiCl) systems,79 I planned to 
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extend my efforts to study radiation-generated electron-induced site specific formation of 
neutral aminyl radicals (RNH•) and their reactions in 2'-azido-2'-deoxycytidine (2'-AZdC, 
106) and 4'-azidocytidine (4'-AZC, 107). In 2'-AZdC the aminyl radical site would be 
attached to a 2
o 
C-atom (2') and in 4'-AZdC, to a 3
o 
C-atom (4') in the sugar moiety. This 
difference in the stereo and electronic environment of these site-specific aminyl radicals 
is expected to give clear idea about the difference in their reactivity 
3.2.3.2. Synthesis of 2'-AZdC and 4'-AZC. 
 
The 2'-azido-2'-deoxycytidine (2'-AZdC, 106) was synthesized from 2'-azido-2'-
deoxyuridine, 66 (Scheme 39), which was readily obtained from uridine.
144
 Shortly, 
acetylation of free hydroxyl groups in 66 yielded 3',5'-di-O-acetyl-2'-azido-2'-
deoxyuridine, 170.  Conversion of the 3',5'-di-O-acetyl-2'-azido-2'-deoxyuridine, 170 to 
2'-azido-2'-deoxycytidine, 106 was achieved in good yield (85%) employing modification 
of the literature procedure by Fritz et al.
145
 Thus treatment of 170 with 2,4,6-
triisopropylbenzenesulfonyl chloride, 171 afforded trisylated compound 172. Subsequent 
global deprotection of compound 172 with aqueous ammonium hydroxide in THF 
afforded 2'-AZdC 106 (85%).  
 
Scheme 39. Synthesis of 2'-azido-2'-deoxycytidine (2'-AZdC). 
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The 4'-azidocytidine (4'-AZC, 107) was also synthesized from the conversion of 
uridine counterpart 177. The 4'-azidouridine was prepared as reported (Scheme 40).
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Shortly, treatment of unprotected uridine 166 with triphenylphosphine and iodine in the 
presence of imidazole leads to selective iodination at 5' to produce the 5'-halonucleoside 
intermediate. Dehydrohalogenation of the incipient 5'-halonucleoside with the aid of 
NaOMe readily generates the 4'-olefin, 174. In a critical step stereoselective addition of 
iodine azide (generated in situ from iodine monochloride and sodium azide in DMF) to 
the 4'-methylene uridine derivative 174 produced 175.  Iodine added preferentially to the 
β-face of the double bond to generate the iodium ion intermediate which was open on the 
α-side, at 4', and stereospecific addition of the azide ion at that site produced 175. 
Protection of the hydroxyl groups in 175, with benzyl protection group generated the 
protected compound 176. Treatment of 176, with m-chloroperbenzoic acid in 
dichloromethane yielded the 5'-O-benzoyl-3'-hydroxyl analogue 177 in which migration 
of the 3',5'-trans oriented benzoyl protection group occurred via formation of the 3',5'-
cyclic benzoxonium ion.
146
 Removal of benzoyl protection using sodium methoxide in 
methanol gave 178. Conversion of 4'-azido uridine, 178 to 4'-azidocytidine, 107 was 
achieved by modification of the literature procedure.
147
 Reaction of 178 with 2,4,6-
triisopropyl benzene sulfonyl chloride in the presence of TEA and DMAP in 
dichloromethane resulted in the regioselective trisylation at O
4 
position. The incipient 
trisylated derivative 179 without further purification was directly converted to the 4'-
azidocytidine (4'-AZC, 107) upon treatment with aqueous ammonium hydroxide in THF 
in 80% yield. 
118
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Scheme 40.  Synthesis of 4'-azidocytidine (4'-AZC) 
 
3.2.3.3. EPR characterization during one electron oxidation of 2'-AZdC and  4'-
AZC. 
 
The electron-induced site specific formation of neutral aminyl radicals (RNH•) 
and their reactions in 2'-azido-2'-deoxycytidine (2'-AZdC, 106, Figure 26) and 4'-
azidocytidine (4'-AZC, 107, Figure 27) in γ-irradiated aqueous glassy (7.5 M LiCl) 
systems have been studied by EPR spectroscopy. 
The ESR spectra of the γ-irradiation produced radicals in matched samples of 2'-
AZdU (black) and 2'-AZdC (blue) at the native pD (ca. 5) of the homogeneous glassy 
solutions of 7.5 M LiCl in D2O as well as of the subsequent reactions of these radicals are 
shown in Figure 26. The ESR spectroscopic studies presented here have provided the 
evidence for the formation of neutral and localized aminyl radical at C2' in 2'-AZdU 
75 
 
(dU(C2')-ND•) or in 2'-AZdC (dC(C2')-ND•) owing to electron attachment in the azido 
group of 2'-AZdU or of 2'-AZdC at 77 K. 
It is evident from Figure 26 that the ESR characteristics (e.g., overall hyperfine 
splitting, g-value at the center, lineshape) of the spectra obtained from the commercially 
available 2'-AZdU and the in-house synthesized 2'-AZdC samples are quite identical. We 
note here that the central doublets in Figure 26A are assigned to the uracil anion radical 
(U•¯, black) and cytosine anion radical (C•¯, blue) and the ESR characteristics (e.g., 
overall hyperfine splitting, g-value at the center, lineshape) of these doublets are identical 
to the spectra of U•¯ and C•¯ reported in the literature.148 Furthermore, the spectra shown 
in Figure 26A (and also in 26(B)) have the line components owing to dU(C2')-ND• (or 
dC(C2')-ND•). 
Via progressive annealing from 140 K up to 167 K (spectra shown in Figures 
26(C) to 26(G)), we find that owing to the softening of the glass caused by the increase in 
the temperature, either dU(C2')-ND• (black) (or dC(C2')-ND• (blue)) migrates and reacts 
with a 2'-AZdU or 2'-AZdC molecule in its proximity. The spectra presented in Figure 
26(G) show that the final radical formed via bimolecular reaction of either dU(C2')-ND• 
(or dC(C2')-ND•) with an unreacted 2'-AZdU or 2'-AZdC (blue) molecule leads to the 
formation of a C-centered radical. There are two possible assignments of this C-centered 
radical. The radical site could be at the C5- or C6 site of the C5-C6 double bond in 
uridine or in cytosine since the aminyl radical may add to the C5 or C6-site of the C5-C6 
double bond. This observation is in consistent with the literature where it is reported that 
in cytosine, RNH• undergoes electrophilic addition to the C=C double bond.109,126,149-151 
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Alternatively, the aminyl radical might cause H-atom abstraction from the 5'-site and the 
resulted C5'• could have a similar spectrum owing to an anisotropic α-H coupling at C5' 
and owing to an isotropic β-H coupling due to C4'.148,152 
Comparison of the ESR spectra presented in Figures 26 and 27 clearly 
demonstrate that unlike dU(C2')-ND• (or dC(C2')-ND•), the C(C4')-ND• does not have 
any isotropic β-H HFCC. Comparison of spectra in Figure 26 (G) with those in Figure 
27(G) suggests that RNH• attached to the tertiary alkyl carbon (generated from 107) 
could be less reactive.  
Its ESR characteristics are as follows: anisotropic 
14
N-atom HFCC (37.5, 0, 0) G, 
and anisotropic a-D (N-D) (4.5, 0, 6) G, a mixed Lorentzian/Gaussian (1/1) linewidth of 
10 G, with g-values of (2.0020, 2.0043, 2.0043). The simulated spectrum (red) of C(C4')-
ND• obtained by employing these ESR parameters match the experimental spectrum very 
well.  
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Figure 26. The electron-induced site specific formation of neutral aminyl radicals (RNH•) and their 
reactions in 2'-azido-2'-deoxycytidine 
 
Figure 26. Shows first derivative ESR spectra of matched samples of commercially 
available (from Santa Cruz Biotechnology, CA, USA) 2'-AZdU (black) and the in-house 
synthesized 2'-AZdC (blue) at the native pD (ca. 5) of the homogeneous glassy solution 
of 7.5 M LiCl in D2O. (A) After g-irradiation (absorbed dose = 500 Gy) produced one-
electron addition at 77 K. (B) After visible illumination of samples employing a 
photoflood lamp at 77 K for 15 to 20 minutes. The central doublet in both spectra due to 
the cytosine anion radical (C•¯) is removed by photoejection of the excess electron. 
Spectra (C) to (G) are obtained after subsequent annealing for 10 to 15 min in the dark 
from 150 to 167 K. All ESR spectra shown in Figures A to E were recorded at 77 K. The 
three reference markers in this figure and in subsequent figures are Fremy’s salt 
resonances with central marker is at g= 2.0056 and each of three markers is separated 
from one another by 13.09 G.  
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Figure 27. The electron-induced site specific formation of neutral aminyl radicals (RNH•) and their 
reactions in 4'-azidocytidine 
 
Figure 27. Shows first derivative ESR spectra of matched samples of the in-house 
synthesized 4'-AZCyd (black) and 2'-AZdC (blue, also shown in Figure 26) at the native 
pD (ca. 5) of the homogeneous glassy solution of 7.5 M LiCl in D2O. (A) After g-
irradiation (absorbed dose = 500 Gy) produced one-electron addition at 77 K. (B) After 
visible illumination of samples employing a photoflood lamp at 77 K for 20 minutes. The 
central doublet in both spectra due to the cytosine anion radical (C•¯) is removed by 
photoejection of the excess electron. The simulated spectrum of C(C4')-ND• is also 
shown (for simulation parameters, see below). Spectra (C) to (G) are obtained after 
subsequent annealing for 10 to 15 min in the dark from 140 to 165 K. All ESR spectra 
shown in Figures A to G were recorded at 77 K.   
 
3.3. Sulfenamide modified nucleosides 
 
Formation of neutral aminyl radical (RNH•) has also been speculated from  
nucleoside modified with sulfenamide moiety. Kuttappan synthesized N
6
-
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[Phenylsulphenyl]-2'-deoxyadenosine and N
6
-[2-nitrophenylsulphenyl]-2'-
deoxyadenosine analogues,
121
 and studied the formation of aminyl radicals by UV 
photolysis and γ-irradiation. The formation of dAdo N6-aminyl radical was observed by 
pulse radiolysis.
121
  
Sulfenamide modified nucleosides analogues with the sulfenamido substitution at 
specific sites either in the sugar (111and 112) or base (113) have been prepared (Figure 
28). To see if the nucleoside(sugar)-based aminyl radical can be generated from 
sulfenamide derivatives, I designed 2'-deoxy-2'-sulfenamide uridine (2'-SAdU) analogue 
111 and 112 with the alkyl-NH-S-aryl frame. To study the effect of the substitution in the 
aromatic ring attached to sulfur, 2'-deoxy-2'-sulfenamide uridine analogue 112 with EWG 
substituents in the aryl ring has been synthesized. 
Also, to investigate the sulfenamide derivative with the aryl-NH-S-aryl frame 
which is expected to be more stable and more reliable precursor to the aminyl radicals, 
the 2'-deoxyadenosine (dAdo) analogue N
6
-[phenylsulphenyl]-2'-deoxyadenosine 113 
(Figure 28) has been prepared. These sulfenamide modified nucleosides are expected to 
serve as precursors to site-specific generation of RNH• via radiation-produced electrons 
(Figure 29).  
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Figure 28. Sulfenamide modified nucleosides as possible substrate for the generation of N-centered 
radical at sugar or base 
 
 
Figure 29. Plausible formation of aminyl radical in 2'-N-phenylsulphenyl-2'-amino-2'-deoxyuridine 
 
Characterization of the reactive RNH• and investigation of the DNA damage it 
promotes will be carried out using electron spin resonance (ESR) spectroscopy. If these 
sulfenamide modified nucleosides would generate aminyl radical successfully I anticipate 
that they would be more stable compared to the azido modified nucleosides towards the P 
(III)-base phosphorylation protocols. Azido group in the modified nucleosides reacts 
intramolecularly with the phosphoramidite and greatly affects the oligo 
coupling.
94,107,118,153
 
3.3.1. Synthesis of 2'-N-phenylsulphenyl-2'-amino-2'-deoxyuridine and its 
analogues.  
 
The 2'-N-phenylsulphenyl-2'-amino-2'-deoxyuridine, 111 and 2'-N-(4-
trifluoromethylphenyl)-sulphenyl-2'-amino-2'-deoxyuridine, 112 were prepared 
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employing the general method reported by Davis and co-workers
116,154
 as depicted in 
Scheme 41. Thus, treatment of diphenyl disulfide, 183 at 45ºC with readily available 2'-
deoxy 2'-aminouridine,
154
 182 in presence of AgOAc afforded 2'-N-phenylsulphenyl-2'-
amino-2'-deoxyuridine 111 as a white solid in 38% yield.  Analogues treatment of 4,4'-
bis(trifluoromethyl)-2,2'-diphenyl disulfide, 184 with 2'-deoxy-2'-aminouridine afforded 
2'-N-(4-trifluoromethylphenyl)-sulphenyl-2'-amino-2'-deoxyuridine 112 as a white solid 
in 12% yield. 
 
Scheme 41. Synthesis of 2'-N-phenylsulphenyl-2'-amino-2'-deoxyuridine 
 
Similarly, synthesis of N
6
-[phenylsulphenyl]-2'-deoxyadenosine 113 was 
accomplished by employing the general method reported by Davis and co-workers. Thus, 
treatment of diphenyl disulfide, 183 with readily available 2'-deoxyadenosine, 182 in the 
presence of AgOAc afforded N
6
-[phenylsulphenyl]-2'-deoxyadenosine, 113 as a white 
solid in 12% yield (Scheme 42). 
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Scheme 42. Synthesis of N
6
-[phenylsulphenyl]-2'-deoxyadenosine 
 
3.3.2. 2'-N-Phenylsulphenyl-2'-amino-2'-deoxyuridine and its analogues as substrate 
for the aminyl radicals 
 
4. EXPERIMENTAL PROCEDURES 
4.1. General procedures 
The 
1
H (400 or 500 MHz) and 
13
C (100 or 125 MHz) NMR spectra were determined with 
solutions in CDCl3 unless otherwise noted. HRMS were obtained in TOF-ESI mode 
unless otherwise noted. TLC was performed with Merck kieselgel 60-F254 sheets and 
products were detected with 254 nm light or by visualization with 
Ce(SO4)2/(NH4)6Mo7O24∙4H2O/H2SO4/H2O reagent. Merck kieselgel 60 (230-400 mesh) 
was used for column chromatography. Reagent grade chemicals were used, and solvents 
were dried by reflux over and distillation from CaH2 (except for THF/potassium) under 
argon or by passing the solvents through the activated alumina cartridges using solvent 
purification system. 
4.2. Synthesis 
  Methyl 6-O-Benzoyl-1,5-dideoxy-2,3-O-isopropylidene-β-D-ribo-
hexofuranoside (121).
 
To a solution of methyl 1,5-dideoxy-2,3-isopropylidene-β-ribo-
hexofuranoside
48 
(120; 13.0 g, 58.8 mmol) and Et3N (8.9 g, 12.3 mL, 88.2 mol) in 
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CH2Cl2 (50 mL) was added dropwise BzCl (12.4 g, 10.2 mL, 88.2 mmol) at 0 °C. The 
cooling bath was removed and after 1 h the
 
reaction mixture was quenched by addition of 
MeOH (2 mL). After additional 30 min the volatiles were evaporated and the residue was 
column chromatographed (hexanes  hexanes/EtOAc, 6:1) to give 121 as pale yellow oil 
(17.3 g, 92%):
 1
H NMR  1.32, 1.49 (2  s, 2  3H), 2.01–2.04 (m, 2H), 3.38 (s, 3H), 
4.39–4.52 (m, 3H), 4.62–4.65 (m, 2H), 4.98 (s, 1H), 7.42–7.57 (m, 3H), 8.04–8.06 (m, 
2H); 
13
C NMR  24.6, 26.2, 33.9, 54.8, 61.6, 83.6, 84.0, 85.2, 109.6, 112.0, 128.1, 129.3, 
129.9, 132.6, 166.0; MS FAB m/z 345 (3, [M+Na]
+
), 291 (100, [M-OMe]
+
); HRMS ESI 
m/z calcd for C17H22O6Na [M+Na]
+
 345.1314, found 345.1317. 
6-O-Benzoyl-1,5-dideoxy-D-ribo-hexofuranose (122) and 6-O-Benzoyl-1,5-
dideoxy-2,3-O-isopropylidene-D-ribo-hexofuranose (123). To a stirred solution of 121 
(18.0 g, 55.9 mmol) and Et3SiH (19.4 g, 26.7 mL, 167.7 mmol) in CH2Cl2 (10 mL) was 
added BF3•OEt2 (23.8 g, 21.3 mL, 167.7 mmol). Mildly exothermic reaction ensued after 
approx. 15 min and the reaction mixture was allowed to stir for an additional 3h. The 
reaction flask was placed in an ice slush and a saturated NaHCO3/H2O solution (200 mL) 
was added slowly with vigorous stirring. CH2Cl2 was added (50 mL), aqueous phase was 
separated and washed with CH2Cl2 (50 mL). Organic fractions were combined and 
evaporated to dryness. Column chromatography (hexanes/EtOAc, 6:1  EtOAc) gave 
contaminated (~10%) 123 (1.5 g, 9%) and 122 (6.1 g, 43%) as syrup. Compound 122 
had: 
1
H NMR (CD3OD)  1.87–1.94 (m, 1H), 2.12–2.19 (m, 1H), 3.70 (dd, J = 2.9, 9.8 
Hz, 1H), 3.79 (dd, J = 5.4, 7.3 Hz, 1H), 3.85–3.89 (m, 1H), 4.07 (dd, J = 4.9, 9.8 Hz, 
1H), 4.16 (td, J = 2.9, 4.9 Hz, 1H), 4.38–4.50 (m, 2H), 7.45–7.61 (m, 3H), 8.02–8.04 (m, 
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2H); 
13
C NMR (CD3OD)  32.4, 61.9, 70.8, 72.2, 75.9, 78.9, 128.3, 129.5, 129.9, 133.0, 
166.8; MS FAB m/z 275 (100, [M+Na]
+
); HRMS ESI m/z calcd for C13H16O5Na 
[M+Na]
+
  275.1531, found 275.0902. 
Diol 122 (6.1 g, 24.2 mmol) and TsOH hydrate (0.5 g, 2.6 mmol) were dissolved in a 
mixture of acetone (40 mL) and 2,2-dimethoxypropane (10 mL) and left to stir at room 
temperature for 30 min. Neutralization with sat. NaHCO3 (100 mL) followed by EtOAc 
extraction (2  50 mL) and evaporation to dryness provided oil that was filtered through 
silica to give 123 (6.4 g, 91%):  
1
H NMR  1.33, 1.52 (2  s, 2  3H), 1.86–1.92 (m, 2H), 
3.86 (dd, J = 4.4, 10.7 Hz, 1H), 3.97 (dd, J = 1.5, 10.7 Hz, 1H), 4.23–4.26 (m, 1H), 4.36–
4.49 (m, 2H), 4.52 (dd, J = 1.5, 6.3 Hz, 1H), 4.80–4.83 (m, 1H), 7.42–7.57 (m, 3H), 
8.03–8.05 (m, 2H); 13C NMR  24.9, 26.5, 29.7, 61.5, 71.6, 80.8, 81.2, 85.0, 112.8, 
128.3, 129.5, 130.1, 132.9, 166.4. MS FAB m/z 293 (100, [M+H]
+
), 315 (15, [M+Na]
+
); 
HRMS ESI m/z calcd for C16H20O5Na [M+Na]
+ 
315.1208, found 315.1209. 
1,5-Dideoxy-2,3-O-isopropylidene-D-ribo-hexofuranose (124). To a stirred solution 
of 123 (14.0 g, 47.9 mmol) in MeOH (50 mL) was added a solution of KOH (2.0 g, 35.7 
mol) in MeOH (50 mL). After 1 h the volatiles were evaporated and the residue was 
column chromatographed (hexanes/EtOAc, 2:1 EtOAc) to give 124 (8.0 g, 87%): 1H 
NMR  1.33, 1.51 (2  s, 2  3H), 1.63–1.76 (m, 2H), 3.74–3.82 (m, 2H), 3.89 (dd, J = 
4.4, 10.4 Hz, 1H), 3.94 (d, J = 10.3 Hz, 1H), 4.19–4.22 (m, 2H), 4.48 (dd, J = 1.5, 5.8 Hz, 
1H), 4.81 (t, J = 5.1 Hz, 1H); 
13
C NMR  24.5, 26.2, 32.4, 59.2, 71.1, 80.4, 82.2, 84.6, 
112.3. MS FAB m/z 189 (100, [M+H]
+
); HRMS ESI m/z calcd for C9H17O4 [M+H]
+
 
189.1127, found 189.1123.  
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6-Iodo-1,5,6-trideoxy-2,3-O-isopropylidene-D-ribo-hexofuranose (125). To a 
stirred solution of 124 (9.0 g, 47.9 mmol), Ph3P (15.1 g, 57.6 mmol) and imidazole (7.9 
g, 116.2 mmol) in toluene (225 mL) was added iodine (14.6 g, 57.5 mmol) at 70 °C. The 
suspension was vigorously stirred another 2 h, then allowed to cool to ambient 
temperature and the solution decanted to another flask. Volatiles were evaporated and the 
residue was column chromatographed (hexanes  hexanes/EtOAc, 6:1) to give 125 
(13.03 g, 85%): 
1
H NMR  1.33, 1.52 (2  s, 2  3H), 1.88–1.97 (m, 2H), 3.14–3.27 (m, 
2H), 3.78 (dd, J = 4.4, 10.7 Hz, 1H), 3.95 (dd, J = 1.5, 10.7 Hz, 1H), 4.10 (ddd, J = 1.5, 
4.9, 9.2 Hz, 1H), 4.23 (dd, J = 2.0, 6.3 Hz, 1H), 4.78 (m, 1H); 
13
C NMR  1.0, 24.7, 26.2, 
34.0, 71.2, 80.4, 83.6, 84.1, 112.3; MS FAB m/z 321 (12, [M+Na]
+
), 319 (100); HRMS 
ESI m/z calcd for C9H15IO3Na [M+Na]
+
 320.9964, found 320.9970. 
6-Iodo-1,5,6-trideoxy-D-ribo-hexofuranose (126). A solution of 125 (14.0 g, 47.0 
mmol) in a mixture of MeOH (100 mL), H2O (25 mL) and conc. HCl (25 mL) was stirred 
at room temperature 3 h. Volatiles were evaporated and the residue was column 
chromatographed (hexanes/EtOAc, 2:1  EtOAc) to give 126 (8.73 g, 72%):  1H NMR  
2.00–2.07 (m, 1H), 2.16–2.25 (m, 1H), 3.22–3.45 (m, 4H), 3.74–3.77 (m, 2H), 3.84 (br s, 
1H), 4.10 (dd, J = 4.9, 10.3 Hz, 1H), 4.27 (br s, 1H); 
13
C NMR  1.7, 37.3, 70.9, 72.8, 
75.6, 81.6; MS FAB m/z 258 (10, [M]
+
), 74 (100); HRMS ESI m/z calcd for C6H11IO3, 
257.9753, found 257.9740. 
1,5-Dideoxy-6-O-nitro-D-ribo-hexofuranose (127).
 
A suspension of 126 (12.0 g, 
46.5 mmol) and AgNO3 (15.8 g, 93.0 mmol) in CH3CN (150 mL) was stirred at room 
temperature for 2 days. The yellow precipitate was filtered off, washed with EtOAc and 
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the volatiles were evaporated. Column chromatography (hexanes/EtOAc, 1:1  EtOAc) 
gave 127 (7.99 g, 89%):
 1
H NMR  1.88–1.96 (m, 1H), 2.08–2.15 (m, 1H), 3.43 (br s, 
2H), 3.73–3.83 (m, 3H), 4.12 (dd, J = 4.9, 10.3 Hz, 1H), 4.23–4.26 (m, 1H), 4.56–4.66 
(m, 2H); 
13
C NMR  30.2, 70.1, 70.8, 72.6, 75.9, 77.8; MS FAB m/z 216 (100, [M+Na]+); 
HRMS ESI m/z calcd for C6H11NO6Na [M+Na]
+
, 216.0484 found 216.0497. 
1,5-Dideoxy-6-O-nitro-2-O-tosyl-D-ribo-hexofuranose (96). Method A. A solution 
of diol 127 (370 mg, 1.92 mmol) and Bu2SnO (477 mg, 1.92 mmol) in anhydrous MeOH 
(40 mL) was heated in a sealed flask at 75 °C for 1 h. After the flask was cooled to 0 °C, 
Et3N (1.15 g, 1.6 mL, 11.4 mmol) was added with stirring followed by TsCl (2.17 g, 11.4 
mmol) dissolved in a minimum volume of acetone. The volatiles were evaporated, and 
the residue was suspended in acetone and deposited on silica. Column chromatography 
(hexanes/EtOAc, 6:1  3:1) gave a 5:2 mixture of two isomers (670 mg) from which the 
main product 96 (320 mg, 48%) was isolated after second column chromatography:
 1
H 
NMR  1.85–1.92 (m, 1H), 2.09–2.17 (m, 1H), 2.46 (s, 3H), 2.76 (d, J = 7.8 Hz, 1H), 
3.75 (dt, J = 3.9, 8.3 Hz, 1H), 3.80 (dd, J = 3.1, 11.2 Hz, 1H), 3.89 (dt, J = 5.4, 7.8 Hz, 
1H), 4.06 (dd, J = 4.9, 11.2 Hz, 1H), 4.52–4.62 (m, 2H), 4.93 (dt, J = 3.0, 5.3 Hz, 1H), 
7.38, 7.82 (2  d, J = 8.3 Hz, 2  2H); 13C NMR  21.6, 30.2, 69.8, 70.1, 74.9, 77.8, 79.4, 
127.8, 130.1, 132.8, 145.6; MS FAB m/z 370 (100, [M+Na]
+
); HRMS ESI m/z calcd for 
C13H17NO8SNa [M+Na]
+
 370.0573, found 370.0587. 
Method B. Step a. TsCl (66 mg, 0.35 mmol) was added to a stirred solution of 128 
(100 mg, 0.32 mmol) in anhydrous pyridine (1mL) at ambient temperature.  After 16 h, 
the volatiles were evaporated and residue was partitioned between ice-cold AcOH/H2O 
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(1:99, 30 mL) and CHCl3 (30 mL). The aqueous layer was extracted with CHCl3 and the 
combined organic phase was washed with ice-cold saturated NaHCO3/H2O (30 mL), 
brine (30 mL) and dried (Na2SO4).  Column chromatography (EtOAc/hexane, 5:95 → 
35:65) gave 1,5-dideoxy-3-O-(p-methoxybenzyl)-6-O-nitro-2-O-tosyl-D-ribo-
hexofuranose (129; 82 mg, 55%): 
1H NMR δ 1.78-1.81 (m, 1H), 2.00-2.02 (m, 1H), 2.47 
(s, 3H), 3.59 (dd, J = 5.0, 8.6 Hz, 1H), 3.83 (s, 3H), 3.86 (dt, J = 2.2, 9.6 Hz, 2H), 4.04 
(dd, J = 4.5, 11.2 Hz, 2H) , 4.26 (d, J = 11.2 Hz, 1H), 4.47 (m, 2H), 4.58 (d, J = 11.2Hz, 
1H), 5.13 (dt, J = 4.7, 7.0 Hz, 1H), 6.88 and 7.21 (2 x d, J = 9.5Hz, 2 x 2H), 7.34 and 
7.84 (2 x d, J = 8.3 Hz, 2 x 2H). Step b. A solution of CAN (176 mg, 0.32 mmol) and 129 
(75 mg, 0.16 mmol) in MeCN (1.5 mL) and water (0.15 mL) was stirred at ambient 
temperature for 22 h. Volatiles were evaporated and the residue was column 
chromatographed (EtOAc/hexane, 3:97 → 30:70) to give 96 (54 mg, 98%) with data as 
above.  
1,5-Dideoxy-3-O-(p-methoxybenzyl)-6-O-nitro-D-ribo-hexofuranose (128). A 
suspension of diol 127 (1.20 g, 6.22 mmol) and Bu2SnO (1.70 g, 6.84 mmol) in 
anhydrous MeOH (10 mL) was heated in a sealed flask at 75 °C for 1 h. After the flask 
was cooled to ambient temperature, the volatiles were evaporated. DMF (5 mL) and 
PMBCl (1.95 g, 1.7 mL, 12.44) were added, and the reaction mixture was heated at 90 °C 
for 18 h. Volatiles were evaporated, and the residue was chromatographed 
(hexanes/EtOAc, 6:1  1:1) to give 1,5-dideoxy-2,3-di-O-(p-methoxybenzyl)-6-O-nitro-
D-ribo-hexofuranose (1.55 g; 20% contaminated) followed by 1,5-dideoxy-2-O-(p-
methoxybenzyl)-6-O-nitro-D-ribo-hexofuranose (0.47 g, 24%) and 128 (0.60 g; 31%) of 
sufficient purity for use in subsequent reaction. Sample of 128 was repurified on column 
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chromatography for spectroscopic characterization:
 1
H NMR  1.77–1.85 (m, 1H), 1.93–
2.00 (m, 1H), 3.20 (br s, 1H), 3.60 (dd, J = 5.4, 7.3 Hz, 1H), 3.76 (dd, J = 2.9, 10.3 Hz, 
1H), 3.81 (s, 3H), 3.85 (dt, J = 3.9, 7.3 Hz, 1H), 4.01 (dd, J = 4.9, 10.3 Hz, 1H), 4.18 (m, 
1H), 4.47–4.61 (m, 4H), 6.88–6.92 (m, 2H), 7.24–7.30 (m, 2H); 13C NMR  30.5, 55.2, 
69.1, 70.0, 72.6, 73.3, 76.1, 82.4, 114.0, 128.8, 129.7, 159.7; MS FAB m/z 336 (100, 
[M+Na]
+
); HRMS ESI m/z calcd for C14H19NO7Na [M+Na]
+
 336.1059, found 336.1072. 
2-Chloro-3-O-(p-methoxybenzyl)-6-O-nitro-1,2,5-trideoxy-D-arabino-
hexofuranose (130).
 
To a solution of Ph3P (2.18 g, 8.31 mmol) and DIAD (1.26 g, 1.22 
mL, 6.23 mmol) in THF (14 mL) was added a solution of 128 (0.65 g, 2.08 mmol) in 
THF (6 mL) followed by freshly prepared HCl•pyridine (0.72 g, 6.23 mmol; prepared by 
slow addition of TMSCl (0.68 g, 0.8 mL, 6.31 mmol) to a solution of pyridine (0.98 g, 
1.0 mL, 12.4 mmol) in  MeOH (0.32 g, 0.4 mL, 9.9 mmol) and CH2Cl2 (10 mL) at 0 °C. 
Volatiles were evaporated and the crystalline residue was dried at 80 °C under vacuum 
overnight). The suspension was stirred overnight at room temperature. Volatiles were 
evaporated, and the residue was column chromatographed (hexanes/EtOAc, 10:1  6:1) 
to give 130 (0.43 g, 62%): 
1
H NMR 2.05–2.10 (m, 2H), 3.82 (br s, 4H), 3.81–3.86 (m, 
1H), 3.90 (br d, J = 3.4 Hz, 1H), 4.02 (d, J = 10.3 Hz, 1H), 4.13 (dd, J = 4.4, 10.7 Hz, 
1H), 4.47–4.65 (m, 4H), 6.90–6.93 (m, 2H), 7.25-7.28 (m, 2H); 13C NMR 30.9, 55.2, 
60.1, 70.0, 72.1, 74.2, 80.9, 89.8, 113.9, 128.8, 129.6, 159.5; MS FAB m/z 209 (100, 
[M]
+
); HRMS ESI m/z Calcd for C14H18ClNO6Na [M+Na]
+
 354.0720, found 354.0706. 
2-Chloro-1,2,5-trideoxy-6-O-nitro-D-arabino-hexofuranose (97). A solution of 130 
(0.43 g, 1.30 mmol) and CAN (1.42 g, 2.59 mmol) in CH3CN (7 mL) and H2O (0.7 mL) 
was stirred for 1.5 h. The reaction mixture was concentrated, and the residue was 
89 
 
deposited on silica gel and column chromatographed (hexanes/EtOAc, 10:1  3:1) to 
give 97 (0.21 g, 78%):
 1
H NMR  2.10–2.22 (m, 2H), 2.69 (br s, 1H), 3.80–3.84 (m, 1H), 
4.02 (br d, J = 10.8 Hz, 1H), 4.14–4.25 (m, 3H), 4.58–4.68 (m, 2H); 13C NMR  30.9, 
62.3, 70.0, 73.3, 81.7, 83.2; MS FAB m/z 212 (5, [M+H]
+
), 120 (100); HRMS ESI m/z 
calcd for C6H11ClNO5[M+H]
+
 212.0326, found 212.0327. 
2-Bromo-1,2,5-trideoxy-6-O-nitro-D-arabino-hexofuranose (98).
 
Step a. To a 
solution of Ph3P (2.85 g, 10.09 mmol) and DIAD (1.65 g, 8.15 mmol) in THF (30 mL) 
was added a stirred solution of 10 (1.75 g, 5.43 mmol) in THF (10 mL) followed by 
freshly prepared HBr•pyridine (1.30 g, 8.15 mmol; prepared by slow addition of TMSBr 
(0.93 g, 0.8 mL, 6.06 mmol) to a solution of pyridine (0.98 g, 1.0 mL, 12.4 mmol) in  
MeOH (0.32 g, 0.4 mL, 9.9 mmol) and CH2Cl2 (10 mL) at 0 °C. Volatiles were 
evaporated and the crystalline residue was dried at 80 °C under vacuum overnight). The 
suspension was stirred at room temperature for 22 h. Volatiles were evaporated, and the 
residue was column chromatographed (hexanes/EtOAc, 10:1  6:1) to give crude 2-
bromo-3-O-(p-methoxybenzyl)-6-O-nitro-1,2,5-trideoxy-D-arabino-hexofuranose (131; 
1.0 g, 49%) which was directly used in next step. Step b. A solution of crude 131 (1.0 g, 
2.66 mmol) and CAN (2.91 g, 5.32 mmol) in a mixture of CH3CN (14 mL) and H2O (1.4 
mL) was stirred for 1.5 h. The resulting mixture was concentrated and the residue was 
deposited on silica and column chromatographed (hexanes/EtOAc, 10:1  4:1) to give 
98 (0.54 g, 79%): 
1H NMR δ 2.14-2.26 (m, 2H), 3.80-3.86 (dt, J = 5.2, 8.8 Hz, 1H), 4.10 
(dd, J = 4.0, 10.6 Hz, 1H), 4.16-4.22 (m, 1H), 4.26-4.33 (m, 2H), 4.58-4.72 (m, 2H); 
13
C 
NMR δ 31.2, 51.5, 69.9, 73.6, 81.5, 83.5. HRMS ESI/DART m/z calcd for 
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C6H14
79
BrN2O5 [M+NH4]
+
 273.0081, found 273.0084; calcd for C6H14
81
BrN2O5 
[M+NH4]
+
 275.0061, found 275.0061.  
1,5-Dideoxy-3-O-(p-methoxybenzyl)-6-O-nitro-D-arabino-hexofuranose (133). 
Step a..
 
A solution of compound 128 (2.70 g, 8.63 mmol) in THF (8 mL) followed by a 
solution of  DIAD (2.09 g, 2.03 mL, 10.35 mmol) in THF (3 mL).were slowly (12 min) 
added to a stirred solution of Ph3P (2.71 g, 10.35 mmol) and PhCO2H (1.26 g, 10.35 
mmol) in THF (40 mL) at -50 °C under nitrogen atmosphere. The resulting mixture was 
allowed to warm to ambient temperature within 1 h (it became colorless at -20 °C). 
Volatiles were evaporated, and the residue was column chromatographed (hexanes  
hexanes/EtOAc, 3:1) to give 2-O-benzoyl-1,5-dideoxy-3-O-(p-methoxybenzyl)-6-O-
nitro-D-arabino-hexofuranose (132 ;2.87 g, 80%): 
1H NMR δ 2.0-2.07 (m, 2H), 3.79 (s, 
3H), 3.85 (td, J = 1.0, 4.6 Hz, 1H), 3.90 (td, J = 5.0, 7.6 Hz, 1H), 4.08-4.12 (m, 2H), 
4.51-4.59 (m, 3H), 4.75 (d, J = 11.7 Hz, 1H), 5.43 (td, J = 1.4, 2.7 Hz, 1H), 6.86 (d, J = 
8.7 Hz, 2H), 7.27 (d, J = 8.7, 2H), 7.47 (t, J = 7.7 Hz, 2H), 7.61 ( tt, J = 1.5, 7.5 Hz, 1H), 
8.03 (d, J = 7.6 Hz, 2H). Step b. A suspension of KOH (0.40 g, 7.14 mol) in MeOH (20 
mL) was added to a stirred solution of 132 (2.82 g, 6.76 mmol) in MeOH (20 mL) at 
ambient temperature. After 1 h, the solution was neutralized with AcOH to pH 7. The 
volatiles were evaporated and the residue was column chromatographed (hexanes/EtOAc, 
3:1  2:1) to give 133 (1.64 g, 77%): 1H NMR  1.26 (d, J = 2.9 Hz, 1H), 2.00–2.04 (m, 
2H), 3.64 (d, J = 2.9 Hz, 1H), 3.80 (br s, 4H), 3.83 (d, J = 10.3 Hz, 1H), 3.91 (dd, J = 3.9, 
10.3 Hz, 1H), 4.27–4.29 (m, 1H), 4.48–4.58 (m, 4H), 6.88–6.91 (m, 2H), 7.24–7.27 (m, 
2H); 
13
C NMR  30.9, 55.2, 70.2, 71.8, 74.1, 76.1 80.3, 89.2, 113.9, 128.4, 129.5, 159.4; 
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MS FAB m/z 336 (100, [M+Na]
+
); HRMS ESI m/z calcd for C14H19NO7Na [M+Na]
+ 
336.1059, found 336.1047. 
1,5-Dideoxy-6-O-nitro-2-O-tosyl-D-arabino-hexofuranose (99). Step a. TsCl (134 
mg,  0.70 mmol) was added to a stirred solution of 133 (100 mg, 0.32 mmol) in 
anhydrous pyridine (1mL) at ambient temperature. After 16 h, the volatiles were 
evaporated and residue was partitioned between ice-cold AcOH/H2O (1:99, 30 mL) and 
CHCl3 (30 mL). The organic layer was separated and the aqueous layer was extracted 
with CHCl3 (30 mL). Combined organic phase was washed with ice-cold saturated 
NaHCO3/H2O (30 mL), brine (30 mL) and dried (Na2SO4), concentrated in vacuo and 
column chromatographed (EtOAc/hexane, 5:95 → 35:65) to give 1,5-dideoxy-3-O-(p-
methoxybenzyl)-6-O-nitro-2-O-tosyl-D-arabino-hexofuranose (134a; 128 mg, 86%) as a 
colorless oil: 
1
H NMR δ 1.90-1.96 (m, 2H), 2.46 (s, 3H), 3.72-3.78 (m, 1H), 3.82 (s, 3H), 
3.84 (dt, J = 1.2, 4.6 Hz, 1H),  3.87 (d, J = 4.0 Hz, 1H), 3.92 (d, J = 11.3 Hz, 1H), 4.33 
(d, J = 11.3 Hz, 1H), 4.42-4.49 (m, 3H), 4.93 (dt, J = 1.2, 4.0 Hz, 1H), 6.87 (d, J = 8.7 
Hz, 2H), 7.16 (d, J = 8.7 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.81 (d, J = 8.2 Hz, 2H); 
13
C 
NMR δ 21.6, 30.3, 55.3, 69.8, 71.4, 71.8, 80.2, 83.9, 86.3, 114.0, 127.8, 128.8, 129.5, 
130.1, 133.4, 145.4, 159.6. Step b. A solution of CAN (352 mg, 0.64 mmol) and 134a 
(100 mg, 0.21 mmol) in MeCN (1mL) and H2O (0.1 mL) was stirred at ambient 
temperature for 22 h. Volatiles were evaporated and the residue was column 
chromatographed (EtOAc/hexane, 3:97 → 30:70) to give  99 (73 mg, 98%) as a colorless 
oil: 
1H NMR δ 1.97-2.07 (m, 1H), 2.07-2.17 (m, 1H),  2.47 (s, 3H),  3.69-3.76 (m, 1H),  
3.85-3.90 (m, 1H),  3.95 (dd, J = 5.5, 11.3 Hz, 1H), 4.17 (dd, J = 2.5, 6.0 Hz, 1H), 4.51-
4.63 (m, 2H),  4.76 (dt, J = 2.5, 5.5 Hz, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.80 (d, J = 8.5 Hz, 
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2H); 
13C NMR δ 21.6, 30.2, 69.7, 70.3, 80.5, 80.9, 86.5, 127.9, 130.1, 132.8, 145.6. 
HRMS ESI/DART m/z calcd for C13H21N2O8S [M+NH4]
+
 365.1013, found 365.1031. 
2-Chloro-1,2,5-trideoxy-3-O-(p-methoxybenzyl)-6-O-nitro-D-ribo-hexofuranose 
(135). Step a. TfCl (160 mg, 0.95 mmol) was added to a stirred solution of 133 (250 mg, 
0.80 mmol) and DMAP (295 mg, 2.4 mmol) in anhydrous CH2Cl2 (2 mL) at 0°C (ice-
bath).  After 1 h, the reaction mixture was partitioned between ice-cold AcOH/H2O (1:99, 
30 mL) and CH2Cl2 (30 mL). The aqueous layer was extracted with CH2Cl2 (30 mL) and 
the combined organic phase was washed with ice-cold saturated NaHCO3/H2O (30mL), 
brine (30mL) and dried (Na2SO4) to give 1,5-dideoxy-3-O-(p-methoxybenzyl)-2-O-
(trifluoromethanesulfonyl)-6-O-nitro-D-arabino-hexofuranose as a colorless oil (134b; 
313 mg, 88%) of sufficient purity to be used in next step. Column chromatography 
(EtOAc/hexane, 5:95 → 30:70) gave pure sample of 134b: 1H NMR δ 1.93-2.02 (m, 2H), 
3.80-3.84 (m, 1H), 3.82 (s, 3H), 3.92 (dt, J = 1.2, 4.6 Hz, 1H), 4.02 (dd, J =3.5, 12.0 
Hz,1H), 4.18 (br d, J = 12.1 Hz, 1H), 4.47-4.52 (m, 3H), 4.66 (d, J = 11.5 Hz, 1H), 5.32 
(d, J = 3.5 Hz, 1H), 6.91 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H). Step b. A solution 
of crude 134b (50 mg, 0.11 mmol; from step a) and dried LiCl (23 mg, 0.54 mmol) in 
DMF (1 mL) was stirred for 5 h at ambient temperature under N2. Volatiles were 
evaporated and residue was partitioned between ice-cold saturated NaHCO3/H2O (15 mL) 
and EtOAc (15 mL). The separated organic phase was washed with brine (30 mL), dried 
(Na2SO4) and  column chromatographed (EtOAc/hexane, 5:95 → 15:85) to give 135  (30 
mg, 80.6%) as a colorless oil: 
1H NMR δ 1.82-1.91 (m , 1H), 2.01-2.1 (m,1H), 3.72 (dd, J 
= 5.2, 8.2 Hz, 1H), 3.82 (s, 3H), 3.99 (dt, J = 4.0, 8.2 Hz, 1H), 4.06 (dd, J = 2.8,10.7 Hz, 
1H), 4.30 (dd,  J = 5.07,10.7 Hz,1H), 4.40 (d, J =  11.2 Hz, 1H), 4.44 (dt, J = 2.2, 5.2 Hz, 
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2H), 4.48-4.59 (m, 2H), 4.69 (d, 11.3 Hz, 1H), 6.90 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 8.7 
Hz, 2H); 
13
C NMR δ 30.4, 55.2, 57.8, 69.9, 72.1, 74.0, 76.3, 81.5, 114.0, 128.8, 129.8, 
159.7. HRMS ESI m/z calcd for C14H18
35
ClNO6Na [M+Na]
+
 354.0715, found 354.0718; 
calcd for C14H18
37
ClNO6Na [M+Na]
+
 356.0691, found 356.0694. 
2-Chloro-1,2,5-trideoxy-6-O-nitro-D-ribo-hexofuranose (94). A solution of CAN 
(74 mg, 0.13 mmol) and 19 (15 mg, 0.04 mmol) in MeCN (1mL) and H2O (0.1 mL) was 
stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue was 
column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give  94 (6.2 mg, 66%) as a 
colorless oil: 
1H NMR δ 1.87-1.98 (m,1H), 2.11-2.20 (m,1H),  2.25 (d, J = 8.7 Hz, 1H), 
3.82-3.88 (m,1H),  3.93-4.00 (m, 1H), 4.02 (dd, J = 4.0, 10.7 Hz, 1H), 4.33 (dd, J = 5.4, 
10.5 Hz,1H), 4.44-4.48 (m, J = 4.2, 5.3 Hz, 1H), 4.55-4.67 (m, 2H); 
13C NMR δ 30.5, 
61.1, 69.8, 72.9, 75.7, 78.3; HRMS ESI/DART m/z calcd for C6H14
35
ClN2O5 [M+NH4]
+
 
229.0586, found 229.0588; calcd for C6H14
37
ClN2O5 [M+NH4]
+
 231.0562, found 
231.0561. 
2-Bromo-1,2,5-trideoxy-3-O-(p-methoxybenzyl)-6-O-nitro-D-ribo-hexofuranose 
(136). A solution of 134b (30 mg, 0.06 mmol; prepared as described for 135, step a) and 
dried LiBr (29 mg, 0.33 mmol) in DMF (1 mL) was stirred for 7 h at ambient temperature 
under N2. Volatiles were evaporated and the resulting residue was partitioned between 
ice-cold saturated NaHCO3/H2O (15 mL) and EtOAc (15 mL). The separated organic 
phase was washed with brine (30 mL), dried (Na2SO4) and column chromatographed 
(EtOAc/hexane, 5:95 → 15:85) to give 136 (18 mg, 71%) as a colorless oil: 1H NMR δ 
1.83-1.94 (m, 1H), 2.02-2.12 (m,1H), 3.6 (dd, J = 5.0, 7.6 Hz, 1H), 3.84 (s, 3H), 4.03 (dt, 
J = 4.0, 8.0 Hz, 1H), 4.22 (dd, J = 2.8,10.6 Hz, 1H), 4.44 (d, J = 11.1 Hz, 1H), 4.43-4.51 
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(m, 2 H), 4.51-4.61 (m, 2H), 4.71 ( d, J = 11.1 Hz, 1H) 6.92 (d, J = 8.6 Hz, 2H), 7.33 (d, 
J = 8.6 Hz, 2H); 
13
C NMR δ 30.4, 49.7, 55.3, 69.9, 72.1, 74.1, 76.6, 81.2, 114.0, 128.81, 
129.8, 159.71. HRMS ESI m/z calcd for C14H18
79
BrNO6Na [M+Na]
+
 398.0210, found 
398.0203; calcd for C14H18
81
BrNO6Na [M+Na]
+
 400.0191, found 400.0183. 
2-Bromo-1,2,5-trideoxy-6-O-nitro-D-ribo-hexofuranose (95). A solution of CAN 
(78 mg, 0.14 mmol) and 136 (18 mg, 0.05 mmol) in MeCN (1 mL) and water (0.1 mL) 
was stirred at ambient temperature for 22 h. Volatiles were evaporated and the residue 
was column chromatographed (EtOAc/hexane, 3:97 → 30:70) to give 95 (12 mg, 96%) 
as a colorless oil: 
1H NMR δ 1.89-1.98 (m, 1H), 2.11-2.20 (m, 2H), 3.78-3.84 (m, 1H), 
3.85-3.92 (m, 1H), 4.13 (dd, J = 4.6 Hz, 1H), 4.43 (dd, J = 5.4 Hz, 1H), 4.48 (dd,  J = 5.0 
Hz, 1H), 4.55-4.70 (m, 2H); 
13C NMR δ 31.6, 53.7, 69.8, 72.9, 75.3, 78.8. HRMS 
ESI/DART m/z calcd for C6H14
79
BrN2O5 [M+NH4]
+
 273.0081, found 273.0077; calcd for 
C6H14
81
BrN2O5 [M+NH4]
+
 275.0066, found 275.0058. 
1,5-Dideoxy-3-O-methyl-6-O-nitro-D-ribo-hexofuranose (137) and 1,5-Dideoxy-
2-O-methyl-6-O-nitro-D-ribo-hexofuranose (138) and:
 
A suspension of 127 (0.34 g, 
1.76 mmol) and Bu2SnO (0.44 g, 1.76 mmol) in anhydrous MeOH (8 mL) was refluxed 
for 30 min. Volatiles were evaporated after the flask was cooled to ambient temperature. 
DMF (1 mL) and MeI (1.14 g, 0.5 mL, 8.03 mmol) were added, the flask was sealed and 
the solution was stirred at 40 °C for 12 h. Volatiles were evaporated and the residue was 
column chromatographed (hexanes/EtOAc, 4:1  1:1) to give 137 (145 mg, 38%) and 
138 (134 mg, 35 %). Compound 137 had:
 1
H NMR  1.85–1.92 (m, 1H), 2.09–2.16 (m, 
1H), 2.79 (d, J = 8.8 Hz, 1H), 3.44 (s, 3H), 3.67 (ddd, J = 3.9, 7.8, 8.8 Hz, 1H), 3.74–3.84 
(m, 3H), 4.06 (dd, J = 4.4, 5.4 Hz, 1H), 4.56–4.65 (m, 2H); 13C NMR  30.5, 57.7, 70.0, 
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70.1, 75.4, 78.6, 79.4; MS FAB m/z 230 (100, [M+Na]
+
); HRMS ESI m/z calcd for 
C7H13NO6Na [M+Na]
+
 230.0641, found 230.0651. Compound 138 had:
 1
H NMR  1.89–
1.96 (m, 1H), 2.04–2.11 (m, 1H), 2.70 (d, J = 3.9 Hz, 1H), 3.45 (dd, J = 4.9, 6.8 Hz, 1H), 
3.47 (s, 3H), 3.79 (dd, J = 2.9, 9.8 Hz, 1H), 3.86 (ddd, J = 3.9, 6.8, 8.3 Hz, 1H), 3.79 (dd, 
J = 4.4, 10.2 Hz, 1H), 4.31 (m, 1H), 4.55–4.65 (m, 2H); 13C NMR  30.8, 58.3, 68.9, 
70.0, 73.2, 75.9, 85.2; MS FAB m/z 208 (100, [M+H]
+
); HRMS ESI m/z calcd for 
C7H14NO6 [M+H]
+
 208.0821, found 208.0819. 
1,5-Dideoxy-2-O-tosyl-3-O-methyl-6-O-nitro-D-ribo-hexofuranose (102). TsCl 
(101 mg, 0.53 mmol) was added to a stirred solution of 137 (100 mg, 0.48 mmol) in 
anhydrous pyridine (1 mL) at ambient temperature. After 16 h, the volatiles were 
evaporated and residue was partitioned between ice-cold AcOH/H2O (1:99, 30 mL) and 
CHCl3 (30 mL). The organic layer was separated and the aqueous layer was extracted 
with CHCl3 (30 mL). Combined organic phase was washed with ice-cold NaHCO3/H2O 
(30 mL), brine (30 mL), dried (Na2SO4), concentrated in vacuo and column 
chromatographed (EtOAc/hexane, 5:95 → 35:65) to give 102 (110 mg, 63%) as a 
colorless oil. 
1H NMR δ 1.86-1.96 (m, 1H), 2.05-2.15 (m, 1H), 2.48 (s, 3H), 3.31 (s, 3H), 
3.47 (dd, J = 5.0, 8.6 Hz, 1H), 3.85 (dd, J = 4.2, 8.6 Hz, 1H), 3.89 (dd, J = 2.44, 11.5 Hz, 
1H), 4.07 (dd, J = 4.44, 11.5 Hz, 1H), 4.51-4.63 (m, 2H), 5.12 (dt, J = 2.2, 4.7 Hz, 1H), 
7.39 (d, J = 8.15 Hz, 2H), 7.85 (d, J = 8.15 Hz, 2H);
 13C NMR δ  21.6, 30.5, 58.3, 69.8, 
70.9, 75.9, 76.7, 83.7, 127.8, 129.9, 133.7, 145.2. HRMS ESI/DART m/z calcd for 
C14H23N2O8S [M+NH4]
+
 379.1170, found 379.1172. 
2-O-Benzoyl-1,5-dideoxy-3-O-methyl-6-O-nitro-D-arabino-hexofuranose (139).
 
Compound 137 (0.20 g, 0.97 mmol) in THF (6 mL) was added to a stirred solution of 
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Ph3P (0.31 g, 1.16 mmol) and PhCO2H (0.14 g, 1.16 mmol) in THF (5 mL) at -50 °C. 
After 5 min. DIAD (0.23 g, 0.22 mL, 1.16 mmol) in THF (2 mL) was added slowly over 
12 min. The reaction mixture was allowed to warm to room temperature within 1 h (it 
became colorless at -20 °C). Volatiles were evaporated, and the residue was column 
chromatographed (hexanes  hexanes/EtOAc, 10:1) to give 139 (0.23 g, 76%): 1H NMR 
 2.07–2.17 (m, 2H), 3.50 (s, 3H), 3.71 (d, J = 3.4 Hz, 1H), 3.86–3.90 (m, 1H), 4.03–4.07 
(m, 2H), 4.57–4.66 (m, 2H), 5.38–5.40 (m, 1H), 7.44–7.62 (m, 3H) , 8.02–8.14 (m, 2H); 
13
C NMR  30.8, 58.0, 70.0, 71.7, 77.9, 80.4, 89.6, 128.4, 129.4, 130.1, 133.4, 165.7; MS 
FAB m/z 334 (15, [M+Na]
+
), 312 (100, [M+H]
+
); HRMS ESI m/z calcd for C14H17O7NNa 
[M+Na]
+
 334.0903, found 334.0904. 
1,5-Dideoxy-3-O-methyl-6-O-nitro-D-arabino-hexofuranose (140). KOH (1.62 g, 
28.9 mmol) in MeOH (80 mL) was added to a stirred solution of 139 (1.82 g, 5.85 mmol) 
in MeOH (80 mL). The reaction mixture was left to stir at room temperature for 1 h, then 
was neutralized with 5% HCl/H2O.
 
Volatiles were evaporated, and the residue was 
column chromatographed (hexanes/EtOAc, 3:1  1:1) to give 140 (0.87 g, 72%): 1H 
NMR (300 MHz)  2.07–2.14 (m, 2H), 2.80 (br s, 1H), 3.42 (s, 3H), 3.48 (td, J = 1.1, 3.9 
Hz, 1H), 3.79 (ddd, J = 3.9, 6.1, 7.3 Hz, 1H), 3.85 (br d, J = 10.3 Hz, 1H), 3.90 (dd, J = 
3.7, 10.3 Hz, 1H), 4.27–4.29 (m, 1H), 4.54–4.67 (m, 2H); 13C NMR  30.9, 57.5, 70.2, 
73.9, 75.2, 80.2, 91.6; MS FAB m/z 208 (5, [M+H]
+
), 71 (100); HRMS ESI m/z calcd for 
C7H14NO6 [M+H]
+
 208.0821, found 208.0807. 
2-Chloro-3-O-methyl-6-O-nitro-1,2,5-trideoxy-D-arabino-hexofuranose (103).
 
 
Solution of 137 (0.60 g, 2.90 mmol) in THF (15 mL) was added to a stirred solution of 
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Ph3P (1.52 g, 5.78 mmol) and DIAD (0.89 g, 0.86 mL, 4.38 mmol) in THF (15 mL) 
followed by addition of freshly prepared HCl•pyridine (0.50 g, 4.33 mmol). The 
suspension was stirred overnight at room temperature. Volatiles were evaporated, and the 
residue was chromatographed (hexanes  hexanes/EtOAc, 6:1) to give 103 (0.38 g, 
61%): 
1
H NMR  2.14–2.18 (m, 2H), 3.44 (s, 3H), 3.73 (d, J = 3.9 Hz, 1H), 3.78–3.82 
(m, 1H), 4.02 (d, J = 10.7 Hz, 1H), 4.10 (dd, J = 4.4, 10.7 Hz, 1H), 4.24–4.27 (m, 1H), 
4.56–4.67 (m, 2H); 13C NMR  31.3, 58.1, 59.4, 70.0, 74.2, 80.9, 92.8; HRMS 
ESI/DART m/z calcd for C7H16
35
ClN2O5 [M+NH4]
+ 
243.0742, found 243.0752; calcd for 
C7H16
37
ClN2O5 [M+NH4]
+ 
245.0716, found 245.0715.
 
 
2-Bromo-3-O-methyl-6-O-nitro-1,2,5-trideoxy-D-arabino-hexofuranose (104).
 
 
Solution of 137 (0.65 g, 3.13 mmol) in THF (15 mL) was added to a stirred solution of 
Ph3P (1.64 g, 6.25 mmol) and DIAD (0.95 g, 0.92 mL, 4.69 mmol) in THF (15 mL) 
followed by addition of freshly prepared HBr•pyridine (0.75 g, 4.69 mmol). The 
suspension was stirred overnight at room temperature. Volatiles were evaporated, and the 
residue was column chromatographed (hexanes/EtOAc, 10:1  6:1) to give 104 (0.39 g, 
46%): 
1H NMR δ 2.19-2.27 (m, 2H), 3.49 (s, 3H), 3.82 (dt, J = 4.2, 6.8 Hz, 1H), 3.92 (d, 
J = 3.8 Hz, 1H), 4.14 (dd, J = 1.86, 11.0 Hz, 1H), 4.21 (dd, J = 4.47, 11.0 Hz, 1H), 4.27-
4.31 (m, 1H), 4.58-4.70 (m, 2H); 
13
C NMR δ 31.5, 48.5, 58.0, 70.0, 74.6, 81.2, 93.0. 
HRMS ESI/DART m/z calcd for C7H16
79
BrN2O5 [M+NH4]
+
 287.0237 ,found 287.0252; 
calcd for C7H16
81
BrN2O5 [M+NH4]
+ 
289.0218, found 289.0233. 
1,5-Dideoxy-2-O-tosyl-3-O-methyl-6-O-nitro-D-arabino-hexofuranose (141). TsCl 
(116 mg, 1.057 mmol) was added to a stirred solution of 140 (200 mg, 0.965 mmol) in 
anhydrous pyridine (1 mL) at ambient temperature. After 16 h, the volatiles were 
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evaporated and residue was partitioned between ice-cold AcOH/H2O (1:99, 30 mL) and 
CHCl3 (30 mL). The organic layer was separated and the aqueous layer was extracted 
with CHCl3 (30 mL). Combined organic phase was washed with ice-cold saturated 
NaHCO3/H2O (30 mL), brine (30 mL) and dried (Na2SO4), concentrated in vacuo and 
column chromatographed (EtOAc/hexane, 5:95 → 35:65) to give 141 (240 mg, 69%) as a 
colorless oil: 
1H NMR δ 1.96-2.11 (m, 2H), 2.47 (s, 3H), 3.29 (s, 3H), 3.65 (td, J = 1.2, 
4.4 Hz, 1H), 3.69-3.75 (m, 1H) , 3.81 (dd, J = 4.1, 11.4 Hz, 1H), 3.92 (d, J = 11.4 Hz, 
1H), 4.48-4.60 (m, 2H), 4.86 (td, J = 1.2, 4.1 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.81 (d, J 
= 8.4 Hz, 2H). 
13C NMR δ 21.6, 30.5, 58.0, 69.8, 71.3, 80.1, 83.1, 89.4, 127.8, 130.0, 
133.4, 145.4. HRMS ESI/DART m/z calcd for C14H23N2O8S [M+NH4]
+ 
379.1170, found 
379.1169. 
2-Chloro-1,2,5-trideoxy-3-O-methyl-6-O-nitro-D-ribo-hexofuranose (100). Step 
a. TfCl (123 μL, 195 mg, 1.16 mmol) was added to a stirred solution of 140 (200 mg, 
0.96 mmol) and DMAP (354 mg, 2.9 mmol) in anhydrous CH2Cl2 (2 mL) at 0°C (ice-
bath). After 1 h, the reaction mixture was partitioned between ice-cold AcOH/H2O (1:99, 
30 mL) and CH2Cl2 (30 mL). The aqueous layer was extracted with CH2Cl2 (30 mL) and 
the combined organic phase was washed with ice-cold saturated NaHCO3/H2O (30 mL), 
brine (30 mL) and dried (Na2SO4) to give 142 as a colorless oil (243 mg, 74%) of 
sufficient purity to be used in next step. Column chromatography (EtOAc/hexane, 5:95 
→ 30:70) gave pure sample of 142: 1H NMR δ  2.01-2.09 (m, 1H), 2.09-2.19 (m, 1H), 
3.46 (s, 3H), 3.75-3.82 (m, 2H), 3.98 (dd, J =3.6, 12.1 Hz,1H), 4.17 (d, J = 12.1 Hz, 1H), 
4.53-4.65 (m, 2H), 5.26 (d, J = 3.5 Hz, 1H); Step b. A solution of crude 142 (100 mg, 
0.29 mmol; from step a) and dried LiCl (62.5 mg, 1.47 mmol) in DMF (1 mL) was stirred 
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for 5 h at ambient temperature under N2. Volatiles were evaporated and residue was 
partitioned between ice-cold saturated NaHCO3/H2O (15 mL) and EtOAc (15 mL). The 
separated organic phase was washed with brine (15 mL), dried (Na2SO4) and  column 
chromatographed (EtOAc/hexane, 5:95 → 15:85) to give 100 (49 mg, 74%)  as a 
colorless oil: 
1H NMR δ 1.89-2.02 (m , 1H), 2.06-2.18 (m, 1H), 3.44 (s, 3H), 3.58 (dd,  J 
= 5.1, 8.0 Hz, 1H), 3.95 (td, J = 4.1, 8.3 Hz, 1H), 4.05 (dd,  J = 2.7, 10.8 Hz, 1H), 4.32 
(dd,  J = 4.8, 10.8 Hz, 1H), 4.49 (td, J = 2.8, 5.0 Hz, 1H), 4.53-4.64 (m, 2H); 
13
C NMR δ 
30.7, 57.6, 58.1, 69.9, 73.9, 76.1, 84.7. HRMS ESI/DART m/z calcd for C7H16
35
ClN2O5 
[M+NH4]
+
 243.0742, found 243.0747; calcd for C7H16
37
ClN2O5 [M+NH4]
+ 
245.0718, 
found 245.0716. 
2-Bromo-1,2,5-trideoxy-3-O-methyl-6-O-nitro-D-ribo-hexofuranose (101). A 
solution of crude 142 (100 mg, 0.29 mmol; prepared as described for 100, step a) and 
dried LiBr (77 mg, 0.88 mmol) in DMF (1 mL) was stirred for 5 h at ambient temperature 
under N2. Volatiles were evaporated and residue was partitioned between ice-cold 
saturated NaHCO3/H2O (15 mL) and EtOAc (15 mL). The separated organic phase was 
washed with brine (15 mL), dried (Na2SO4) and  column chromatographed 
(EtOAc/hexane, 5:95 → 15:85) to give 101 ( 41 mg, 52 %) as a colorless oil: 1H NMR δ 
1.90-2.0 (m , 1H), 2.06-2.16 (m , 1H), 3.39-3.45 (m , 4H), 3.97 (td, J = 4.2, 8.0 Hz, 1H), 
4.20 (dd, J = 3.0, 11 Hz, 1H), 4.45 (dd,  J = 4.8, 11.0 Hz, 1H), 4.50 (td, J = 2.9, 5.0 Hz, 
1H), 4.53-4.64 (m, 2H); 
13
C NMR δ 30.7, 49.5, 58.2, 69.9, 74.0, 76.5, 84.4; HRMS 
ESI/DART m/z calcd for C7H16
79
BrN2O5[M+NH4]
+
 287.0237, found 287.0239;  calcd for 
C7H16
81
BrN2O5 [M+NH4]
+
 289.0222, found 289.0218. 
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Biomimetic studies with the 3-hydroxyl substratess. Typical Procedure. A 
solution of 96 (20 mg, 0.06 mmol), Bu3SnH (77 μL, 83 mg, 0.28 mmol), and AIBN (18 
mg, 0.12 mmol) in dried toluene (2 mL) was deoxygenated (Ar) for 20 min and then 
heated at 95 ºC for 1 h. Volatiles were evaporated carefully (at 25 
o
C and diminished 
pressure ~ 40 mmHg) and the residue was purified by column chromatography 
(EtOAc/hexane, 10:90 → 70:30)  to give 1,2,5-trideoxy-D-glycero-hexofuranose-3-ulose 
143a in equilibrium mixture (~ 1:1) with cyclic hemiacetal 144a (5 mg, 67%) as a 
colorless oil: HRMS ESI/DART m/z calcd for C6H11O3 [M+H]
+
 131.0703, found 
131.0707.  Ketone 143a had: 
1H NMR δ 1.84-1.93 (m, 1H), 1.95-2.06 (m, 2H), 2.15-2.27 
(m, 2H), 3.74-3.85 (m, 2H), 3.88 (dd, J = 4.9, 7.4 Hz, 1H), 4.04-4.16 (m, 2H); 
13
C NMR 
δ 32.9, 38.9, 59.8, 68.9, 78.6, 215.9. Hemiacetal 144a had: 1.95-2.06 (m, 1H), 2.15-2.27 
(m, 1H), 2.46-2.64 (m, 3H), 3.93-4.03 (m, 2H), 4.04-4.16 (m, 1H) 4.28 (dd, J = 2.27, 5.6 
Hz, 1H), 4.37 (dt, J = 4.1, 9.2 Hz, 1H);
 13C NMR δ 32.1, 36.7, 64.6, 68.3, 85.7, 114.9. 
Also isolated from the reaction mixture was 1,5-dideoxy-2-O-tosyl-D-ribo-
hexofuranose (3.3 mg, 19%): 
1
H NMR  1.81-1.94 (m, 2H), 2.46 (s, 3H), 3.74-3.85 (m, 
4H), 3.86-3.93 (m, 1H), 4.12 (dd, J = 4.9, 11.2 Hz, 1H), 4.95 (dt, J = 3.0, 5.3 Hz, 1H), 
7.38 & 7.82 (2  d, J = 8.3 Hz, 2  2H); 
Analogous treatment of 9 (20 mg, 0.06 mmol) with Bu3SnD (77 μL, 83 mg, 0.28 
mmol), instead of Bu3SnH gave 2-deuterio epimers (2R/S, ~1:1) of 143b in equilibrium 
mixture (~ 1:1) with 144b (5.2 mg, 71%) as a colorless oil: 
1
H NMR spectrum of 
143b/144b corresponded to this of the above 143a/144a with reduction of the integrated 
intensity for the H2/2' signal at δ 2.15-2.27 and 2.46-2.64 to approximately half and 
simplification of the H1/1' signals at δ 4.04-4.16 (m, 1H) and 4.33-4.40 (m, 1H). 13C 
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NMR spectrum of 143b/144b showed triplets at δ 36.7 and 38.9 (J = 20.1 Hz) for C2 
carbons because of splitting to deuterium and two close peaks of equal intensity for each 
hemiacetals carbons. HRMS ESI/DART m/z calcd for C6H10DO3 [M+H]
+
 132.0765, 
found 132.0768. Isotopic incorporation (MS) was calculated to be 85-95% for [
2
H] 
isotopomers of 143b/144b depends on the experiments. The 
13
C NMR spectrum for the 
sample of 143b/144b (2R/S, ~1:1, [
2
H] incorporation ~85%) showed residual peaks at 
38.9 ppm and 36.7 for the unlabeled 143a and 144a, respectively and isotopically upfield 
shifted carbon signals for 143b (two sets of triplets of equal intensity at 38.60 and 38.63 
ppm with JC2-D = 20.1 Hz) and 144b two sets of triplets of equal intensity at 36.35 and 
3.36 with JC2-D = 20.1 Hz), respectively.   
6-O-Benzoyl-1,2,5-trideoxy-D-glycero-hexofuranose-3-ulose (145a) BzCl (23 µL, 
28 mg, 0.2 mmol), pyridine (44 µL, 43 mg, 0.54 mmol), and DMAP (4 mg, 0.032 mmol) 
were added to a stirred solution of 143a/144a (30 mg, 0.23 mmol), in CH2Cl2 (2 mL). 
Stirring was continued at ambient temperature for 3 h and MeOH (0.3 mL) was added. 
Volatiles were evaporated and the residue was chromatographed (EtOAc/hexane, 5:95 
→15:85) to give 145a (22 mg, 81%) as an colorless oil: 1H NMR δ 2.06-2.16 (m, 1H), 
2.18-2.28 (m, 1H), 2.51 (dd, J = 6.50, 8.26 Hz, 2H), 3.90 (dd, J = 4.71, 7.0 Hz, 1H), 4.05-
4.13 (m,1H), 4.28-4.36 (m, 1H), 4.39-4.46 (m,1H), 4.47-4.54 (m, 1H), 7.41-7.47(m, 2H), 
7.56 (tt, J = 1.5, 7.4 Hz, 1H), 8.0 (d, J = 8.57 Hz, 2H); 
13C NMR δ 29.9, 36.8, 60.9, 64.7, 
76.8, 128.5, 129.7, 130.2, 133.1, 166.5, 215.5. HRMS TOF/DART m/z calcd for 
C13H18NO4 [M+NH4]
+
 252.1230, found 252.1234. 
6-O-Benzoyl-2-deuterio-1,2,5-trideoxy-D-glycero-hexofuranose-3-ulose (145b). 
Treatment of 143b/144b (30 mg, 0.23 mmol) with BzCl, as described for 145a, gave 
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145b (12 mg, 67%) as an colorless oil: 
1
H NMR spectrum of 144b corresponded to this 
of the above 145a with reduction of the integrated intensity for the H2/2' signal at δ 2.51 
to half and simplification of the H1/1' signals at 4.05-4.13 and 4.28-4.36. 
13
C NMR 
spectrum showed triplet at δ 36.4 (J = 20.1 Hz) for C2 because of splitting to deuterium. 
HRMS ESI/DART m/z calcd for C13H13DNaO4 [M+Na]
+
 258.0847, found 258.0836. 
Biomimetic studies with 3-O-methyl precursors. 2-(Hydroxyethyl)-3-
methoxyfuran (152a). A solution of 102 (25 mg, 0.069 mmol), Bu3SnH (92 μL, 100 mg, 
0.34 mmol), and AIBN (22.7 mg, 0.14 mmol) in dried toluene (2 mL), was deoxygenated 
(Ar) for 20 min and then heated at 95 ºC for 1.5 h. Volatiles were evaporated and the 
residue was purified by column chromatography (EtOAc/hexane, 10:90 → 75:25) to give 
152a (6.2 mg, 63%) followed by 1,5-dideoxy-2-O-tosyl-3-O-methyl-D-ribo-
hexofuranose (152b, 4.8 mg, 22%) as a colorless oils. Compound 152a had: 
1
H NMR  
2.89 (t, J = 6.0 Hz, 2H), 3.76 (s, 3H), 3.86 (t, J = 6.0 Hz, 2H), 6.31 (d, J = 2.1 Hz, 1H), 
7.16 (d, J = 2.1 Hz, 1H);
 13
C NMR  29.3, 59.4, 60.9, 102.9, 136.7, 139.7, 144.3. HRMS 
ESI/FT-ICR m/z calcd for C7H11O3 [M+H]
+
 143.0702, found 143.0701. Compound 152b 
had:  
1H NMR δ 1.74-1.84 (m, 1H), 1.85-1.94 (m, 1H), 2.29 (t, J = 5.9 Hz, 1H), 2.46 (s, 
3H), 3.32 (s, 3H), 3.49 (dd, J = 4.9, 8.3 Hz, 1H), 3.72-3.79 (m, 2H), 3.85-3.94 (m, 2H), 
4.07 (dd, J = 4.7, 11.3 Hz, 1H), 5.11 (dt, J = 2.4, 4.8 Hz, 1H), 7.36 (d, J = 8.1 Hz, 2H), 
7.83 (d, J = 8.1 Hz, 2H); 
13C NMR δ 21.6, 35.6, 58.3, 60.6, 70.9, 76.5, 79.1, 83.8, 127.8, 
129.9, 133.8, 145.1. HRMS ESI/DART m/z calcd for C14H21O6S [M+H]
+
 317.1053, 
found 317.1055. 
Analogous treatment of 102 with Bu3SnD gave 152a (6.0 mg, 61%) and (152b, 4.8 
mg, 22%) with spectroscopic data as above. 
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Treatment of 141 (25 mg, 0.069 mmol) with Bu3SnH, as described for 152a, gave 
152a (5.0 mg, 51%) with data as above and 1,5-dideoxy-2-O-tosyl-3-O-methyl-D-
arabino-hexofuranose 152c (8.3 mg, 38%) as a colorless oil: 
1
H NMR δ 1.86-1.94 (m, 
2H), 2.04-2.11 (m, 1H), 2.47 (s, 3H), 3.31 (s, 3H), 3.70 (dt, J = 1.2, 5.0 Hz, 1H), 3.73-
3.82 (m, 3H), 3.83 (d, J = 4.3 Hz, 1H), 3.93 (d, J = 11.7 Hz, 1H), 4.88 (dt, J = 1.3, 4.2 
Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H); 
13
C NMR δ 21.6, 35.3, 58.0, 
60.5, 71.3, 82.7, 83.4, 89.7, 127.8, 130.0, 133.5, 145.3. HRMS ESI/DART m/z calcd for 
C14H21O6S [M+H]
+
 317.1053, found 317.1050. 
Analogous treatment of 141 with Bu3SnD gave 152a (4.9 mg, 50%) and 152c (8.2 
mg, 38%) with spectroscopic data as above. 
1,2,5-Trideoxy-3-O-methyl-D-glycero-hex-2-enofuranose (155). Typical 
Procedure. A solution of 104 (20 mg, 0.074 mmol), Bu3SnD (99 μL, 108 mg, 0.369 
mmol), and AIBN (24 mg, 0.146 mmol) in dried toluene (2 mL), was deoxygenated (Ar) 
for 20 min and then heated at 95 ºC for 2 h. Volatiles were evaporated and the residue 
was purified by column chromatography (EtOAc/hexane, 10:90 → 70:30) to give 15535 
(5.0 mg, 47%) as a colorless oil: 
1H NMR δ 1.73-1.87 (m, 1H), 1.94-2.09 (m, 1H), 2.58 
(t, J = 5.6 Hz, 1H), 3.68 (s, 3H), 3.76-3.82 (m, 2H), 4.60-4.70 (m, 3H), 4.73-4.79 (m, 
1H);
 13C NMR δ 35.6, 57.6, 60.6, 72.8, 81.2, 90.2, 157.7. HRMS ESI/DART m/z calcd 
for C7H16NO3 [M+NH4]
+
 162.1125, found 162.1131 
Comparison of Reaction Rates of 96, 97 or 99 with Bu3SnH. Independent solutions 
of 0.057 mmol samples of 96, 97 and 99 in toluene–d8 (2.0 mL) were treated with 5 molar 
equiv of Bu3SnH and 2 molar equiv of AIBN at 75
º
C. Aliquots of the individual reaction 
mixtures (0.3 mL) were diluted in toluene–d8 (0.2 mL) and directly analyzed by 
1
H NMR. 
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The 143a/144a (1:1)/starting material ratios were obtained by integrating disappearance 
of the peak at 4.55 ppm for H2 of 96 or 97 or at 3.96 ppm for H6 of 99 and appearance of 
the peak at 4.10 ppm for the H4 of 143a. The determinations were conducted under the 
pseudo-first-order conditions:  
k1t = -2.303 log(C/Co) + a 
Where C/Co is the ratio of the concentration of starting material 96, 97, or 99 in the 
mixture at time t to the initial concentration of starting material. Values of the term [-
log(C/Co)] were plotted against [t(min)k(s
-1
) = k1 (min
-1)
/3600]. 
Methyl D-xylofuranoside (157a). D-Xylose 156a (504 mg, 3.36 mmol) was 
dissolved in 0.5% HCl/MeOH (3 mL) and stirred at ambient temperature overnight. 
Reaction mixture was neutralized with Ag2CO3 (272 mg), stirred for an additional 30 min 
and filtered. The filtrate was evaporated to give 157a (474 mg, 86%; α/β, 3:2) with data 
as reported:
155
 
1H NMR  δ 3.44 (s, 1.2H, OMe-β), 3.49 (s, 1.8H, OMe-α), 3.84-3.94 (m, 
4H, H5-α, H5'-α, H5-β, H5'-β), 4.09 (t, J = 4.7 Hz, 1H, H2-α), 4.18-4.24 (m, 3H, H4-α, 
H4-β, H2-β), 4.32 (dd, J = 5.1, 6.2 Hz, 1H, H3-α), 4.43 (dd, J = 4.9, 9.9Hz, 1H,  H3-β), 
4.87 (s, 0.4H, H1-β), 4.98 (d, J = 4.4 Hz, 0.6H, H1-α). 
Methyl 5-[
2
H]-D-xylofuranoside (157b). Commercially available 5-[
2
H]-D-Xylose 
156b (250 mg, 1.66 mmol) was treated with 0.5% HCl/MeOH (3.6 mL) and Ag2CO3 
(500 mg) as described above for 157a to give 157b (271 mg, 99%; α/β, 3:2): 1H NMR 
was as described above for 157a except for the 50% reduction in intensities for the H5 
and H5' peaks at 3.84-3.94 ppm. 
[
2
H3]-Methyl D-xylofuranoside (157c). Commercially available D-xylose 156a (150 
mg, 0.1mmol) was treated with 0.5% DCl/MeOD (1 mL) and Ag2CO3 (163 mg), as 
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described above for 157a to give 157c (155 mg, 92%; α/β, 3:2) with data as reported for 
157a except for the absence of the peak for OMe-β at 3.44 ppm and OMe-α at 3.49 ppm.  
[
2
H3]-Methyl D-4-[
2
H]-xylofuranoside (163a). Commercially available D-4-[
2
H]-
xylose 162a (45 mg, 0.29 mmol) was treated with 0.5% DCl/MeOD (1 mL) and Ag2CO3 
(49 mg), as described above for 157a to give 163a (46 mg, 92%; α/β, 3:2) with 1H NMR 
as described above for 157a except for the absence of the peak for OMe-β at 3.44 ppm, 
OMe-α at 3.49 ppm and H4-α, H4-β at 4.18-4.24 ppm and simplification of peaks for H5-
α, H5'-α, H5-β, H5'-β at 3.84-3.94 ppm,  H3-α at 4.32 ppm and H3-β at 4.43 ppm.  
 [
2
H3]-Methyl D-5,5'-[
2
H2]-xylofuranoside (163b). Commercially available D-[5,5'-
2
H2]-xylose 162b (45 mg, 0.29 mmol) was treated with 0.5% DCl/MeOD (1 mL) and 
Ag2CO3 (49 mg), as described above for 157a to give 163b (47mg, 93%; α/β, 3:2) with 
1
H NMR as described above for 157a except for the absence of the peaks for OMe-β at 
3.44 ppm, OMe-α at 3.49 ppm, H5 and H5' at 3.84-3.94 ppm and simplification of H4 
peak at 4.18-4.24 ppm.  
Methyl 3,5-O-isopropylidene-α-D-xylofuranoside (158a). H2SO4 (18 M, 1 drop) 
was added to a solution of 157a (474 mg, 2.89 mmol; α/β, 3:2) in acetone (3 mL) and the 
resulting mixture was stirred at ambient temperature for 60 min. The reaction mixture 
was neutralized NH4OH (14.8 M) to a slightly basic pH and was filtered and evaporated. 
The oily residue was column chromatographed (EtOAc/hexane, 3:7) to give α anomer of 
158a (185 mg, 31%) and β anomer of 158a (90 mg, 16%) with spectral data as 
reported.
156
 The α anomer had: 1H NMR δ 1.38 (s, 3H, Me), 1.42 (s, 3H, Me), 2.94 (br. d, 
J = 2.0 Hz, 1H, OH), 3.55 (s, 3H, OMe), 3.97 (dd, J = 2.8, 13.7 Hz, 1H, H5), 4.04 (dd, J 
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= 2.8, 10.0 Hz, 1H, H5'), 4.04-4.07 (m, 1H, H4), 4.14 (br. s, 1H, H2), 4.22 (br. d, J = 1.8 
Hz, 1H, H3), 5.21 (d, J = 4.2 Hz, 1H, H1). 
Methyl 5-[
2
H]-3,5-O-isopropylidene-α-D-xylofuranoside (158b). Treatment of 
157b (294 mg, 1.78 mmol) with acetone/H2SO4, as described for 158a, gave α anomer of 
158b (53 mg, 15%) with data as described for 158a except for the 50% reduction in 
intensities of H5 and H5' peaks at 3.93 ppm (br. s, 0.7H) and 4.00 ppm (br. s, 0.3H) and 
simplification of proton splitting for H4 at 4.12 ppm (br. t, J = 3.6 Hz). 
[
2
H3]-Methyl 3,5-O-isopropylidine-α-D-xylofuranoside (158c). Treatment of 157c 
(155 mg, 0.92 mmol, α/β, 3:2) with acetone/H2SO4, as described for 158a, gave α anomer 
of 158c (42 mg, 22%) and β anomer of 158c (39 mg, 21%).The α anomer had data as 
described for 158a except for the absence of the peak for OMe at 3.55 ppm.  
 [
2
H3]-Methyl 3,5-O-isopropylidine-α-D-4-[
2
H]-xylofuranoside (164a). Treatment 
of 163a (46 mg, 0.27 mmol) with acetone/ H2SO4, as described for 158a, gave α anomer 
of 164a (14 mg, 25%) and β anomer of 164a (13 mg, 23%).The α anomer had data as 
described for 158a except for absence of the peak for OMe at 3.55 ppm and H4 at 4.04-
4.07 ppm and simplification of H5 peak at 3.97 ppm (d, J = 13.2 Hz, 1H, H5), H5' peak 
at 4.04 ppm (d, J = 13.2 Hz, 1H, H5') and H3 peak at 4.22 ppm (s, 1H, H3).  
 [
2
H3]-Methyl 3,5-O-isopropylidine-α-D-5-[
2
H2]-xylofuranoside (164b). Treatment 
of 163b (46 mg, 0.3 mmol) with acetone/ H2SO4, as described for 158a, gave α anomer of 
164b (13 mg, 23%) and β anomer of 164b (10 mg, 18%). The α anomer had data as 
described for 158a except for the absence of the peak for OMe at 3.55 ppm,  H5 at 3.97 
ppm and H5' at 4.04 ppm and simplification of H4 peak 4.05 ppm (d, J = 2.7 Hz, 1H, 
H4). 
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Methyl 2-azido-2-deoxy-3,5-O-isopropylidene-α-D-lyxofuranoside (159a). Step a. 
Procedure A. TfCl (37 µL, 58.64 mg, 0.35 mmol) was added to a cold (0 
o
C, ice-bath) 
stirred solution of 158a (54 mg, 0.26 mmol) and DMAP (97 mg, 0.79 mmol) in dry 
CH2Cl2 (5 mL). After 15 min the ice-bath was removed and the resulting solution was 
stirred at ambient temperature for an additional 15 min and was partitioned between ice-
cold AcOH/H2O (1:99, 25 mL) and CH2Cl2. The organic layer was washed with ice-cold 
saturated NaHCO3/H2O, brine, and dried (MgSO4), filtered and evaporated. The residual 
oil was column chromatographed (EtOAc/hexane, 1:1) to give methyl 3,5-O-
isopropylidene-2-O-trifluromethanesulfonyl-α-D-xylofuranoside (159a; 70 mg, 80%) 
with spectroscopic data as reported:
138
 
1H NMR δ 1.36 (s, 3H, Me), 1.40 (s, 3H, Me), 
3.48 (s, 3H, OMe) 3.85 (dd, J = 3.6, 12.6 Hz, 1H, H5), 4.00 (dd, J = 3.6, 12.6 Hz, 1H, 
H5'), 4.12 ("q", J = 3.8 Hz, 1H, H4), 4.44 (dd, J = 1.9, 3.7 Hz, 1H, H3), 5.01 (dd, J = 1.7, 
4.2 Hz, 1H, H2), 5.22 (d, J = 4.3 Hz, 1H, H1). 
Step b. Procedure B. NaN3 (65 mg, 1.01 mmol) was added to a solution of 159a (70 
mg, 0.21 mmol) in DMF (4 mL) and the mixture was stirred at 100 ºC for 18 h. The 
volatiles were evaporated and the residue was partitioned between CH2Cl2 and H2O. The 
organic layer was washed (brine), dried (MgSO4) and evaporated. The oily residue was 
chromatographed (25 → 40% EtOAc/hexane) to give 160a (38 mg, 80%) with data as 
reported:
138
 
1H NMR δ 1.46 (s, 6H, 2 × Me), 3.48 (s, 3H, OMe), 3.63 (t, J = 4.7 Hz, 1H, 
H2), 3.98 (dd, J = 2.1, 13.6 Hz, 1H, H5), 3.98-3.99 (m, 1H, H4), 4.06 (dd, J = 3.2, 13.7 
Hz,1H, H5'), 4.44 (dd, J = 2.2, 4.5 Hz, 1H, H3), 5.22 (d, J = 4.8 Hz, 1H, H1). 
Methyl 2-[
15
N]-azido-2-deoxy-3,5-O-isopropylidene-α-D-lyxofuranoside ([15N]-
160a). Treatment of 159a (64 mg, 0.19 mmol) with [
15
N]-NaN3 (60 mg, 0.91 mmol) by 
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procedure B provided [
15
N]-160a (31 mg, 71%) with data as described for 160a, except 
for additionally broadened signal for H2 at 3.63 ppm ("t", J = 4.7 Hz). 
Methyl 5-[
2
H]-2-azido-2-deoxy-3,5-O-isopropylidene-α-D-lyxofuranoside (160b). 
Step a. Triflation of 158b (50 mg, 0.24 mmol) by procedure A gave 159b (60 mg, 75%) 
with identical spectroscopical properties as 159a except for H4, H5 and H5' signals: 
1
H 
NMR δ 3.85 (br. "d", J = 3.6 Hz, 0.7H, H5), 4.00 (br. "d", J = 3.6 Hz, 0.3H, H5'), 4.12 (t, 
J = 3.9 Hz, 1H, H4). Step b. Azidation of 159b (58 mg, 0.17 mmol) by procedure B 
provided 160b (26 mg, 66%) with data as described for 160a except for the 50% 
reduction in the intensities for the H5 and H5' peaks at 3.98 ppm and 4.06 ppm and 
simplification of the H4 peak at 3.98-3.99 ppm. 
[
2
H3]-Methyl 2-azido-2-deoxy-3,5-O-isopropylidene-α-D-lyxofuranoside (160c). 
Step a.  Triflation of 158c (42 mg, 0.20 mmol) with TfCl (33 µL, 51 mg, 0.3 mmol) and 
DMAP (74.3 mg, 0.6 mmol) in dry CH2Cl2 (1 mL) by procedure A gave 159c (55 mg, 
80%) with identical spectroscopical properties except for the ~100% reduction in the 
intensity of OMe peak at 3.48 ppm. This material was sufficiently pure to be used 
directly in next step without column chromatography. Step b. Treatment of 159c (36.9 
mg, 0.56 mmol) with NaN3 (55 mg, 0.16 mmol) in DMF (1.5 mL) by procedure B gave 
160c (20 mg, 54 %) with data as reported for 160a except for the absence of the peak for 
OMe at 3.55 ppm. 
[
2
H3]-Methyl 2-azido-2-deoxy-3,5-O-isopropylidene-α-D-4-[
2
H]-lyxofuranoside 
(166a). Step a.   Triflation of 164a (13mg, 0.06 mmol) with TfCl (10 µL, 15.8 mg, 0.09 
mmol) and DMAP (22.9 mg, 0.19 mmol) in dry CH2Cl2 (1 mL) by procedure A gave 
165a (14.6 mg, 69%). This material was sufficiently pure to be used directly in next step 
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without column chromatography. Step b. Treatment of 165a (14.6 mg, 0.04 mmol) with 
NaN3 (9.8 mg, 0.15 mmol) in DMF (1 mL) by procedure B gave 166a (7 mg, 70%) with 
data as reported for 160a except for absence of peaks for OMe at 3.55 ppm and H4 at 
3.98-3.99 ppm and simplification of H5 peak at 3.98 ppm (d, J = 13.3 Hz, 1H, H5), H5' 
peak at 4.06 ppm (d, J = 13.3 Hz, 1H, H5') and H3 peak at 4.44 ppm (d, J = 4.5 Hz, 1H, 
H3). 
 [
2
H3]-Methyl 2-azido-2-deoxy-3,5-O-isopropylidene-α-D-5-[
2
H2]-lyxofuranoside 
(166b). Step a. Triflation of 164b (13mg, 0.06 mmol) with TfCl (10 µL, 15.8 mg, 0.09 
mmol) and DMAP (22.7 mg, 0.18 mmol) in dry CH2Cl2 (1 mL) by procedure A gave 
165b (20 mg, 94%). This material was sufficiently pure to be used directly in next step 
without column chromatography. Step b. Treatment of 165b (20 mg, 0.06 mmol) with 
NaN3 (13.4 mg, 0.2 mmol) in DMF (1 mL) by procedure B gave 166b (9 mg, 66 %) with 
data as reported for 160a except absence of peaks for H5 at 3.98 ppm and H5' at 4.06 
ppm and simplification of H4 peak at 3.98-3.99 ppm (d, J = 2.4 Hz, 1H, H4). 
Methyl 2-azido-2-deoxy-α-D-lyxofuranoside (161a). Procedure C. A solution of 
160a (38 mg, 0.17 mmol) in AcOH/H2O (7:3, 5 mL) was stirred at 50 ºC for 60 min. The 
volatiles were evaporated and the crude product was column chromatographed (50 → 
75% EtOAc/hexane) to give 161a
138
 (18 mg, 56%): 
1H NMR δ 3.38 (s, 3H, OMe), 3.88 
(dd, J = 2.8, 12.4 Hz, 1H, H5), 3.94 (dd, J = 1.7, 5.4 Hz, 1H, H2), 3.95 (dd, J = 3.4, 12.4 
Hz, 1H, H5'), 4.15 (td, J = 3.3, 6.3 Hz, 1H, H4), 4.68 (t, J = 5.8 Hz, 1H, H3), 4.92 (d, J = 
1.7 Hz, 1H, H1); 
13C NMR δ 55.44 (OCH3), 61.39 (C5), 67.89 (C2), 73.34 (C3), 78.19 
(C4), 105.57 (C1). 
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Methyl 2-[
15
N]-azido-2-deoxy-α-D-lyxofuranoside ([15N]-161a). Deprotection of 
[
15
N]-160a (30 mg, 0.13 mmol) by procedure C gave [
15
N]-161a (15 mg, 61%): 
1
H NMR 
was as described for 161a except for broadening the signals at 4.92 ppm  (H1) and 4.68 
ppm (H3). On 
13
C NMR additional spin-spin splitting was observed for C2 signal at 
67.88 ppm (d, J15Nα-C2 = 2.3 Hz; 50% intensity of the C2 peak) in agreement with 
literature value for 
15
N labeled 2'-azido-2'-deoxyuridine.
16
 
Methyl 5-[
2
H]-2-azido-2-deoxy-α-D-lyxofuranoside (161b). Deprotection of 160b 
(25 mg, 0.11 mmol) by procedure C gave 161b (10 mg, 48%): 
1
H NMR was as described 
for 161a except for the simplification and 50% reduction in the intensities of H5 and H5' 
peaks at 3.85-3.95 ppm and simplification of proton splitting for H4 at 4.15 ppm (dd, J = 
3.3, 6.3 Hz).  
[
2
H3]-Methyl 2-azido-2-deoxy-α-D-lyxofuranoside (108). Deprotection of 160c (20 
mg, 0.09 mmol) with AcOH/H2O (7:3, 1 mL) as described for 161a gave 108 (12 mg, 
73%) with data as reported for 161a except for the absence of the peak for OMe at 3.38 
ppm in 
1
HNMR and 
13
C NMR spectrum showed small intensity broad singlet at δ 54.61 
for OCD3 because of splitting to deuterium. 
[
2
H3]-Methyl 2-azido-2-deoxy-α-D-4-[
2
H]-lyxofuranoside (167a). Deprotection of 
166a (7 mg, 0.03 mmol) with AcOH/H2O (7:3, 1 mL) as described for 161a gave 167a 
(4.2 mg, 73%) with 
1
H NMR data as reported for 161a except  for absence of peaks for 
OMe at 3.38 ppm and H4 at 4.15 ppm and simplification of H5 peak at 3.88 ( d, J = 12.5 
Hz, 1H, H5), H5' peak at 3.95 (d, J = 12.4 Hz, 1H, H5') and H3 peak at 4.68 (d, J = 5.7 
Hz, 1H, H3). 
13
C NMR spectrum showed small intensity broad singlet at δ 55.44 ppm  for 
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OCD3 and triplet at δ 75.54 ppm (J = 22.1 Hz) for C4 peak because of splitting to 
deuterium.   
 [
2
H3]-Methyl 2-azido-2-deoxy-α-D-5-[
2
H2]-lyxofuranoside (167b).  Deprotection 
of 166b (9 mg, 0.05 mmol) with AcOH/H2O (7:3, 1 mL) as described for 161a gave 167b 
(5.2 mg, 71 %) with data as reported for 161a except for absence of peaks for OMe at 
3.38 ppm, H5 at 3.88 ppm, and H5' at 3.95 ppm and simplification of H4 peak at 4.15 
ppm (d, J = 6.3Hz, 1H, H4). 
13
C NMR spectrum showed small intensity broad singlet at 
δ 55.38 for OCD3 and at δ 61.39 ppm for C5 peak because of splitting to deuterium.   
2'-Azido-2'-deoxycytidine (106). Step a. To a solution of 2'-azido-3',5'-O-diacetyl-2'-
deoxyuridine 170 (85 mg, 0.24 mmol), in anhydrous CH2Cl2 (3 mL) under argon added 
DMAP (3.5 mg, 0.02 mmol) and triethylamine (50.37 µL, 0.36 mmol). 2,4,6-
triisopropylbenzenesulfonyl chloride (110 mg, 0.36 mmol) was slowly added and the 
solution stirred for 2 h at room temperature. Reaction mixture diluted with CH2Cl2, 
extracted with saturated sodium bicarbonate solution, dried over Na2SO4 and evaporated 
to yield 2'-azido-3',5'-O-diacetyl-O
6
-(2,4,6-triisopropylbenzenesulfonyl)-2'-deoxyuridine, 
172 (140.2 mg, 93.7%) as cream foam. The crude compound was used for next step 
without further purification; Step b. Crude compound 172 (140.2 mg, 0.22 mmol) dried 
under vacuum, was dissolved in THF (2 mL) and treated with aqueous ammonium 
hydroxide (2.62 mL). The solution was stirred at room temperature for 14 h. Solvent 
evaporated, the reaction mixture was diluted with dichloromethane, extracted with water, 
dried over Na2SO4 and evaporated. The residue was column chromatographed (MeOH/ 
CHCl3, 2:8) to give 106 (51 mg, 85%) with data as reported.
145
  
1H NMR δ (CD3OD) 
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3.69-3.86 (m, 2H, H5',5''), 3.92-4.07 (m, 2H, H2', H4'), 4.43 (t, J = 5.9 Hz, 1H, H3'), 5.9 
(d, J = 3.7 Hz, 1H, H1'), 5.9 (d, J = 3.7 Hz, 1H, H5), 8.05 (d, J = 7.5 Hz, 1H, H6).  
4'-Azidocytidine (107). Step a. To a solution of 4'-azidouridine, 178 (60 mg, 0.14 
mmol), in anhydrous CH2Cl2 (3 mL) under argon added DMAP (2.12 mg, 0.02 mmol) 
and triethylamine (30 µL, 0.21 mmol). 2,4,6-triisopropylbenzenesulfonyl chloride (110 
mg, 0.36 mmol) was slowly added and the solution stirred for 2 h at room temperature. 
Reaction mixture diluted with CH2Cl2, extracted with saturated sodium bicarbonate 
solution, dried over Na2SO4 and evaporated to yield 4'-azido-O
6
-(2,4,6-
triisopropylbenzenesulfonyl)uridine, 179 (100 mg, 85%)  as cream foam.  The crude 
compound was used for next step without further purification; Step b. Crude compound 
178 (100 mg, 0.14 mmol) dried under vacuum, was dissolved in THF (4 mL) and treated 
with aqueous ammonium hydroxide (2 mL). The solution was stirred at room temperature 
for 14 h. Solvent evaporated, the reaction mixture was diluted with dichloromethane, 
extracted with water, dried over Na2SO4 and evaporated. The residue was column 
chromatographed (MeOH/CHCl3, 2:8) to give 107 (41 mg, 80%) with data as reported.
157
 
1H NMR δ (CD3OD) 3.40-3.53 (m, 2H, H5', 5''), 4.15-4.21 (m, 2H, H2', H3'), 5.5 (d, J = 
6.14 Hz, 1H, OH), 5.60-5.64 (m, 2H, 2XOH), 5.78 (d, J = 7.44 Hz, 1H, H5), 6.1 (d, J = 
5.17 Hz, 1H, H1'), 7.2-7.4 (m, 2H, NH2), 7.75 (d, J = 7.47 Hz, 1H, H6).  
2'-N-Phenylsulphenyl-2'-amino-2'-deoxyuridine (111). Silver acetate (55 mg, 0.32 
mmol) was added to a solution of diphenyl disulfide, 183 (72 mg, 0.32 mmol) in 
anhydrous DMF (2 mL) followed by 2'-amino-2'-deoxyuridine 182 (40 mg, 0.16 mmol). 
The resulting solution was stirred at 55º C for 16 h in dark. The silver mercaptide was 
removed by filtration. The filtrate was evaporated under reduced pressure and the residue 
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was column chromatographed (MeOH/CHCl3, 1:9) to give 111 as a white solid (22 mg, 
38%): 
1HNMR δ (DMSO-d6) 3.38-3.46 (m, 1H, H2'), 3.52-3.56 (m, 2H, H5',5''), 3.88-
3.92 (m, 1H, H4'), 4.08-4.12 (m, 1H, H3'), 4.61 (d, J = 8.5 Hz, 1H, NH), 5.10 (br. s, 1H, 
OH), 5.60 (d, J = 8.0 Hz, 1H, H5), 5.69 ( br s, 1H, OH), 5.94 (d, J = 8.2 Hz, 1H, H1'), 
7.04-7.09 (m, 1H, Ar), 7.15-7.19 (m, 2H, Ar), 7.21-7.27 (m, 2H, Ar), 7.78 (d, J = 8.1 Hz, 
1H, H6); 
13
C NMR  61.2 (C5'), 67.9 (C2'), 70.2 (C3'), 78.9 (C4'), 86.1 (C1'), 102.1 (C5), 
121.8 (Ar), 124.9 (Ar), 128.6 (Ar), 140.6 (Ar-S), 142.3 (C6), 150.8 (C2), 163.0 (C4). 
ESI-MS (m/z): 350 [M-H]
+
. 
2'-N-(4-trifluoromethylphenyl)sulphenyl-2'-amino-2'-deoxyuridine (112). 
Treatment of the 4,4'-bis(trifluoromethyl)-2,2'-diphenyl disulfide (184;73 mg, 0.20 
mmol) with 2'-amino-2'-deoxyuridine 182 (25 mg, 0.10 mmol) and AgNO3 (34.31 mg), as 
described for 111, afforded 112 as a white solid (3.8 mg, 12%): 
1HNMR δ (CD3OD)   
3.72-3.82 (m, 2H, H5',5''),  4.04-4.07 (m, 1H, H4'), 4.24-4.31 (m, 2H, H2', H3'), 5.7 (d, J 
= 8.1 Hz, 1H, H5), 6.03 (d, J = 7.5 Hz, 1H, H1'), 7.33-7.38 (m, 2H, Ar), 7.51-7.57 (m, 
2H, Ar), 8.07 (d, J = 8.1 Hz, 1H, H6).  
N
6
-[Phenylsulphenyl]-2'-deoxyadenosine (113). Silver acetate (66 mg, 0.4 mmol) 
was added to a solution of diphenyl disulfide 183 (87 mg, 0.4 mmol) in anhydrous DMF 
(1 mL) followed by 2'-deoxyadenosine 182(50 mg, 0.2 mmol). The resulting solution was 
stirred at 55º C for 16 h in dark. The silver mercaptide was removed by filtration. The 
filtrate was evaporated under reduced pressure and the residue was column 
chromatographed (MeOH/CHCl3, 1:9) to give 113 as a white solid (6.9 mg, 10%): 
1HNMR δ (DMSO-d6) 2.28-2.31 (m, 1H, H2'), 2.72-2.81 (m, 1H, H2''), 3.50-3.57 (m, 1H, 
H5'), 3.60-3.68 (m, 1H, H5''), 3.87-3.92 (m, 1H, H4'), 4.41-4.46 (m, 1H, H3'), 5.08 (t, J = 
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5.8 Hz, 1H, OH), 5.35 (d, J = 4.1 Hz, 1H, OH), 6.41 (t, J = 7.1 Hz, 1H, H1), 7.1-7.2 (m, 
3H, Ar), 7.28-7.33 (m, 2H, Ar), 8.39 (s, 1H, H8), 8.55 (s, 1H, H2); 
13
C NMR  40.0 
(C2'), 61.7 (C5'), 70.8 (C3'), 83.9 (C4'), 88.0 (C1'), 121.4 (C5), 122.6 (Ar), 125.4 (Ar), 
128.8 (Ar), 140.6 (Ar), 141.2 (C8), 149.6 (C6), 152.1 (C4), 155.12 (C2). HRMS TOF m/z 
calcd for C16H17N5O3S [M+H]
+ 
360.1125, found 360.1151. 
4.3 EPR protocols 
 
1. Preparation of Solutions of Nucleosides and Sugars: 
Homogenous solutions of nucleosides or sugars were separately prepared by 
dissolving approximately 0.5 to 10 mg of each compound in 1mL of 7.5 M LiCl in H2O 
or D2O.
79,141,142 
2. Preparation of Glassy Sample and their Storage 
Following our works,
79,141,142
 these homogenous solutions were thoroughly 
bubbled with nitrogen gas and then immediately were drawn into 4 mm Suprasil quartz 
tubes (cat. No 734-PQ-8 WILMAD Glass co., Inc., Buena, NJ). These quartz tubes were 
rapidly immersed into liquid N2 (77 K). Due to the rapid cooling, the homogeneous liquid 
solutions formed transparent homogeneous glassy solutions. These homogeneous glassy 
solutions were used for γ-irradiation and subsequent progressive annealing experiments. 
All glassy samples were stored at 77 K in Teflon containers in the dark. 
3. γ-irradiation and the storage of Irradiated Samples 
Following our works,
79,141,142
 these glassy samples were γ-irradiated with the aid 
of 109-GR a irradiator containing shielded 
60
Co source with an absorbed dose 525 – 700 
Gy (45 min to 1 hr) at 77 K and were in Teflon containers in the dark before recording 
EPR spectra of these irradiated samples at 77 K in the dark. Owing to the irradiation of 
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the 7.5M LiCl glass (H2O or D2O) with only 0.5 to 10 mg sample per mL, nearly all the 
initial ionization takes place in the solution there by creating matrix electrons and holes. 
The electrons are scavenged by the solute (sugars) and the holes remain in the glass as 
Cl2•¯. 
4. Thermal Annealing and storage of these samples 
The γ-irradiated samples were annealed in the dark in a variable temperature 
assembly (Air Products) in the temperature range of ca. 140 K to 175 K employing 
cooled nitrogen gas. These transparent glassy samples are not crystalline solids. They are 
actually supercooled homogeneous solutions. These supercooled solutions soften on 
warming via progressive thermal annealing at higher temperatures; this softening 
facilitates molecular migration in these solutions thereby allowing solution phase 
chemistry. After annealing these samples were immediately immersed in liquid nitrogen 
(77 K) for ESR analysis. 
5. Electron Paramagnetic Resonance 
Following our works,
79,141,142
 the EPR spectra of samples were recorded in 
suprasil quartz dewar (cat. No WG-850(-Q), WILMAD Glass co., Inc., Buenas, NJ) at 77 
K and 45dB (6.3μW) using a Varian Century series EPR spectrometer operating at 9.2 
GHz with an E-4531 dual cavity, 9in. magnet and a 200mW klystron. For field 
calibration, Fremy’s salt (g(center of the spectrum)= 2.0056, AN= 13.096) 
6. Analyses of EPR Spectra 
Each EPR spectrum was stored in a 1000 point array along with field calibration 
marks from the three EPR lines of the Fremy’s salt. Following our works on DNA and 
RNA-radicals,
79,141,142,148,152,158-166
 the anisotropic simulations of the experimentally 
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recorded ESR spectra were carried out by employing the Bruker programs (WIN-EPR 
and SimFonia). The ESR parameters (e.g., hyperfine coupling constant (HFCC) values, 
linwidth, etc.) were adjusted to obtain the “best fit” simulated spectrum that matched the 
experimental ESR spectrum well. A small singlet “spike” was subtracted from an 
irradiated quartz at g=2.0006 from the recorded spectra for our analyses. 
5. CONCLUSIONS 
In this dissertation, I have successfully synthesized the 6-O-nitro-1-deoxyhomosugar 
derivatives with chlorine, bromine or tosyl substituent at the C2 position from diacetone 
glucose via multistep synthetic routes. Biomimetic studies with these 6-O-nitro 
homoribose derivatives revealed that the substituents (chloro, bromo, or O-tosyl) are 
departing from the C2 position in a heterolytic manner which is enhanced by the 
intramolecular hydrogen bonding between C3-hydroxyl group and chloro, bromo, or O-
tosyl at C2 position (Figure 30). Reaction of the 1,5-dideoxy-6-O-nitro-2-O-tosyl-D-ribo-
hexofuranose, 96 with Bu3SnH/AIBN in toluene/∆ gave (R)-(2-hydroxyethyl)-
3(2H)dihydrofuranone, 143a and its cyclic hemiacetal, 144a as 1:1 mixture. Similarly, 
reaction of 96 with Bu3SnD yielded 143a and 144a with up to 95% of deuterium 
incorporation at C2 position. The first step in the proposed mechanism is the generation 
of the 6-oxyl radical with subsequent abstraction of H3 to generate C3 radical leading to 
the elimination of the tosylate anion. Proposed mechanism is in agreement with the 
mechanism proposed by Stubbe and is also consistent with the Robins biomimetic 
findings with 6'-O-nitro-2'-O-tosylhomoadenosine substrates.
167,168
 Analogous treatment 
of 2-chloro(or bromo)-1,2,5-trideoxy-6-O-nitro-D-ribo-hexofuranose with Bu3SnD also 
leads to formation of 143a/144a. Chloride or bromide departed as anion with subsequent 
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deuterium incorporation at C2. This proposed mechanism in which the substituents from 
the C2 position are departing as anion is contradictory to the biomimetic studies done by 
Robins with 2-chloro substituted homouridine in which β-elimination of chlorine atom 
was observed upon generation of α-hydroxyl radical at C3.137,167 Steric and/or 
stereoelectronic as well as conformational effects may be responsible for this difference 
in the radical promoted fragmentation of my 1-deoxy homoribofuranoses (lacking 
possibilities of anomeric effects) and adenine and uracil heterocyclic bases.  
 
Figure 30. Hydrogen bonding facilitated elimination of the C-2 substituents as anions upon 
generation of C3 radical. 
 
Interestingly, analogous studies with 6-O-nitro homoarabino derivatives also showed 
that the substituents from the C2 position are departing as anions. Thus, reaction of 6-O-
nitro-D-arabino-hexofuranoses with chloro, bromo, or O-tosyl substituents at C2 with 
Bu3SnD also resulted in the formation of 3-keto/hemiacetal mixture 143a/144a with 
deuterium incorporation at C2 indicating departure of substituents from C2 as anions. In 
the arabino substrates the substituents at C2 and the hydroxyl at C3 are in anti-orientation 
which prevents the formation of the hydrogen bonding between them. Plausibly the 
substituent at C2 might form the hydrogen bonding with 6-hydroxyl group and 
subsequently departs as anion. 
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I also performed biomimetic studies with the 6-O-nitro homosugar derivatives having 
3-O-methyl substituent. Such 3-O-methyl substrates lack the possibility of being 
hydrogen bonding donor and been not converted to the 3-keto product. Subjection of the 
3-O-methyl-2-halo substrates to the free radical-induced relay reactions with Bu3SnD 
lead to formation of the (R)-2-(2-hydroxyethyl)-3-O-methyl-2,3-dihydrofuran-3-ol, 155 
without deuterium incorporations indicating that the halo substituents departed as radical. 
Thus the results with 3-O-methyl-2-halo substrates were consistent with β-elimination of 
the chlorine or bromine atom upon generation of α-oxy radicals at C3 leading to the 
formation of 155. However, treatment of 3-O-methyl-2-O-tosyl substrates with Bu3SnH 
(D) led to elimination of the toluenesulfonic acid from C2 and abstraction of the 
hydrogen from C1 to produce 2-(hydroxyethyl)-3-methoxyfuran, 152. 
Kinetic studies with the substrates arabino tosylate 99 and arabino chloride 97 in 
toluene-d8 (Bu3SnH/ AIBN) at 75º C revealed that the fragmentation of tosylate 99 was 
slightly faster than the chloro substituted substrate 97. Biomimetic and kinetic studies 
with 6-O-nitro-1-deoxy homosugar derivatives provided plausible mechanistic 
explanation of the heterolytic elimination of hydrogen-bonded water from the substrate 
nucleoside di (or tri)phosphate inactivators of ribonucleotide reductases and the MoaA 
enzyme. Thus, results obtained from my studies add clarity to the previously described 
ambiguous hypotheses postulated for radical chemistry-based inactivation of the RNRs 
and MoaA. 
In the second goal of my dissertation, I have successfully synthesized the nucleosides 
with azido and sulfenamide modifications at specific sites in the sugar or in the base 
moieties to study generation and the subsequent reactions of the aminyl radical produced 
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upon one electron reductive conditions. Thus, the 2-azido-2-deoxy-α-D-lyxofuranoside 
derivatives with 2-[
15
N]-azido and deuterium labeled at C4 or C5 were prepared by the 
substitution of the corresponding 2'-O-triflate substrates with NaN3 or Na
15
N3. Upon 
subjection of 2-azido-2-deoxy-α-D-lyxofuranoside derivatives to radiation-produced 
electrons in homogeneous aqueous glassy (7.5 M LiCl) solutions lead to the formation of 
unstable azide anion radical intermediate (RN3•¯) in the absence of oxygen. The RN3•¯, 
underwent a rapid loss of N2 and formed a highly unstable nitrene anion radical (RN•¯) at 
77 K, which upon subsequent rapid protonation at 77 K, produced the neutral aminyl 
radical (RNH•). 
2-[
15
N]-azido isotopomer clearly showed the formation of the neutral aminyl radical 
(RNH•). In case of methyl 5-[2H]-2-azido-2-deoxy-α-D-lyxofuranoside we observed 
formation of the aminyl radical and subsequently this aminyl radical abstracted hydrogen 
from the C5. Similarly, [
2
H3]-methyl 2-azido-2-deoxy-α-D-5-[
2
H2]-lyxofuranoside upon 
electron attachment at 77 K  produced  aminyl radical followed by the abstraction of the 
hydrogen from C5 to generate C5-radical. Concentration dependent studies with these 
labeled azido sugar unequivocally identify fast unimolecular conversion of the aminyl 
radical to the C5-radical. 
Studies with the methyl-d3 xylofuranoside, 5-deuterium labeled azido sugar, 
methyl-d3 5-dideuterium labeled azidolyxofuranoside and methyl-d3 4-deuterium labeled 
azido sugar provided also data which helped us explicitly to determine a subsequent fast 
conversion of C5-radical to the ring opened C4-radical which is in agreement with the 
theoretical calculations. These observations suggest that the ring opened C4-radical might 
exist in a variety of conformations. 
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The 2'-azido-2'-deoxycytidine (2'-AZdC) and 4'-azidocytidine (4'-AZC) produced the 
electron-induced site specific neutral aminyl radicals (RNH•). This aminyl radical 
(dC(C2')-ND•) in 2'-AZdC  showed the abstraction of the H-atom from the C5′-atom of a 
proximate 2'-AZdC to produce carbon-centered radical, C5′•, 187 which is a strand break 
precursor. However the aminyl radical also added bimolecularly to the C5=C6 double 
bond yielding a 6-yl (addition to C5), 188 as well as a 5-yl (addition to C6), 189 (Scheme 
43).  
 
Scheme 43. Formation of aminyl radical in 2'-AZdC and its reaction 
 
Comparison of the ESR spectra of the 2'-AZdC and 4'-AZC clearly suggests that 
RNH• attached to the tertiary alkyl carbon generated from 4'-AZC is less reactive as 
compared to the RNH• attached to the secondary carbon generated from 2'-AZdC.Thus 
our radiation-chemical results demonstrate that: (a) stereo and electronic environment 
affect the formation and reactivity of various types of RNH• generated from 
azidonucleosides, and (b) electron-induced site specific formation of RNH• augments 
radiation damage in DNA-model systems either in the base or in the sugar moiety. 
Therefore, these studies may have potential for improvement of cancer radiotherapy as 
this reaction mechanism would be effective in anoxic conditions. 
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